	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
therapy	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
pulmonary	O
toxicity	O
,	O
including	O
cough	O
and	O
dyspnea	O
.	O
	
During	O
periods	O
of	O
stress	O
,	O
a	O
severe	O
COPD	O
exacerbation	O
,	O
or	O
a	O
severe	O
asthma	O
attack	O
,	O
patients	O
who	O
have	O
been	O
withdrawn	O
from	O
systemic	O
corticosteroids	O
should	O
be	O
instructed	O
to	O
resume	O
oral	O
corticosteroids	O
(	O
in	O
large	O
doses	O
)	O
immediately	O
and	O
to	O
contact	O
their	O
physicians	O
for	O
further	O
instruction	O
.	O
	
The	O
treatment	O
cycle	O
was	O
repeated	O
at	O
approximately	O
6-week	O
intervals	O
up	O
to	O
three	O
additional	O
times	O
,	O
for	O
a	O
maximum	O
of	O
8	O
total	O
injection	O
procedures	O
and	O
4	O
total	O
modeling	O
procedures	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
of	O
Insulin	O
Secretagogues	O
or	O
Insulin	O
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
TRULICITY	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
Approximately	O
one	O
third	O
of	O
the	O
patients	O
who	O
had	O
eye	O
examinations	O
performed	O
after	O
approximately	O
4	O
years	O
of	O
treatment	O
were	O
found	O
to	O
have	O
retinal	B
pigmentary	I
abnormalities	I
.	O
	
Interrupt	O
BLINCYTO	O
if	O
prolonged	O
neutropenia	O
occurs	O
.	O
	
(	O
N	O
for	O
females	O
:	O
Placebo=677	O
,	O
FARXIGA	O
5	O
mg=581	O
,	O
FARXIGA	O
10	O
mg=598	O
)	O
.	O
	
5.2	O
Corporal	O
Rupture	O
(	O
Penile	O
Fracture	O
)	O
or	O
Other	O
Serious	O
Injury	O
to	O
the	O
Penis	O
in	O
the	O
Treatment	O
of	O
Peyronie	O
's	O
Disease	O
Corporal	B
rupture	I
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
after	O
XIAFLEX	O
injections	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX	O
treated	O
patients	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
.	O
	
Eye	O
disorders	O
:	O
Optic	B
neuritis	I
,	O
retinal	B
hemorrhage	I
,	O
and	O
uveitis	B
.	O
	
In	O
these	O
patients	O
,	O
a	O
comprehensive	O
evaluation	O
of	O
urologic	O
symptoms	O
prior	O
to	O
and	O
during	O
treatment	O
with	O
POTIGA	O
may	O
be	O
appropriate	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Suicidal	B
Behavior	I
:	O
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behavior	O
.	O
	
Fractures	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
Extrapyramidal	B
symptoms	I
included	O
dystonia	B
,	O
oculogyration	B
,	O
dyskinesia	B
,	O
tardive	B
dyskinesia	I
,	O
muscle	B
rigidity	I
,	O
parkinsonism	B
,	O
tremor	B
,	O
and	O
extrapyramidal	B
disorder	I
(	O
excluding	O
akathisia	B
)	O
.	O
	
The	O
ovaries	O
normally	O
stop	O
making	O
estrogens	O
when	O
a	O
woman	O
is	O
between	O
45	O
and	O
55	O
years	O
old	O
.	O
	
5.2	O
Malignancies	O
Malignancies	O
in	O
Pediatric	O
Patients	O
Malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
among	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
who	O
received	O
treatment	O
with	O
TNF-blocking	O
agents	O
(	O
initiation	O
of	O
therapy	O
<	O
=	O
18	O
years	O
of	O
age	O
)	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
.	O
	
If	O
patients	O
taking	O
FANAPT	O
experience	O
symptoms	O
that	O
could	O
indicate	O
the	O
occurrence	O
of	O
cardiac	O
arrhythmias	O
,	O
e.g.	O
,	O
dizziness	O
,	O
palpitations	O
,	O
or	O
syncope	O
,	O
the	O
prescriber	O
should	O
initiate	O
further	O
evaluation	O
,	O
including	O
cardiac	O
monitoring	O
.	O
	
Overall	O
,	O
6	O
pediatric	O
patients	O
(	O
4.3	O
%	O
)	O
reported	O
at	O
least	O
one	O
adverse	O
reaction	O
following	O
DOTAREM	O
administration	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
avoid	O
becoming	O
pregnant	O
while	O
being	O
treated	O
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
in	O
Asthma	O
BREO	O
ELLIPTA	O
for	O
the	O
treatment	O
of	O
asthma	O
was	O
studied	O
in	O
18	O
double-blind	O
,	O
parallel-group	O
,	O
controlled	O
trials	O
(	O
11	O
with	O
placebo	O
)	O
of	O
4	O
to	O
76	O
weeks	O
'	O
duration	O
,	O
which	O
enrolled	O
9,969	O
subjects	O
with	O
asthma	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
being	O
treated	O
with	O
Kyprolis	O
.	O
	
Table	O
2	O
:	O
Monitored	O
Adverse	O
Reactions	O
-	O
Application	O
Site	O
Symptoms	O
Event	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
Vehicle	O
Application	B
site	I
Irritation	I
2	O
%	O
(	O
11/478	O
)	O
1	O
%	O
(	O
2/336	O
)	O
Application	B
site	I
anesthesia	I
2	O
%	O
(	O
10/478	O
)	O
0	O
%	O
(	O
0/336	O
)	O
Pain	B
1	O
%	O
(	O
5/478	O
)	O
0	O
%	O
(	O
1/336	O
)	O
The	O
subset	O
of	O
subjects	O
who	O
did	O
not	O
have	O
pruritus	O
,	O
erythema	O
,	O
edema	O
or	O
pyoderma	O
of	O
skin	O
and	O
scalp	O
,	O
or	O
ocular	O
irritation	O
prior	O
to	O
treatment	O
were	O
assessed	O
for	O
these	O
signs	O
and	O
symptoms	O
after	O
treatment	O
;	O
the	O
results	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
5.5	O
Pre-existing	O
Neuromuscular	O
Disorders	O
Individuals	O
with	O
peripheral	O
motor	O
neuropathic	O
diseases	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
or	O
neuromuscular	O
junction	O
disorders	O
(	O
e.g.	O
,	O
myasthenia	O
gravis	O
or	O
Lambert-Eaton	O
syndrome	O
)	O
should	O
be	O
monitored	O
particularly	O
closely	O
when	O
given	O
botulinum	O
toxin	O
.	O
	
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
Table	O
2	O
Adverse	O
Drug	O
ReactionsFrequencies	O
of	O
adverse	O
reactions	O
are	O
based	O
on	O
all	O
treatment-emergent	O
adverse	O
events	O
,	O
attributed	O
to	O
study	O
drugs	O
.	O
	
No	O
apparent	O
correlation	O
of	O
antibody	O
development	O
to	O
clinical	O
response	O
or	O
adverse	O
events	O
was	O
observed	O
.	O
	
Tuberculosis	O
Cases	O
of	O
reactivation	B
of	I
tuberculosis	I
or	O
new	B
tuberculosis	I
infections	I
have	O
been	O
observed	O
in	O
patients	O
receiving	O
TNF-blockers	O
,	O
including	O
patients	O
who	O
have	O
previously	O
received	O
treatment	O
for	O
latent	O
or	O
active	O
tuberculosis	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
=2	O
%	O
more	O
than	O
placebo	O
)	O
for	O
TECFIDERA	O
were	O
flushing	B
,	O
abdominal	B
pain	I
,	O
diarrhea	B
,	O
and	O
nausea	B
.	O
	
The	O
type	O
and	O
frequency	O
of	O
adverse	O
drug	O
reactions	O
appeared	O
to	O
be	O
consistent	O
over	O
time	O
.	O
	
Polyoma	B
virus-associated	I
nephropathy	I
can	O
lead	O
to	O
kidney	B
graft	I
loss	I
;	O
consider	O
reduction	O
in	O
immunosuppression	O
.	O
	
Bleeding	B
results	O
from	O
the	O
AMPLIFY-EXT	O
study	O
are	O
summarized	O
in	O
Table	O
7	O
.	O
	
Doses	O
ranged	O
from	O
18	O
to	O
98	O
Units/kg	O
,	O
with	O
a	O
median	O
dose	O
of	O
49	O
Units/kg	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
}	O
}	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Inc.	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Administration	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
is	O
not	O
recommended	O
until	O
skin	O
is	O
healed	O
from	O
any	O
previous	O
drug	O
or	O
surgical	O
treatment	O
.	O
	
Analyses	O
of	O
patients	O
in	O
PRISTIQ	O
pre-marketing	O
short-term	O
controlled	O
studies	O
who	O
met	O
criteria	O
for	O
sustained	O
hypertension	B
revealed	O
a	O
consistent	O
increase	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
developed	O
sustained	O
hypertension	B
.	O
	
T-cell-depleting	O
therapies	O
to	O
treat	O
acute	O
rejection	O
should	O
be	O
used	O
cautiously	O
.	O
	
Serum	O
parathyroid	O
hormone	O
levels	O
and	O
1.25	O
Vitamin	O
D	O
levels	O
were	O
also	O
higher	O
in	O
subjects	O
receiving	O
tenofovir	O
DF	O
.	O
	
If	O
anaphylaxis	O
occurs	O
,	O
immediately	O
discontinue	O
the	O
infusion	O
(	O
5.2	O
)	O
.	O
	
d	O
Includes	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I
and	O
keratoacanthoma	B
.	O
	
This	O
product	O
's	O
label	O
may	O
have	O
been	O
updated	O
.	O
	
Gastrointestinal	B
(	I
GI	I
)	I
hemorrhage	I
,	O
ileus	B
,	O
enterocolitis	B
,	O
neutropenic	B
enterocolitis	I
,	O
including	O
fatal	B
outcome	O
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
JEVTANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
*	O
Increased	O
risk	O
of	O
serious	O
infections	B
leading	O
to	O
hospitalization	O
or	O
death	B
including	O
tuberculosis	B
(	O
TB	B
)	O
,	O
bacterial	B
sepsis	I
,	O
invasive	B
fungal	I
infections	I
(	O
such	O
as	O
histoplasmosis	B
)	O
,	O
and	O
infections	B
due	I
to	I
other	I
opportunistic	I
pathogens	I
(	O
5.1	O
)	O
.	O
	
5.5	O
Immediate	O
Hypersensitivity	O
Reactions	O
Immediate	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
(	O
including	O
swelling	B
of	I
the	I
lips	I
)	O
,	O
urticaria	B
,	O
rash	B
,	O
bronchospasm	B
,	O
or	O
itching	B
,	O
have	O
occurred	O
after	O
administration	O
of	O
TUDORZA	O
PRESSAIR	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
experienced	O
by	O
patients	O
with	O
sALCL	O
were	O
septic	B
shock	I
(	O
3	O
%	O
)	O
,	O
supraventricular	B
arrhythmia	I
(	O
3	O
%	O
)	O
,	O
pain	B
in	I
extremity	I
(	O
3	O
%	O
)	O
,	O
and	O
urinary	B
tract	I
infection	I
(	O
3	O
%	O
)	O
.	O
	
Measure	O
serum	O
ALT	O
,	O
AST	O
,	O
and	O
bilirubin	O
prior	O
to	O
initiation	O
of	O
PROMACTA	O
,	O
every	O
2	O
weeks	O
during	O
the	O
dose	O
adjustment	O
phase	O
,	O
and	O
monthly	O
following	O
establishment	O
of	O
a	O
stable	O
dose	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
narrow-angle	O
glaucoma	O
and	O
instruct	O
patients	O
to	O
consult	O
a	O
physician	O
immediately	O
if	O
this	O
occurs	O
.	O
	
Complete	O
blood	O
counts	O
(	O
with	O
white	O
blood	O
cell	O
differential	O
counts	O
)	O
should	O
be	O
obtained	O
at	O
pretreatment	O
,	O
and	O
at	O
Treatment	O
Weeks	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
12	O
,	O
and	O
should	O
be	O
monitored	O
closely	O
at	O
other	O
time	O
points	O
,	O
as	O
clinically	O
appropriate	O
.	O
	
5.3	O
Gastrointestinal	O
Adverse	O
Reactions	O
Nausea	B
,	O
vomiting	B
and	O
severe	O
diarrhea	B
,	O
at	O
times	O
,	O
may	O
occur	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
delays	O
in	O
more	O
than	O
5	O
%	O
of	O
ADCETRIS-treated	O
patients	O
in	O
Study	O
3	O
were	O
neutropenia	B
(	O
22	O
%	O
)	O
,	O
peripheral	B
sensory	I
neuropathy	I
(	O
16	O
%	O
)	O
,	O
upper	B
respiratory	I
tract	I
infection	I
(	O
6	O
%	O
)	O
,	O
and	O
peripheral	B
motor	I
neuropathy	I
(	O
6	O
%	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
anorexia	B
,	O
appetite	B
decreased	I
,	O
dehydration	B
,	O
diabetes	B
mellitus	I
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
hyperlipidemia	B
,	O
hypertriglyceridemia	B
,	O
hypokalemia	B
,	O
weight	B
decreased	I
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
risk	O
appears	O
lower	O
for	O
patients	O
with	O
chronic	O
,	O
moderate	O
kidney	O
disease	O
(	O
GFR	O
30	O
to	O
59	O
mL/min/1.73m	O
2	O
)	O
and	O
little	O
,	O
if	O
any	O
,	O
for	O
patients	O
with	O
chronic	O
,	O
mild	O
kidney	O
disease	O
(	O
GFR	O
60	O
to	O
89	O
mL/min/1.73m	O
2	O
)	O
.	O
	
You	O
may	O
report	O
side	O
effects	O
to	O
FDA	O
at	O
1-800-FDA-1088	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
experienced	O
by	O
patients	O
with	O
classical	O
HL	O
include	O
peripheral	B
motor	I
neuropathy	I
(	O
4	O
%	O
)	O
,	O
abdominal	B
pain	I
(	O
3	O
%	O
)	O
,	O
pulmonary	B
embolism	I
(	O
2	O
%	O
)	O
,	O
pneumonitis	B
(	O
2	O
%	O
)	O
,	O
pneumothorax	B
(	O
2	O
%	O
)	O
,	O
pyelonephritis	B
(	O
2	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
2	O
%	O
)	O
.	O
	
5.4	O
Drug	O
Interactions	O
with	O
CYP2D6	O
Administration	O
of	O
Coartem	O
Tablets	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP2D6	O
may	O
significantly	O
increase	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	O
and	O
increase	O
the	O
risk	O
of	O
adverse	O
effects	O
.	O
	
Perform	O
an	O
ophthalmological	O
evaluation	O
consisting	O
of	O
best	O
corrected	O
visual	O
acuity	O
,	O
retinal	O
photographs	O
,	O
visual	O
fields	O
,	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
and	O
other	O
evaluations	O
as	O
appropriate	O
for	O
new	O
onset	O
of	O
severe	O
visual	O
loss	O
.	O
	
For	O
additional	O
information	O
,	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
consult	O
the	O
VIREAD	O
prescribing	O
information	O
.	O
	
In	O
a	O
controlled	O
trial	O
in	O
patients	O
with	O
chronic	O
liver	O
disease	O
and	O
thrombocytopenia	O
not	O
related	O
to	O
ITP	O
undergoing	O
elective	O
invasive	O
procedures	O
(	O
N	O
=	O
292	O
)	O
,	O
the	O
risk	O
of	O
thrombotic	B
events	I
was	O
increased	O
in	O
patients	O
treated	O
with	O
75	O
mg	O
of	O
PROMACTA	O
once	O
daily	O
.	O
	
Table	O
1	O
:	O
Per	O
Patient	O
Incidence	O
of	O
Grade	O
1	O
and	O
2	O
Adverse	O
Reactions	O
Assessed	O
as	O
Possibly	O
,	O
Probably	O
,	O
or	O
Definitely	O
Related	O
to	O
VORAXAZE	O
Excluding	O
Hematologic	O
,	O
Hepatic	O
,	O
or	O
Renal	O
Adverse	O
Reactions	O
1	O
This	O
incidence	O
includes	O
the	O
following	O
terms	O
:	O
flushing	B
,	O
feeling	B
hot	I
,	O
burning	B
sensation	I
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
and	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
4.1	O
,	O
5.1	O
)	O
.	O
	
This	O
was	O
seen	O
at	O
all	O
doses	O
with	O
a	O
suggestion	O
of	O
a	O
higher	O
rate	O
at	O
400	O
mg	O
per	O
day	O
.	O
	
In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
neutropenia	O
,	O
frequent	O
blood	O
cell	O
counts	O
should	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
JEVTANA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Bone	B
marrow	I
suppression	I
(	O
particularly	O
neutropenia	B
)	O
and	O
its	O
clinical	O
consequences	O
(	O
febrile	B
neutropenia	I
,	O
neutropenic	B
infections	I
)	O
:	O
Monitor	O
blood	O
counts	O
frequently	O
to	O
determine	O
if	O
dosage	O
modification	O
or	O
initiation	O
of	O
G-CSF	O
is	O
needed	O
.	O
	
Gamma	O
Glutamyltransferase	O
(	O
GGT	O
)	O
Increase	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
the	O
adverse	O
event	O
of	O
increased	B
GGT	I
occurred	O
more	O
frequently	O
in	O
the	O
group	O
treated	O
with	O
TANZEUM	O
(	O
0.9	O
%	O
and	O
1.5	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
Study	O
2	O
is	O
an	O
ongoing	O
expanded	O
access	O
program	O
.	O
	
Hepatitis	O
B	O
Virus	O
Reactivation	O
The	O
use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
reactivation	B
of	I
hepatitis	I
B	I
virus	I
)	O
in	O
patients	O
who	O
are	O
chronic	O
hepatitis	O
B	O
carriers	O
(	O
i.e.	O
,	O
surface	O
antigen	O
positive	O
)	O
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
Trials	O
In	O
the	O
two	O
well-controlled	O
studies	O
demonstrating	O
effectiveness	O
,	O
1529	O
patients	O
received	O
TECFIDERA	O
with	O
an	O
overall	O
exposure	O
of	O
2244	O
person-years	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Some	O
infections	B
were	O
fatal	B
.	O
	
CRNM	O
=	O
clinically	O
relevant	O
nonmajor	O
.	O
	
Use	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
due	O
to	O
an	O
increased	O
risk	O
of	O
graft	O
loss	O
and	O
death	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Table	O
2	O
displays	O
the	O
frequency	O
of	O
adverse	O
drug	O
reactions	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
subjects	O
in	O
any	O
treatment	O
arm	O
.	O
	
5.7	O
Risk	O
of	O
Ptosis	O
in	O
Patients	O
Treated	O
with	O
XEOMIN	O
for	O
Glabellar	O
Lines	O
Do	O
not	O
exceed	O
the	O
recommended	O
dosage	O
and	O
frequency	O
of	O
administration	O
of	O
XEOMIN	O
.	O
	
Patients	O
with	O
smaller	O
neck	O
muscle	O
mass	O
and	O
patients	O
who	O
require	O
bilateral	O
injections	O
into	O
the	O
sternocleidomastoid	O
muscles	O
have	O
been	O
reported	O
to	O
be	O
at	O
greater	O
risk	O
of	O
dysphagia	B
.	O
	
In	O
both	O
cases	O
,	O
the	O
patients	O
were	O
taking	O
a	O
1.25	O
mg	O
dose	O
of	O
fingolimod	O
(	O
higher	O
than	O
the	O
recommended	O
0.5	O
mg	O
dose	O
)	O
and	O
had	O
received	O
high-dose	O
corticosteroid	O
therapy	O
to	O
treat	O
suspected	O
MS	O
relapses	O
.	O
	
These	O
cases	O
were	O
reported	O
post-marketing	O
and	O
are	O
derived	O
from	O
a	O
variety	O
of	O
sources	O
,	O
including	O
registries	O
and	O
spontaneous	O
post-marketing	O
reports	O
.	O
	
FANAPT	O
should	O
be	O
discontinued	O
in	O
patients	O
who	O
are	O
found	O
to	O
have	O
persistent	O
QTc	O
measurements	O
>	O
500	O
msec	O
.	O
	
In	O
monotherapy	O
trials	O
in	O
patients	O
with	O
partial-onset	O
seizures	O
[	O
Study	O
1	O
and	O
Study	O
2	O
,	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
,	O
365	O
patients	O
received	O
APTIOM	O
,	O
of	O
whom	O
225	O
were	O
treated	O
for	O
longer	O
than	O
12	O
months	O
and	O
134	O
for	O
longer	O
than	O
24	O
months	O
.	O
	
In	O
MS	O
placebo-controlled	O
trials	O
,	O
the	O
overall	O
rate	O
of	O
infections	B
(	O
72	O
%	O
)	O
with	O
GILENYA	O
was	O
similar	O
to	O
placebo	O
.	O
	
The	O
majority	O
of	O
application	B
site	I
reactions	I
were	O
transient	O
and	O
self-limited	O
.	O
	
EXCERPT	O
:	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=3	O
%	O
of	O
KALBITOR-treated	O
patients	O
and	O
greater	O
than	O
placebo	O
are	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
injection	B
site	I
reactions	I
,	O
and	O
nasopharyngitis	B
.	O
	
Assure	O
good	O
venous	O
access	O
prior	O
to	O
starting	O
TREANDA	O
infusion	O
and	O
monitor	O
the	O
intravenous	O
infusion	O
site	O
for	O
redness	O
,	O
swelling	O
,	O
pain	O
,	O
infection	O
,	O
and	O
necrosis	O
during	O
and	O
after	O
administration	O
of	O
TREANDA	O
.	O
	
In	O
the	O
pooled	O
analysis	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
,	O
the	O
incidence	O
of	O
renal-related	B
adverse	I
reactions	I
was	O
3.7	O
%	O
with	O
placebo	O
,	O
8.9	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
9.3	O
%	O
with	O
INVOKANA	O
300	O
mg.	O
Discontinuations	O
due	O
to	O
renal-related	B
adverse	I
events	I
occurred	O
in	O
1.0	O
%	O
with	O
placebo	O
,	O
1.2	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
1.6	O
%	O
with	O
INVOKANA	O
300	O
mg	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
distance	O
of	O
a	O
z-score	O
from	O
0	O
represents	O
the	O
distance	O
of	O
a	O
percentile	O
from	O
the	O
median	O
,	O
measured	O
in	O
standard	O
deviations	O
(	O
SD	O
)	O
.	O
	
Table	O
1	O
.	O
	
No	O
serious	O
events	O
were	O
reported	O
through	O
Year	O
3	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
:	O
Bleeding	B
and	O
injection	B
site	I
reactions	I
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
bleeding	O
.	O
	
Anti-belatacept	O
antibody	O
development	O
was	O
not	O
associated	O
with	O
altered	O
clearance	O
of	O
belatacept	O
.	O
	
Patients	O
may	O
require	O
a	O
lower	O
dose	O
of	O
sulfonylurea	O
or	O
insulin	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
in	O
this	O
setting	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
event	O
of	O
new	O
or	O
worsening	O
pulmonary	O
symptoms	O
,	O
hold	O
ADCETRIS	O
dosing	O
during	O
evaluation	O
and	O
until	O
symptomatic	O
improvement	O
.	O
	
Psychiatric	O
disorders	O
:	O
bruxism	B
,	O
depression	B
,	O
obsessive-compulsive	B
disorder	I
.	O
	
Since	O
the	O
protein	O
components	O
in	O
XIAFLEX	O
(	O
AUX-I	O
and	O
AUX-II	O
)	O
have	O
some	O
sequence	O
homology	O
with	O
human	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
anti-product	O
antibodies	O
could	O
theoretically	O
interfere	O
with	O
human	O
MMPs	O
.	O
	
(	O
5.1	O
)	O
*	O
Liver	B
disease	I
:	O
Discontinue	O
Natazia	O
if	O
jaundice	O
occurs	O
.	O
	
If	O
SJS	O
or	O
TEN	O
occurs	O
,	O
discontinue	O
ADCETRIS	O
and	O
administer	O
appropriate	O
medical	O
therapy	O
.	O
	
Stop	O
Natazia	O
at	O
least	O
4	O
weeks	O
before	O
and	O
through	O
2	O
weeks	O
after	O
major	O
surgery	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Retinal	O
Abnormalities	O
and	O
Potential	O
Vision	O
Loss	O
POTIGA	O
can	O
cause	O
abnormalities	B
of	I
the	I
retina	I
.	O
	
1.7	O
2.9	O
3.8	O
Male	O
genital	O
mycotic	O
infectionsGenital	O
mycotic	B
infections	I
include	I
the	I
following	I
adverse	I
reactions	I
,	I
listed	I
in	I
order	I
of	I
frequency	I
reported	I
for	I
males	I
:	O
balanitis	B
,	O
fungal	B
genital	I
infection	I
,	O
balanitis	B
candida	I
,	O
genital	B
candidiasis	I
,	O
genital	B
infection	I
male	I
,	O
penile	B
infection	I
,	O
balanoposthitis	B
,	O
balanoposthitis	B
infective	I
,	O
genital	B
infection	I
,	O
posthitis	B
.	O
	
Table	O
1	O
presents	O
selected	O
adverse	O
reactions	O
from	O
Study	O
1	O
,	O
which	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
in	O
the	O
YERVOY-containing	O
arms	O
and	O
with	O
at	O
least	O
5	O
%	O
increased	O
incidence	O
over	O
the	O
control	O
gp100	O
arm	O
for	O
all-grade	O
events	O
and	O
at	O
least	O
1	O
%	O
incidence	O
over	O
the	O
control	O
group	O
for	O
Grade	O
3-5	O
events	O
.	O
	
Case	O
reports	O
and	O
epidemiological	O
studies	O
(	O
case-control	O
and	O
cohort	O
design	O
)	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
drugs	O
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
gastrointestinal	B
bleeding	I
.	O
	
Approximately	O
15	O
%	O
of	O
patients	O
with	O
retinal	B
pigmentary	I
abnormalities	I
had	O
no	O
such	O
discoloration	B
.	O
	
In	O
a	O
historically	O
controlled	O
post-marketing	O
trial	O
,	O
the	O
incidence	O
of	O
skin	B
laceration	I
(	O
22	O
%	O
)	O
was	O
higher	O
for	O
subjects	O
treated	O
with	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
compared	O
with	O
subjects	O
treated	O
with	O
up	O
to	O
three	O
single	O
injections	O
in	O
the	O
placebo-controlled	O
premarketing	O
trials	O
(	O
9	O
%	O
)	O
.	O
	
Exposure	O
to	O
YERVOY	O
3	O
mg/kg	O
for	O
4	O
doses	O
given	O
by	O
intravenous	O
infusion	O
in	O
previously	O
treated	O
patients	O
with	O
unresectable	O
or	O
metastatic	O
melanoma	O
was	O
assessed	O
in	O
a	O
randomized	O
,	O
double-blind	O
clinical	O
study	O
(	O
Study	O
1	O
)	O
.	O
	
A	O
total	O
of	O
111	O
patients	O
were	O
treated	O
with	O
pemetrexed/cisplatin	O
.	O
	
Therefore	O
,	O
the	O
possibility	O
of	O
an	O
association	O
between	O
neutralizing	O
antibody	O
titer	O
and	O
treatment	O
effect	O
can	O
not	O
be	O
assessed	O
.	O
	
In	O
a	O
pooled	O
population	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
N=1085	O
)	O
with	O
baseline	O
eGFR	O
of	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
(	O
mean	O
baseline	O
eGFR	O
48	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
the	O
overall	O
incidence	O
of	O
these	O
events	O
was	O
lower	O
than	O
in	O
the	O
dedicated	O
trial	O
but	O
a	O
dose-dependent	O
increase	O
in	O
incident	O
episodes	O
of	O
significant	O
renal	B
function	I
decline	I
compared	O
to	O
placebo	O
was	O
still	O
observed	O
.	O
	
These	O
patients	O
may	O
be	O
at	O
greater	O
risk	O
for	O
cardiac	O
complications	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8	O
)	O
]	O
.	O
	
In	O
these	O
pooled	O
trials	O
,	O
the	O
median	O
exposure	O
for	O
subjects	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
and	O
placebo	O
arm	O
was	O
52.3	O
and	O
51.0	O
weeks	O
,	O
respectively	O
.	O
	
Reduce	O
or	O
withhold	O
dose	O
as	O
appropriate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Discontinue	O
ERWINAZE	O
for	O
severe	O
or	O
hemorrhagic	O
pancreatitis	O
manifested	O
by	O
abdominal	O
pain	O
>	O
72	O
hours	O
and	O
amylase	O
elevation	O
>	O
=	O
2.0	O
x	O
ULN	O
.	O
	
Varicella	O
Zoster	O
Virus	O
Antibody	O
Testing/Vaccination	O
Patients	O
without	O
a	O
healthcare	O
professional	O
confirmed	O
history	O
of	O
chickenpox	O
or	O
without	O
documentation	O
of	O
a	O
full	O
course	O
of	O
vaccination	O
against	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
should	O
be	O
tested	O
for	O
antibodies	O
to	O
VZV	O
before	O
initiating	O
GILENYA	O
.	O
	
Approximately	O
half	O
the	O
cases	O
were	O
lymphomas	B
,	O
including	O
non-Hodgkin	B
's	I
lymphoma	I
.	O
	
When	O
distant	O
effects	O
occur	O
,	O
additional	O
respiratory	O
muscles	O
may	O
be	O
involved	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Some	O
patients	O
who	O
were	O
pre-treated	O
with	O
antihistamines	O
,	O
antipyretics	O
and/or	O
corticosteroids	O
still	O
experienced	O
hypersensitivity	B
reactions	I
.	O
	
Patients	O
with	O
neuromuscular	O
disorders	O
may	O
be	O
at	O
increased	O
risk	O
of	O
clinically	O
significant	O
effects	O
including	O
severe	O
dysphagia	B
and	O
respiratory	B
compromise	I
from	O
typical	O
doses	O
of	O
DYSPORT	O
(	O
r	O
)	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
cimetidine	O
)	O
was	O
not	O
examined	O
by	O
clinical	O
study	O
,	O
some	O
pharmacokinetic	O
interaction	O
is	O
expected	O
,	O
albeit	O
less	O
than	O
that	O
observed	O
with	O
moderate	O
CYP3A4	O
inhibitors	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
141	O
days	O
(	O
range	O
19-451	O
days	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
60	O
days	O
(	O
range	O
21-295	O
days	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
5.14	O
Embryo-fetal	O
Toxicity	O
Kyprolis	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
and	O
findings	O
in	O
animals	O
.	O
	
Eleven	O
out	O
of	O
163	O
(	O
7	O
%	O
)	O
patients	O
treated	O
with	O
600	O
mg	O
of	O
HORIZANT	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
compared	O
with	O
10	O
of	O
the	O
245	O
(	O
4	O
%	O
)	O
patients	O
who	O
received	O
placebo	O
.	O
	
Dose	O
adjustments	O
(	O
interruptions	O
or	O
reductions	O
)	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
52	O
%	O
of	O
AFINITOR-treated	O
patients	O
.	O
	
A	O
total	O
of	O
701	O
subjects	O
received	O
STRIBILD	O
once	O
daily	O
in	O
these	O
two	O
studies	O
.	O
	
(	O
6	O
)	O
6.1	O
Clinical	O
Trials	O
Experience	O
Clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
and	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
Vizamyl	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Adverse	O
Reaction	O
N=	O
290n	O
(	O
%	O
)	O
Paresthesias	B
7	O
(	O
2	O
%	O
)	O
Flushing	B
1,2	O
5	O
(	O
2	O
%	O
)	O
Nausea/Vomiting	O
5	O
(	O
2	O
%	O
)	O
Headache	B
2	O
(	O
1	O
%	O
)	O
Hypotension	B
2	O
(	O
1	O
%	O
)	O
Blurred	B
Vision	I
1	O
(	O
<	O
1	O
%	O
)	O
Diarrhea	B
1	O
(	O
<	O
1	O
%	O
)	O
Hypersensitivity	B
1	O
(	O
<	O
1	O
%	O
)	O
Hypertension	B
1	O
(	O
<	O
1	O
%	O
)	O
Rash	B
1	O
(	O
<	O
1	O
%	O
)	O
Throat	B
irritation/Throat	O
tightness	B
1	O
(	O
<	O
1	O
%	O
)	O
Tremor	B
1	O
(	O
<	O
1	O
%	O
)	O
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
Patients	O
in	O
the	O
XALKORI	O
arm	O
(	O
n=171	O
)	O
received	O
XALKORI	O
250	O
mg	O
orally	O
twice	O
daily	O
until	O
documented	O
disease	O
progression	O
,	O
intolerance	O
to	O
therapy	O
,	O
or	O
the	O
investigator	O
determined	O
that	O
the	O
patient	O
was	O
no	O
longer	O
experiencing	O
clinical	O
benefit	O
.	O
	
(	O
5.11	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
5.9	O
QT	O
Prolongation	O
The	O
effects	O
of	O
SAPHRIS	O
on	O
the	O
QT/QTc	O
interval	O
were	O
evaluated	O
in	O
a	O
dedicated	O
adult	O
QT	O
study	O
.	O
	
e	O
Cases	O
of	O
cutaneous	B
squamous	I
cell	I
carcinoma	I
were	O
required	O
to	O
be	O
reported	O
as	O
Grade	O
3	O
per	O
protocol	O
.	O
	
Selected	O
Adverse	O
Reactions	O
in	O
Phase	O
2/3	O
Trials	O
(	O
Number	O
(	O
%	O
)	O
of	O
Patients	O
)	O
Dalbavancin	O
Comparator*	O
(	O
N	O
=	O
1778	O
)	O
(	O
N	O
=	O
1224	O
)	O
Nausea	B
98	O
(	O
5.5	O
)	O
78	O
(	O
6.4	O
)	O
Vomiting	B
50	O
(	O
2.8	O
)	O
37	O
(	O
3	O
)	O
Diarrhea	B
79	O
(	O
4.4	O
)	O
72	O
(	O
5.9	O
)	O
Headache	B
83	O
(	O
4.7	O
)	O
59	O
(	O
4.8	O
)	O
Rash	B
48	O
(	O
2.7	O
)	O
30	O
(	O
2.4	O
)	O
Pruritus	B
38	O
(	O
2.1	O
)	O
41	O
(	O
3.3	O
)	O
*	O
Comparators	O
included	O
linezolid	O
,	O
cefazolin	O
,	O
cephalexin	O
,	O
and	O
vancomycin	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
fatigue	B
,	O
joint	B
swelling	I
,	O
edema	B
,	O
hot	B
flush	I
,	O
diarrhea	B
,	O
vomiting	B
,	O
cough	B
,	O
hypertension	B
,	O
dyspnea	B
,	O
urinary	B
tract	I
infection	I
and	O
contusion	B
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
(	O
r	O
)	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
CIMZIA	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
patients	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
need	O
of	O
emergency	O
cardiorespiratory	O
support	O
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
(	O
NSF	O
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
*	O
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
Gadavist	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Serious	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
AdreView	O
administration	O
.	O
	
Vascular	O
Disorders	O
:	O
Thrombotic	B
microangiopathy	I
with	O
acute	B
renal	I
failure	I
.	O
	
f	O
NA	O
=	O
not	O
applicable	O
.	O
	
In	O
animal	O
reproduction	O
studies	O
,	O
oral	O
administration	O
of	O
crizotinib	O
in	O
pregnant	O
rats	O
during	O
organogenesis	O
at	O
exposures	O
similar	O
to	O
those	O
observed	O
with	O
the	O
maximum	O
recommended	O
human	O
dose	O
resulted	O
in	O
embryotoxicity	B
and	O
fetotoxicity	B
.	O
	
Small	O
increases	B
in	I
creatinine	I
levels	I
(	O
about	O
0.1	O
mg/dL	O
)	O
following	O
dronedarone	O
treatment	O
initiation	O
have	O
been	O
shown	O
to	O
be	O
a	O
result	O
of	O
inhibition	O
of	O
creatinine	O
's	O
tubular	O
secretion	O
.	O
	
(	O
5.1	O
)	O
*	O
Increases	B
in	I
intraocular	I
pressure	I
have	O
been	O
seen	O
within	O
60	O
minutes	O
of	O
an	O
intravitreal	O
injection	O
.	O
	
At	O
the	O
time	O
of	O
data	O
cut-off	O
,	O
243	O
patients	O
were	O
enrolled	O
and	O
safety	O
data	O
was	O
available	O
for	O
141	O
patients	O
.	O
	
(	O
5.8	O
)	O
*	O
Vaccinations	O
:	O
Avoid	O
live	O
vaccines	O
and	O
close	O
contact	O
with	O
those	O
who	O
have	O
received	O
live	O
vaccines	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Non-infectious	B
pneumonitis	I
:	O
Monitor	O
for	O
clinical	O
symptoms	O
or	O
radiological	O
changes	O
;	O
fatal	B
cases	O
have	O
occurred	O
.	O
	
A	O
total	O
of	O
169	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
500	O
mg/m	O
2	O
in	O
combination	O
with	O
cisplatin	O
75	O
mg/m	O
2	O
(	O
n=91	O
)	O
or	O
carboplatin	O
at	O
a	O
dose	O
calculated	O
to	O
produce	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
or	O
6	O
mg	O
?	O
min/mL	O
(	O
n=78	O
)	O
.	O
	
Eye	B
disorders	I
,	O
including	O
severe	O
eye	B
pain	I
,	O
chemical	B
conjunctivitis	I
,	O
corneal	B
burn	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
periorbital	B
edema	I
can	O
occur	O
after	O
exposure	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
2	O
One	O
of	O
these	O
reactions	O
was	O
classified	O
as	O
Grade	O
3	O
in	O
severity	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
In	O
three	O
randomized	O
,	O
controlled	O
clinical	O
studies	O
(	O
Studies	O
1	O
,	O
2	O
and	O
3	O
)	O
,	O
which	O
were	O
six	O
to	O
12	O
months	O
in	O
duration	O
,	O
the	O
following	O
adverse	O
reactions	O
were	O
reported	O
by	O
the	O
treating	O
physician	O
as	O
related	O
to	O
study	O
drug	O
.	O
	
Events	O
and	O
event	O
rates	O
include	O
one	O
enoxaparin-treated	O
patient	O
in	O
ADVANCE-1	O
who	O
also	O
had	O
intracranial	B
hemorrhage	I
.	O
	
AFINITOR	O
may	O
be	O
reintroduced	O
at	O
a	O
daily	O
dose	O
approximately	O
50	O
%	O
lower	O
than	O
the	O
dose	O
previously	O
administered	O
[	O
see	O
Table	O
1	O
in	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
If	O
a	O
severe	O
hypersensitivity	O
reaction	O
occurs	O
,	O
DIFICID	O
(	O
r	O
)	O
should	O
be	O
discontinued	O
and	O
appropriate	O
therapy	O
should	O
be	O
instituted	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GE	O
Healthcare	O
at	O
1-800-654-0118	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.5	O
Cardiomyopathy	O
Cardiomyopathy	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
bleeding	B
occurred	O
in	O
219	O
(	O
13.3	O
%	O
)	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
72	O
(	O
8.7	O
%	O
)	O
placebo-treated	O
patients	O
.	O
	
All	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
of	O
short	O
duration	O
.	O
	
Appendicitis	O
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
serious	O
events	O
of	O
appendicitis	B
occurred	O
in	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
compared	O
with	O
0	O
%	O
among	O
all	O
comparators	O
.	O
	
Subjects	O
were	O
randomized	O
to	O
receive	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
or	O
placebo	O
twice	O
daily	O
.	O
	
There	O
is	O
evidence	O
to	O
suggest	O
that	O
some	O
patients	O
who	O
develop	O
high	O
sustained	O
titers	O
of	O
anti-alglucosidase	O
alfa	O
antibodies	O
may	O
experience	O
reduced	O
clinical	O
efficacy	O
to	O
alglucosidase	O
alfa	O
treatment	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Table	O
1	O
presents	O
the	O
profile	O
from	O
the	O
9-month	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
of	O
40	O
treatment-naive	O
patients	O
(	O
Trial	O
1	O
)	O
.	O
	
Monitor	O
liver	O
enzymes	O
regularly	O
.	O
	
The	O
duration	O
of	O
driving	B
impairment	I
after	O
starting	O
therapy	O
with	O
HORIZANT	O
is	O
unknown	O
.	O
	
These	O
reactions	O
can	O
occur	O
within	O
hours	O
to	O
weeks	O
after	O
injection	O
with	O
botulinum	O
toxin	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
12-Week	O
Trials	O
Trial	O
1	O
was	O
a	O
12-week	O
trial	O
that	O
evaluated	O
the	O
efficacy	O
of	O
BREO	O
ELLIPTA	O
100/25	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
compared	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
and	O
placebo	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
incidence	O
of	O
Grade	O
>	O
=3	O
ILD	B
was	O
1.3	O
%	O
and	O
resulted	O
in	O
death	B
in	O
1	O
%	O
of	O
GILOTRIF-treated	O
patients	O
.	O
	
Include	O
disseminated	O
herpetic	O
infections	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	O
who	O
are	O
receiving	O
GILENYA	O
and	O
present	O
with	O
an	O
atypical	O
MS	O
relapse	O
or	O
multiorgan	O
failure	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
also	O
may	O
not	O
reflect	O
rates	O
observed	O
in	O
practice	O
.	O
	
*	O
Concomitant	O
neuromuscular	O
disorders	O
may	O
exacerbate	O
clinical	O
effects	O
of	O
treatment	O
(	O
5.5	O
)	O
.	O
	
5.7	O
Embryo-Fetal	O
Toxicity	O
JEVTANA	O
is	O
not	O
indicated	O
for	O
use	O
in	O
female	O
patients	O
.	O
	
[	O
See	O
C	O
ontraindications	O
(	O
4	O
)	O
,	O
W	O
arnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Assessment	O
of	O
the	O
incidence	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
The	O
adverse	O
reactions	O
presented	O
in	O
the	O
table	O
below	O
are	O
based	O
on	O
safety	O
information	O
from	O
769	O
patients	O
treated	O
with	O
TECFIDERA	O
240	O
mg	O
twice	O
a	O
day	O
and	O
771	O
placebo-treated	O
patients	O
.	O
	
(	O
5.5	O
)	O
*	O
Other	O
Malignancies	B
:	O
malignant	B
diseases	I
have	O
been	O
reported	O
.	O
	
*	O
TRULICITY	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
and	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
Episodes	O
of	O
sinus	B
tachycardia	I
,	O
associated	O
with	O
a	O
concomitant	O
increase	B
from	I
baseline	I
in	I
heart	I
rate	I
of	O
>	O
=15	O
beats	O
per	O
minute	O
,	O
were	O
reported	O
in	O
0.7	O
%	O
,	O
1.3	O
%	O
and	O
2.2	O
%	O
of	O
patient	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
Chronic	O
antipsychotic	O
treatment	O
should	O
generally	O
be	O
reserved	O
for	O
patients	O
who	O
suffer	O
from	O
a	O
chronic	O
illness	O
that	O
(	O
1	O
)	O
is	O
known	O
to	O
respond	O
to	O
antipsychotic	O
drugs	O
,	O
and	O
(	O
2	O
)	O
for	O
whom	O
alternative	O
,	O
equally	O
effective	O
,	O
but	O
potentially	O
less	O
harmful	O
treatments	O
are	O
not	O
available	O
or	O
appropriate	O
.	O
	
3.7	O
5.7	O
4.3	O
Back	B
pain	I
3.2	O
3.1	O
4.2	O
Increased	O
urinationIncreased	O
urination	B
includes	O
the	O
following	O
adverse	O
reactions	O
,	O
listed	O
in	O
order	O
of	O
frequency	O
reported	O
:	O
pollakiuria	B
,	O
polyuria	B
,	O
and	O
urine	B
output	I
increased	I
.	O
	
In	O
clinical	O
trials	O
evaluating	O
BREO	O
ELLIPTA	O
in	O
subjects	O
with	O
COPD	O
or	O
asthma	O
,	O
there	O
was	O
no	O
evidence	O
of	O
a	O
treatment	O
effect	O
on	O
serum	O
glucose	O
or	O
potassium	O
.	O
	
Monitor	O
for	O
the	O
development	O
of	O
severe	O
diarrhea	O
or	O
colitis	O
.	O
	
Start	O
Natazia	O
no	O
earlier	O
than	O
4	O
weeks	O
after	O
delivery	O
,	O
in	O
women	O
who	O
are	O
not	O
breastfeeding	O
.	O
	
Half	O
of	O
the	O
patients	O
in	O
the	O
controlled	O
trials	O
who	O
discontinued	O
POTIGA	O
due	O
to	O
hallucinations	B
or	O
psychosis	B
required	O
hospitalization	O
.	O
	
During	O
this	O
period	O
of	O
HPA	O
suppression	O
,	O
patients	O
may	O
exhibit	O
signs	O
and	O
symptoms	O
of	O
adrenal	O
insufficiency	O
when	O
exposed	O
to	O
trauma	O
,	O
surgery	O
,	O
or	O
infection	O
(	O
particularly	O
gastroenteritis	O
)	O
or	O
other	O
conditions	O
associated	O
with	O
severe	O
electrolyte	O
loss	O
.	O
	
(	O
6.1	O
)	O
*	O
In	O
pediatric	O
patients	O
age	O
6	O
years	O
and	O
older	O
with	O
ITP	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
and	O
rhinitis	B
.	O
	
However	O
,	O
pregnancy	O
increases	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
as	O
much	O
or	O
more	O
than	O
the	O
use	O
of	O
COCs	O
.	O
	
Three	O
of	O
these	O
trials	O
were	O
active-controlled	O
(	O
warfarin	O
)	O
(	O
RE-COVER	O
,	O
RE-COVER	O
II	O
,	O
and	O
RE-MEDY	O
)	O
,	O
and	O
one	O
study	O
(	O
RE-SONATE	O
)	O
was	O
placebo-controlled	O
.	O
	
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Menstrual	B
disorder	I
.	O
	
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Infections	B
:	O
Monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
and	O
treat	O
appropriately	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
FARXIGA	O
.	O
	
Given	O
these	O
confounders	O
,	O
the	O
relationship	O
between	O
atypical	O
antipsychotic	O
use	O
and	O
hyperglycemia-related	O
adverse	O
events	O
is	O
not	O
completely	O
understood	O
.	O
	
However	O
,	O
some	O
patients	O
may	O
require	O
treatment	O
with	O
FANAPT	O
despite	O
the	O
presence	O
of	O
the	O
syndrome	O
.	O
	
Two	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
had	O
more	O
extensive	O
diagnostic	O
retinal	O
evaluations	O
.	O
	
Anaphylaxis	B
,	O
presenting	O
as	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
in	O
conjunction	O
with	O
urticaria	B
,	O
have	O
been	O
reported	O
to	O
occur	O
during	O
infusions	O
,	O
regardless	O
of	O
duration	O
of	O
the	O
course	O
of	O
treatment	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
LEO	O
Pharma	O
Inc.	O
at	O
1-877-494-4536	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
moderate	O
renal	O
impairment	O
who	O
are	O
taking	O
medications	O
that	O
interfere	O
with	O
potassium	O
excretion	O
,	O
such	O
as	O
potassium-sparing	O
diuretics	O
,	O
or	O
medications	O
that	O
interfere	O
with	O
the	O
renin-angiotensin-aldosterone	O
system	O
are	O
at	O
an	O
increased	O
risk	O
of	O
developing	O
hyperkalemia	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
a	O
pooled	O
analysis	O
of	O
these	O
14	O
controlled	O
clinical	O
trials	O
,	O
the	O
overall	O
incidence	O
of	O
adverse	O
events	O
was	O
66	O
%	O
in	O
patients	O
treated	O
with	O
NESINA	O
25	O
mg	O
compared	O
to	O
62	O
%	O
with	O
placebo	O
and	O
70	O
%	O
with	O
active	O
comparator	O
.	O
	
In	O
a	O
study	O
of	O
4550	O
postmenopausal	O
women	O
with	O
osteoporosis	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
serum	O
calcium	O
level	O
10	O
days	O
after	O
Prolia	O
dosing	O
was	O
-5.5	O
%	O
in	O
subjects	O
with	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
vs.	O
-3.1	O
%	O
in	O
subjects	O
with	O
creatinine	O
clearance	O
>	O
=	O
30	O
mL/min	O
.	O
	
Endocarditis	B
was	O
reported	O
in	O
no	O
placebo	O
patients	O
and	O
3	O
patients	O
receiving	O
Prolia	O
.	O
	
Five	O
of	O
the	O
9	O
SIRTURO	O
deaths	B
and	O
the	O
2	O
placebo	O
deaths	B
were	O
tuberculosis-related	O
.	O
	
5.6	O
Use	O
in	O
Patients	O
with	O
Hepatic	O
Impairment	O
Cabazitaxel	O
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
.	O
	
Some	O
events	O
occurred	O
when	O
TREANDA	O
was	O
given	O
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O
	
Controlled	O
Clinical	O
Studies	O
Common	O
Adverse	O
Reactions	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
patients	O
in	O
the	O
Qutenza	O
group	O
and	O
at	O
an	O
incidence	O
greater	O
than	O
in	O
the	O
control	O
group	O
were	O
application	B
site	I
erythema	I
,	O
application	B
site	I
pain	I
,	O
application	B
site	I
pruritus	I
and	O
application	B
site	I
papules	I
.	O
	
Rare	O
post-marketing	O
cases	O
of	O
hepatosplenic	B
T-cell	I
lymphoma	I
(	O
HSTCL	B
)	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
Boxed	O
Warning	O
.	O
	
If	O
serious	O
and/or	O
immediate	O
hypersensitivity	O
reactions	O
occur	O
further	O
injection	O
of	O
XEOMIN	O
should	O
be	O
discontinued	O
and	O
appropriate	O
medical	O
therapy	O
immediately	O
instituted	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
in	O
SAPHRIS-Treated	O
Patients	O
with	O
Schizophrenia	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
2	O
%	O
or	O
greater	O
,	O
rounded	O
to	O
the	O
nearest	O
percent	O
,	O
and	O
SAPHRIS	O
incidence	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
therapy	O
(	O
up	O
to	O
6-weeks	O
in	O
patients	O
with	O
schizophrenia	O
)	O
are	O
shown	O
in	O
Table	O
8	O
.	O
	
Most	O
patients	O
(	O
75	O
%	O
)	O
enrolled	O
in	O
the	O
cUTI	O
trial	O
were	O
female	O
,	O
and	O
most	O
patients	O
(	O
58	O
%	O
)	O
enrolled	O
in	O
the	O
cIAI	O
trial	O
were	O
male	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormality	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
was	O
hypophosphatemia	B
.	O
	
(	O
5.4	O
)	O
*	O
*	O
Hyperglycemia	B
and	O
diabetes	B
mellitus	I
:	O
Monitor	O
patients	O
for	O
symptoms	O
of	O
hyperglycemia	O
including	O
polydipsia	O
,	O
polyuria	O
,	O
polyphagia	O
,	O
and	O
weakness	O
.	O
	
5.8	O
Concomitant	O
Administration	O
with	O
CYP3A4	O
Inhibitors	O
*	O
Doses	O
of	O
Toviaz	O
greater	O
than	O
4	O
mg	O
are	O
not	O
recommended	O
in	O
patients	O
taking	O
a	O
potent	O
CYP3A4	O
inhibitor	O
(	O
e.g.	O
,	O
ketoconazole	O
,	O
itraconazole	O
,	O
clarithromycin	O
)	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
these	O
patients	O
were	O
similar	O
to	O
infantile-onset	O
Pompe	O
disease	O
patients	O
who	O
received	O
alglucosidase	O
alfa	O
in	O
other	O
clinical	O
trials	O
.	O
	
5.7	O
Intradermal	O
Immune	O
Reaction	O
The	O
possibility	O
of	O
an	O
immune	O
reaction	O
when	O
injected	O
intradermally	O
is	O
unknown	O
.	O
	
12-Month	O
Trials	O
Long-term	O
safety	O
data	O
is	O
based	O
on	O
two	O
12-month	O
trials	O
(	O
Trials	O
3	O
and	O
4	O
;	O
n	O
=	O
1,633	O
and	O
n	O
=	O
1,622	O
,	O
respectively	O
)	O
.	O
	
Within	O
each	O
MedDRA	O
system	O
organ	O
class	O
,	O
the	O
adverse	O
reactions	O
are	O
presented	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O
	
Since	O
all	O
CAPS	O
patients	O
received	O
ILARIS	O
in	O
Part	O
1	O
,	O
there	O
are	O
no	O
controlled	O
data	O
on	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O
	
The	O
safety	O
data	O
described	O
in	O
this	O
section	O
reflect	O
exposure	O
to	O
BLINCYTO	O
in	O
clinical	O
trials	O
in	O
which	O
212	O
patients	O
with	O
relapsed	O
or	O
refractory	O
ALL	O
received	O
up	O
to	O
28	O
mcg/day	O
.	O
	
Before	O
initiating	O
JARDIANCE	O
,	O
assess	O
for	O
volume	O
contraction	O
and	O
correct	O
volume	O
status	O
if	O
indicated	O
.	O
	
Most	O
were	O
Grade	O
1	O
or	O
2	O
events	O
.	O
	
If	O
anaphylactic	O
or	O
other	O
clinically	O
significant	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
Picato	O
(	O
r	O
)	O
immediately	O
and	O
institute	O
appropriate	O
medical	O
therapy	O
.	O
	
(	O
4	O
)	O
Neutropenia	O
:	O
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
Exercise	O
caution	O
in	O
the	O
peri-surgical	O
period	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
Reactions	I
Including	O
Anaphylaxis	B
:	O
Anaphylaxis	B
has	O
occurred	O
in	O
4	O
%	O
of	O
treated	O
patients	O
.	O
	
(	O
5.4	O
)	O
*	O
Other	O
serious	O
infections	B
:	O
increased	O
risk	O
of	O
protozoal	B
infections	I
,	O
including	O
opportunistic	B
infections	I
and	O
tuberculosis	B
.	O
	
One	O
subject	O
out	O
of	O
761	O
administered	O
Vizamyl	O
experienced	O
a	O
serious	O
hypersensitivity	B
reaction	I
with	O
flushing	B
,	O
dyspnea	B
and	O
chest	B
pressure	I
within	O
minutes	O
following	O
Vizamyl	O
administration	O
and	O
recovered	O
with	O
treatment	O
.	O
	
(	O
5.1	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
*	O
Use	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
due	O
to	O
an	O
increased	O
risk	O
of	O
graft	O
loss	O
and	O
death	O
.	O
	
Three	O
subjects	O
on	O
TANZEUM	O
and	O
one	O
subject	O
in	O
the	O
all-comparator	O
group	O
experienced	O
at	O
least	O
one	O
event	O
of	O
ALT	B
increase	I
of	O
10-fold	O
or	O
greater	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
During	O
clinical	O
development	O
1346	O
patients	O
were	O
exposed	O
to	O
AdreView	O
,	O
251	O
patients	O
with	O
known	O
or	O
suspected	O
pheochromocytoma	O
or	O
neuroblastoma	O
,	O
985	O
patients	O
with	O
heart	O
failure	O
,	O
and	O
110	O
control	O
patients	O
.	O
	
A	O
randomized	O
,	O
parallel-arm	O
,	O
open-label	O
clinical	O
trial	O
was	O
conducted	O
in	O
previously	O
untreated	O
CHC	O
subjects	O
with	O
genotype	O
1	O
infection	O
to	O
compare	O
use	O
of	O
an	O
ESA	O
versus	O
ribavirin	O
dose	O
reduction	O
for	O
initial	O
management	O
of	O
anemia	O
during	O
therapy	O
with	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa-2b	O
and	O
ribavirin	O
.	O
	
5.6	O
Pulmonary	O
Toxicity	O
Cases	O
of	O
interstitial	B
lung	I
disease	I
including	O
pneumonitis	B
and	O
pulmonary	B
fibrosis	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
MULTAQ	O
in	O
the	O
post-marketing	O
setting	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Patients	O
were	O
treated	O
with	O
alglucosidase	O
alfa	O
20	O
or	O
40	O
mg/kg	O
every	O
other	O
week	O
for	O
periods	O
ranging	O
from	O
1	O
to	O
106	O
weeks	O
(	O
mean	O
:	O
61	O
weeks	O
)	O
.	O
	
SERIOUS	O
INFECTIONS	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Initiate	O
treatment	O
for	O
latent	O
tuberculosis	O
prior	O
to	O
SIMPONI	O
ARIA	O
use	O
.	O
	
5.7	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
Use	O
of	O
procoagulant	O
reversal	O
agents	O
such	O
as	O
prothrombin	O
complex	O
concentrate	O
,	O
activated	O
prothrombin	O
complex	O
concentrate	O
,	O
or	O
recombinant	O
factor	O
VIIa	O
may	O
be	O
considered	O
but	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
studies	O
.	O
	
Dronedarone	O
caused	O
fetal	B
harm	I
in	O
animal	O
studies	O
at	O
doses	O
equivalent	O
to	O
recommended	O
human	O
doses	O
.	O
	
A	O
causal	O
association	O
with	O
single-agent	O
ADCETRIS	O
has	O
not	O
been	O
established	O
.	O
	
5.5	O
Recrudescence	O
Food	O
enhances	O
absorption	O
of	O
artemether	O
and	O
lumefantrine	O
following	O
administration	O
of	O
Coartem	O
Tablets	O
.	O
	
(	O
5.4	O
)	O
*	O
Immediate	O
hypersensitivity	B
reactions	I
:	O
Discontinue	O
TUDORZA	O
PRESSAIR	O
at	O
once	O
and	O
consider	O
alternatives	O
if	O
immediate	O
hypersensitivity	O
reactions	O
,	O
including	O
angioedema	O
,	O
bronchospasm	O
,	O
or	O
anaphylaxis	O
,	O
occur	O
.	O
	
*	O
After	O
opening	O
the	O
foil	O
pouch	O
the	O
DUAVEE	O
blisters	O
come	O
in	O
,	O
DUAVEE	O
must	O
be	O
used	O
within	O
60	O
days	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
and	O
trametinib	O
for	O
all	O
Grade	O
4	O
hemorrhagic	O
events	O
and	O
for	O
any	O
Grade	O
3	O
hemorrhagic	O
events	O
that	O
do	O
not	O
improve	O
.	O
	
Administer	O
KALBITOR	O
in	O
a	O
setting	O
equipped	O
to	O
manage	O
anaphylaxis	O
and	O
hereditary	O
angioedema	O
.	O
	
The	O
majority	O
of	O
the	O
events	O
were	O
mild	O
to	O
moderate	O
although	O
serious	O
infections	B
were	O
observed	O
.	O
	
5.3	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
DIFICID	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
C.	O
difficile	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
(	O
4	O
)	O
(	O
5.2	O
)	O
*	O
Gastrointestinal	B
disorders	I
:	O
Nausea	B
,	O
vomiting	B
,	O
and	O
diarrhea	B
may	O
occur	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
monitoring	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TANZEUM	O
[	O
see	O
Contraindications	O
(	O
4.1	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
All	O
patients	O
were	O
treated	O
with	O
ILARIS	O
150	O
mg	O
subcutaneously	O
or	O
2	O
mg/kg	O
if	O
body	O
weight	O
was	O
greater	O
than	O
or	O
equal	O
to	O
15	O
kg	O
and	O
less	O
than	O
or	O
equal	O
to	O
40	O
kg	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Aspiration	B
may	O
result	O
from	O
severe	O
dysphagia	B
and	O
is	O
a	O
particular	O
risk	O
when	O
treating	O
patients	O
in	O
whom	O
swallowing	O
or	O
respiratory	O
function	O
is	O
already	O
compromised	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypersensitivity	B
Reactions	I
,	O
including	O
Anaphylaxis	B
:	O
Serious	O
and	O
fatal	B
reactions	O
have	O
been	O
reported	O
.	O
	
These	O
clinical	O
trials	O
excluded	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
a	O
known	O
risk	O
factor	O
for	O
macular	O
edema	O
(	O
see	O
below	O
Macular	O
Edema	O
in	O
Patients	O
with	O
History	O
of	O
Uveitis	O
or	O
Diabetes	O
Mellitus	O
)	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
5.7	O
Renal	O
Impairment	O
Doses	O
of	O
Toviaz	O
greater	O
than	O
4	O
mg	O
are	O
not	O
recommended	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
[	O
see	O
Use	O
In	O
Specific	O
Populations	O
(	O
8.6	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
(	O
all	O
grades	O
)	O
Reported	O
in	O
>	O
=	O
5	O
%	O
of	O
Subjects	O
in	O
Any	O
Treatment	O
Arm	O
in	O
Studies	O
102	O
and	O
103	O
(	O
Week	O
144	O
analysis	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
:	O
fatigue	B
,	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
back	B
pain	I
,	O
pain	B
in	I
extremities	I
,	O
and	O
upper	B
abdominal	I
pain	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Genzyme	O
Corporation	O
at	O
1-800-745-4447	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Extrapyramidal	B
symptoms	I
included	O
:	O
dystonia	B
,	O
blepharospasm	B
,	O
torticollis	B
,	O
dyskinesia	B
,	O
tardive	B
dyskinesia	I
,	O
muscle	B
rigidity	I
,	O
parkinsonism	B
,	O
gait	B
disturbance	I
,	O
masked	B
facies	I
,	O
and	O
tremor	B
(	O
excluding	O
akathisia	B
)	O
.	O
	
There	O
were	O
no	O
drug-related	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
at	O
the	O
rate	O
of	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
.	O
	
None	O
of	O
these	O
6	O
patients	O
had	O
neutralizing	O
antibodies.In	O
a	O
study	O
with	O
ERWINAZE	O
treatment	O
by	O
intravenous	O
administration	O
(	O
Study	O
2	O
)	O
,	O
4	O
of	O
30	O
(	O
13.3	O
%	O
)	O
patients	O
treated	O
with	O
ERWINAZE	O
developed	O
anti-ERWINAZE	O
antibodies	O
.	O
	
Even	O
in	O
the	O
absence	O
of	O
TNF-blocker	O
therapy	O
,	O
patients	O
with	O
rheumatoid	O
arthritis	O
may	O
be	O
at	O
a	O
higher	O
risk	O
(	O
approximately	O
2-fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
leukemia	O
.	O
	
(	O
5.1	O
)	O
*	O
Inhalation	O
of	O
airborne	O
capsaicin	O
can	O
result	O
in	O
coughing	B
or	O
sneezing	B
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
(	O
total	O
bilirubin	O
>	O
3	O
*	O
ULN	O
)	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
At	O
2	O
years	O
,	O
patients	O
randomized	O
to	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
had	O
placebo-corrected	O
declines	B
in	I
BMD	I
at	I
the	I
total	I
hip	I
of	O
0.3	O
%	O
and	O
0.7	O
%	O
,	O
respectively	O
.	O
	
In	O
a	O
52-week	O
,	O
double-blind	O
,	O
comparator-controlled	O
trial	O
that	O
included	O
primarily	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
decrease	O
from	O
baseline	O
of	O
total	O
cholesterol	O
was	O
6	O
mg/dL	O
and	O
the	O
mean	O
decrease	O
from	O
baseline	O
of	O
fasting	O
triglycerides	O
was	O
9.8	O
mg/dL	O
.	O
	
Six	O
percent	O
of	O
patients	O
receiving	O
IMBRUVICA	O
in	O
the	O
WM	O
trial	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
events	O
.	O
	
Before	O
starting	O
FULYZAQ	O
,	O
rule	O
out	O
infectious	O
etiologies	O
of	O
diarrhea	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
One	O
hundred	O
thirty-one	O
patients	O
(	O
median	O
age	O
57	O
years	O
,	O
60	O
%	O
male	O
)	O
received	O
YERVOY	O
as	O
a	O
single	O
agent	O
,	O
380	O
patients	O
(	O
median	O
age	O
56	O
years	O
,	O
61	O
%	O
male	O
)	O
received	O
YERVOY	O
with	O
an	O
investigational	O
gp100	O
peptide	O
vaccine	O
(	O
gp100	O
)	O
,	O
and	O
132	O
patients	O
(	O
median	O
age	O
57	O
years	O
,	O
54	O
%	O
male	O
)	O
received	O
gp100	O
peptide	O
vaccine	O
alone	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Drug	B
reaction	I
with	I
eosinophilia	I
and	I
systemic	I
symptoms	I
(	O
DRESS	B
syndrome	I
)	O
6.3	O
Immunogenicity	O
In	O
clinical	O
studies	O
,	O
1.1	O
%	O
of	O
1024	O
evaluable	O
patients	O
tested	O
positive	O
for	O
binding	O
antibodies	O
against	O
ipilimumab	O
in	O
an	O
electrochemiluminescent	O
(	O
ECL	O
)	O
based	O
assay	O
.	O
	
There	O
were	O
no	O
differences	O
in	O
the	O
occurrence	O
of	O
3+	O
proteinuria	B
(	O
<	O
4	O
%	O
in	O
both	O
studies	O
)	O
at	O
any	O
time	O
point	O
,	O
and	O
no	O
patients	O
experienced	O
4+	O
proteinuria	B
.	O
	
5.16	O
Hypokalemia	O
and	O
Hyperglycemia	O
Beta-adrenergic	O
agonist	O
medicines	O
may	O
produce	O
significant	O
hypokalemia	B
in	O
some	O
patients	O
,	O
possibly	O
through	O
intracellular	O
shunting	O
,	O
which	O
has	O
the	O
potential	O
to	O
produce	O
adverse	O
cardiovascular	O
effects	O
.	O
	
Table	O
1	O
summarizes	O
the	O
reactions	O
reported	O
at	O
a	O
rate	O
of	O
at	O
least	O
3	O
%	O
in	O
patients	O
treated	O
with	O
CIMZIA	O
200	O
mg	O
every	O
other	O
week	O
compared	O
to	O
placebo	O
(	O
saline	O
formulation	O
)	O
,	O
given	O
concomitantly	O
with	O
methotrexate	O
.	O
	
(	O
5.3	O
)	O
*	O
Effects	B
on	I
Ability	I
to	I
Drive	I
:	O
Advise	O
patients	O
to	O
refrain	O
from	O
driving	O
and	O
engaging	O
in	O
hazardous	O
occupations	O
or	O
activities	O
such	O
as	O
operating	O
heavy	O
or	O
potentially	O
dangerous	O
machinery	O
while	O
BLINCYTO	O
is	O
being	O
administered	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
perforation	O
or	O
for	O
fistula	O
formation	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Injection	O
of	O
XIAFLEX	O
into	O
ligaments	B
of	I
the	I
hand	I
may	I
result	I
in	I
damage	I
to	O
those	O
structures	O
and	O
possible	O
permanent	B
injury	I
such	O
as	O
tendon	B
rupture	I
or	O
ligament	B
damage	I
.	O
	
Rapid	O
titration	O
at	O
greater	O
than	O
the	O
recommended	O
doses	O
appeared	O
to	O
increase	O
the	O
risk	O
of	O
psychosis	B
and	O
hallucinations	B
.	O
	
Interrupt	O
Ferriprox	O
therapy	O
if	O
neutropenia	O
develops	O
.	O
	
Monitor	O
electrocardiograms	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
those	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
.	O
	
Monitor	O
hepatic	O
function	O
prior	O
to	O
and	O
during	O
treatment	O
.	O
	
The	O
clinical	O
significance	O
of	O
the	O
lower	O
mean	O
triglyceride	O
values	O
in	O
NULOJIX-treated	O
patients	O
at	O
one	O
and	O
three	O
years	O
is	O
unknown	O
.	O
	
*	O
Hepatic	B
Decompensation	I
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Thromboembolic	B
Complications	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Cataracts	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
In	O
adult	O
patients	O
with	O
ITP	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
:	O
nausea	B
,	O
diarrhea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
vomiting	B
,	O
increased	B
ALT	I
,	O
myalgia	B
,	O
and	O
urinary	B
tract	I
infection	I
.	O
	
Table	O
3	O
shows	O
adverse	O
reactions	O
on	O
the	O
ZYTIGA	O
arm	O
in	O
Study	O
2	O
that	O
occurred	O
with	O
a	O
>	O
=2	O
%	O
absolute	O
increase	O
in	O
frequency	O
compared	O
to	O
placebo	O
.	O
	
In	O
Study	O
1	O
,	O
patients	O
were	O
randomized	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
HALAVEN	O
(	O
1.4	O
mg/m	O
2	O
on	O
Days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
)	O
or	O
single	O
agent	O
treatment	O
chosen	O
by	O
their	O
physician	O
(	O
control	O
group	O
)	O
.	O
	
Emergency	O
resuscitation	O
equipment	O
and	O
personnel	O
should	O
be	O
immediately	O
available	O
.	O
	
Table	O
2	O
shows	O
treatment-emergent	O
adverse	O
reactions	O
and	O
the	O
category	O
of	O
``	O
any	O
common	O
adverse	O
event	O
''	O
in	O
ESCAPE-1	O
and	O
ESCAPE-2	O
where	O
the	O
rate	O
on	O
Cleviprex	O
exceeded	O
the	O
rate	O
on	O
placebo	O
by	O
at	O
least	O
5	O
%	O
(	O
common	O
adverse	O
reactions	O
)	O
.	O
	
Figure	O
1	O
Adjudicated	O
Major	O
Bleeding	B
by	O
Baseline	O
Characteristics	O
Including	O
Hemorrhagic	O
Stroke	O
Treated	O
Patients	O
Note	O
:	O
The	O
figure	O
above	O
presents	O
effects	O
in	O
various	O
subgroups	O
all	O
of	O
which	O
are	O
baseline	O
characteristics	O
and	O
all	O
of	O
which	O
were	O
pre-specified	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
YERVOY	O
was	O
discontinued	O
for	O
adverse	O
reactions	O
in	O
10	O
%	O
of	O
patients	O
.	O
	
One	O
case	O
of	O
MTC	B
was	O
reported	O
in	O
a	O
patient	O
treated	O
with	O
TRULICITY	O
.	O
	
Monitor	O
clinically	O
and	O
discontinue	O
drug	O
for	O
severe	O
reactions	O
.	O
	
Three	O
active-controlled	O
trials	O
of	O
52	O
weeks	O
in	O
duration	O
were	O
conducted	O
in	O
patients	O
treated	O
with	O
pioglitazone	O
and	O
metformin	O
,	O
in	O
combination	O
with	O
metformin	O
and	O
as	O
monotherapy	O
compared	O
to	O
glipizide	O
.	O
	
Women	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
when	O
receiving	O
TREANDA	O
.	O
	
In	O
Phase	O
2	O
and	O
3	O
placebo-controlled	O
trials	O
combined	O
,	O
the	O
incidences	O
of	O
serious	O
adverse	O
events	O
in	O
patients	O
receiving	O
placebo	O
,	O
Toviaz	O
4	O
mg	O
,	O
and	O
Toviaz	O
8	O
mg	O
were	O
1.9	O
%	O
,	O
3.5	O
%	O
,	O
and	O
2.9	O
%	O
,	O
respectively	O
.	O
	
Hospitalizations	O
due	O
to	O
serious	O
infections	B
in	I
the	I
abdomen	I
(	O
0.0	O
%	O
placebo	O
vs.	O
0.1	O
%	O
Prolia	O
)	O
were	O
reported	O
.	O
	
Adverse	O
reactions	O
are	O
events	O
that	O
occurred	O
after	O
the	O
first	O
dose	O
of	O
study	O
medication	O
treatment	O
and	O
within	O
7	O
days	O
of	O
the	O
last	O
dose	O
of	O
study	O
medication	O
or	O
events	O
present	O
at	O
baseline	O
that	O
increased	O
in	O
severity	O
after	O
the	O
start	O
of	O
study	O
medication	O
treatment	O
.	O
	
In	O
females	B
,	I
discontinuation	I
due	I
to	I
genital	I
mycotic	I
infections	I
occurred	O
in	O
0	O
%	O
and	O
0.7	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
and	O
INVOKANA	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Whether	O
antipsychotic	O
drug	O
products	O
differ	O
in	O
their	O
potential	O
to	O
cause	O
Tardive	B
Dyskinesia	I
(	O
TD	B
)	O
is	O
unknown	O
.	O
	
Patients	O
>	O
=	O
65	O
years	O
of	O
age	O
are	O
more	O
likely	O
to	O
experience	O
certain	O
adverse	O
reactions	O
,	O
including	O
neutropenia	B
and	O
febrile	B
neutropenia	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Imatinib-Resistant	O
or	O
-Intolerant	O
Ph+	O
Chronic	O
Phase	O
(	O
CP	O
)	O
,	O
Accelerated	O
Phase	O
(	O
AP	O
)	O
,	O
and	O
Blast	O
Phase	O
(	O
BP	O
)	O
CML	O
The	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
(	O
Study	O
1	O
)	O
enrolled	O
patients	O
with	O
Ph+	O
chronic	O
,	O
accelerated	O
,	O
or	O
blast	O
phase	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
and	O
with	O
resistance	O
or	O
intolerance	O
to	O
prior	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Of	O
the	O
255	O
patients	O
,	O
66	O
%	O
of	O
patients	O
were	O
female	O
and	O
86	O
%	O
were	O
Caucasian	O
.	O
	
5.4	O
Dysphagia	O
and	O
Breathing	O
Difficulties	O
in	O
Treatment	O
of	O
Cervical	O
Dystonia	O
Treatment	O
with	O
XEOMIN	O
and	O
other	O
botulinum	O
toxin	O
products	O
can	O
result	O
in	O
breathing	B
difficulties	I
.	O
	
Aspiration	B
may	O
result	O
from	O
severe	O
dysphagia	B
and	O
is	O
a	O
particular	O
risk	O
when	O
treating	O
patients	O
in	O
whom	O
swallowing	O
or	O
respiratory	O
function	O
is	O
already	O
compromised	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=20	O
%	O
)	O
adverse	O
reactions	O
observed	O
following	O
treatment	O
with	O
INLYTA	O
were	O
diarrhea	B
,	O
hypertension	B
,	O
fatigue	B
,	O
decreased	B
appetite	I
,	O
nausea	B
,	O
dysphonia	B
,	O
hand-foot	B
)	I
syndrome	I
,	O
weight	B
decreased	I
,	O
vomiting	B
,	O
asthenia	B
,	O
and	O
constipation	B
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=2	O
%	O
of	O
Patients	O
on	O
OTEZLA	O
30	O
mg	O
Twice	O
Daily	O
and	O
>	O
=1	O
%	O
Than	O
That	O
Observed	O
in	O
Patients	O
on	O
Placebo	O
for	O
up	O
to	O
Day	O
112	O
(	O
Week	O
16	O
)	O
a	O
Of	O
the	O
reported	O
gastrointestinal	B
adverse	I
reactions	I
,	O
1	O
subject	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
nausea	B
and	O
vomiting	B
in	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
;	O
1	O
subject	O
treated	O
with	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
diarrhea	B
;	O
1	O
patient	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
headache	B
.	O
	
Monitor	O
serum	O
potassium	O
and	O
magnesium	O
in	O
patients	O
at	O
risk	O
for	O
electrolyte	O
disturbances	O
.	O
	
The	O
rate	O
of	O
adverse	O
reactions	O
resulting	O
in	O
permanent	O
discontinuation	O
was	O
3.8	O
%	O
in	O
the	O
AFINITOR-treated	O
patients	O
.	O
	
Three	O
patients	O
with	O
anti-belimumab	O
antibodies	O
experienced	O
mild	O
infusion	B
reactions	I
of	O
nausea	B
,	O
erythematous	B
rash	I
,	O
pruritus	B
,	O
eyelid	B
edema	I
,	O
headache	B
,	O
and	O
dyspnea	B
;	O
none	O
of	O
the	O
reactions	O
was	O
life-threatening	O
.	O
	
In	O
Study	O
1	O
,	O
diarrhea	B
occurred	O
in	O
96	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
(	O
n=229	O
)	O
,	O
of	O
which	O
15	O
%	O
was	O
Grade	O
3	O
in	O
severity	O
and	O
occurred	O
within	O
the	O
first	O
6	O
weeks	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Trial	O
2	O
was	O
a	O
12-week	O
trial	O
that	O
evaluated	O
the	O
efficacy	O
of	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
and	O
fluticasone	O
furoate	O
100	O
mcg	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
.	O
	
In	O
Study	O
1	O
,	O
liver	B
test	I
abnormalities	I
of	O
any	O
grade	O
occurred	O
in	O
17.5	O
%	O
of	O
the	O
patients	O
treated	O
with	O
GILOTRIF	O
.	O
	
All	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
BLINCYTO	O
.	O
	
(	O
5.1	O
)	O
*	O
Impairment	B
in	I
renal	I
function	I
:	O
Monitor	O
renal	O
function	O
during	O
therapy	O
.	O
	
One	O
(	O
n=106	O
)	O
or	O
2	O
(	O
n=	O
30	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
administered	O
intravenously	O
;	O
the	O
number	O
of	O
doses	O
was	O
not	O
specified	O
in	O
13	O
patients	O
.	O
	
Most	O
subjects	O
(	O
530	O
,	O
70	O
%	O
)	O
received	O
a	O
dose	O
of	O
185	O
MBq	O
(	O
5	O
mCi	O
)	O
.	O
	
Avoid	O
prolonged	O
exposure	O
to	O
UV	O
light	O
and	O
sunlight	O
.	O
	
Avoid	O
accidental	O
transfer	O
of	O
the	O
drug	O
into	O
the	O
eyes	O
and	O
to	O
the	O
periocular	O
area	O
.	O
	
5.4	O
Worsening	O
of	O
Urinary	O
Retention	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
urinary	O
retention	O
.	O
	
Patients	O
with	O
low	O
albumin	O
levels	O
(	O
less	O
than	O
3.5	O
g/dL	O
)	O
or	O
Model	O
for	O
End-Stage	O
Liver	O
Disease	O
(	O
MELD	O
)	O
score	O
greater	O
than	O
or	O
equal	O
to	O
10	O
at	O
baseline	O
had	O
a	O
greater	O
risk	O
for	O
hepatic	B
decompensation	I
on	O
the	O
arm	O
receiving	O
treatment	O
with	O
PROMACTA	O
plus	O
antivirals	O
.	O
	
Hepatobiliary	O
Disorders	O
:	O
cholelithiasis/cholecystitis	O
,	O
hepatic	B
steatosis	I
,	O
hepatitis	B
,	O
hepatomegaly	B
.	O
	
The	O
average	O
age	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
in	O
the	O
NULOJIX	O
recommended	O
dose	O
and	O
cyclosporine	O
control	O
regimens	O
was	O
49	O
years	O
,	O
ranging	O
from	O
18	O
to	O
79	O
years	O
.	O
	
All	O
patients	O
were	O
monitored	O
for	O
adverse	O
reactions	O
over	O
a	O
24	O
hour	O
period	O
following	O
AdreView	O
administration	O
.	O
	
41.1	O
%	O
were	O
current	O
or	O
previous	O
smokers	O
.	O
	
Should	O
a	O
stroke	O
occur	O
or	O
be	O
suspected	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
immediately	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
.	O
	
The	O
elevation	O
has	O
a	O
rapid	O
onset	O
,	O
reaches	O
a	O
plateau	O
after	O
7	O
days	O
and	O
is	O
reversible	O
after	O
discontinuation	O
.	O
	
Patients	O
with	O
histoplasmosis	O
or	O
other	O
invasive	O
fungal	O
infections	O
may	O
present	O
with	O
disseminated	O
,	O
rather	O
than	O
localized	O
,	O
disease	O
.	O
	
The	O
mechanism	O
and	O
long-term	O
consequences	O
of	O
these	O
events	O
are	O
currently	O
unknown	O
.	O
	
Protamine	O
sulfate	O
and	O
vitamin	O
K	O
are	O
not	O
expected	O
to	O
affect	O
the	O
anticoagulant	O
activity	O
of	O
apixaban	O
.	O
	
The	O
use	O
of	O
SAPHRIS	O
should	O
be	O
avoided	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
prolong	O
QTc	O
including	O
Class	O
1A	O
antiarrhythmics	O
(	O
e.g.	O
,	O
quinidine	O
,	O
procainamide	O
)	O
or	O
Class	O
3	O
antiarrhythmics	O
(	O
e.g.	O
,	O
amiodarone	O
,	O
sotalol	O
)	O
,	O
antipsychotic	O
medications	O
(	O
e.g.	O
,	O
ziprasidone	O
,	O
chlorpromazine	O
,	O
thioridazine	O
)	O
,	O
and	O
antibiotics	O
(	O
e.g.	O
,	O
gatifloxacin	O
,	O
moxifloxacin	O
)	O
.	O
	
Cataracts	B
were	O
observed	O
in	O
toxicology	O
studies	O
of	O
eltrombopag	O
in	O
rodents	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
,	O
including	O
histoplasmosis	B
,	O
coccidioidomycosis	B
,	O
candidiasis	B
,	O
aspergillosis	B
,	O
blastomycosis	B
and	O
pneumocystosis	B
.	O
	
5.3	O
Thromboembolic	O
Events	O
There	O
is	O
a	O
potential	O
risk	O
of	O
arterial	B
thromboembolic	I
events	I
(	O
ATEs	B
)	O
following	O
intravitreal	O
use	O
of	O
VEGF	O
inhibitors	O
,	O
including	O
EYLEA	O
.	O
	
CNS	B
PTLD	I
,	O
PML	B
,	O
and	O
other	O
CNS	B
infections	I
were	O
more	O
frequently	O
observed	O
in	O
association	O
with	O
a	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
compared	O
to	O
the	O
recommended	O
regimen	O
;	O
therefore	O
,	O
administration	O
of	O
higher	O
than	O
the	O
recommended	O
doses	O
and/or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
is	O
not	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
In	O
Study	O
3	O
,	O
pulmonary	B
toxicity	I
was	O
reported	O
in	O
8	O
patients	O
(	O
5	O
%	O
)	O
in	O
the	O
ADCETRIS-treated	O
arm	O
and	O
5	O
patients	O
(	O
3	O
%	O
)	O
in	O
the	O
placebo	O
arm	O
.	O
	
5.6	O
Hepatic	O
and	O
Renal	O
Impairment	O
Coartem	O
Tablets	O
have	O
not	O
been	O
studied	O
for	O
efficacy	O
and	O
safety	O
in	O
patients	O
with	O
severe	O
hepatic	O
and/or	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
]	O
.	O
	
In	O
the	O
Phase	O
3	O
randomized	O
controlled	O
studies	O
,	O
the	O
incidences	O
of	O
adjudicated	O
APTC	O
events	O
per	O
100	O
patient-years	O
of	O
exposure	O
were	O
:	O
Placebo	O
0	O
(	O
95	O
%	O
CI	O
0.00-6.16	O
)	O
,	O
ULORIC	O
40	O
mg	O
0	O
(	O
95	O
%	O
CI	O
0.00-1.08	O
)	O
,	O
ULORIC	O
80	O
mg	O
1.09	O
(	O
95	O
%	O
CI	O
0.44-2.24	O
)	O
,	O
and	O
allopurinol	O
0.60	O
(	O
95	O
%	O
CI	O
0.16-1.53	O
)	O
.	O
	
Two	O
percent	O
demonstrated	O
a	O
decrease	B
in	I
LVEF	I
below	O
institutional	O
lower	O
limits	O
of	O
normal	O
with	O
an	O
absolute	B
decrease	I
in	I
LVEF	I
of	O
>	O
=20	O
%	O
below	O
baseline	O
.	O
	
Consider	O
appropriate	O
empiric	O
antifungal	O
therapy	O
and	O
take	O
into	O
account	O
both	O
the	O
risk	O
for	O
severe	O
fungal	O
infection	O
and	O
the	O
risks	O
of	O
antifungal	O
therapy	O
while	O
a	O
diagnostic	O
workup	O
is	O
being	O
performed	O
.	O
	
If	O
accidental	O
exposure	O
occurs	O
,	O
flush	O
eyes	O
with	O
water	O
and	O
seek	O
medical	O
care	O
.	O
	
The	O
Study	O
1	O
population	O
enrolled	O
patients	O
with	O
a	O
median	O
age	O
of	O
18	O
years	O
(	O
1	O
month	O
to	O
85	O
years	O
)	O
;	O
63	O
%	O
were	O
male	O
,	O
and	O
the	O
underlying	O
malignancies	O
were	O
osteosarcoma/sarcomas	O
in	O
32	O
%	O
,	O
and	O
leukemia	O
or	O
lymphoma	O
in	O
63	O
%	O
of	O
patients	O
.	O
	
Consider	O
anti-tuberculosis	O
therapy	O
prior	O
to	O
initiation	O
of	O
SIMPONI	O
ARIA	O
in	O
patients	O
with	O
a	O
past	O
history	O
of	O
latent	O
or	O
active	O
tuberculosis	O
in	O
whom	O
an	O
adequate	O
course	O
of	O
treatment	O
can	O
not	O
be	O
confirmed	O
,	O
and	O
for	O
patients	O
with	O
a	O
negative	O
test	O
for	O
latent	O
tuberculosis	O
but	O
having	O
risk	O
factors	O
for	O
tuberculosis	O
infection	O
.	O
	
In	O
clinical	O
trials	O
,	O
761	O
adults	O
(	O
367	O
men	O
and	O
394	O
women	O
,	O
91	O
%	O
Caucasian	O
)	O
with	O
a	O
mean	O
age	O
of	O
62	O
years	O
(	O
range	O
18-93	O
years	O
)	O
received	O
Vizamyl	O
.	O
	
Among	O
the	O
290	O
patients	O
included	O
in	O
the	O
safety	O
evaluation	O
of	O
VORAXAZE	O
,	O
there	O
were	O
8	O
deaths	B
within	O
30	O
days	O
of	O
VORAXAZE	O
exposure	O
that	O
were	O
not	O
related	O
to	O
progressive	O
disease	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
*	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
,	O
but	O
other	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
caused	O
thyroid	B
C-cell	I
tumors	I
in	O
rodents	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
If	O
Grade	O
3	O
or	O
4	O
neutropenia	O
develops	O
,	O
consider	O
dose	O
delays	O
,	O
reductions	O
,	O
discontinuation	O
,	O
or	O
G-CSF	O
prophylaxis	O
with	O
subsequent	O
doses	O
(	O
5.3	O
)	O
.	O
	
In	O
clinical	O
trials	O
with	O
NULOJIX	O
,	O
two	O
cases	O
of	O
PML	B
were	O
reported	O
in	O
patients	O
receiving	O
NULOJIX	O
at	O
higher	O
cumulative	O
doses	O
and	O
more	O
frequently	O
than	O
the	O
recommended	O
regimen	O
,	O
along	O
with	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
and	O
corticosteroids	O
;	O
one	O
case	O
occurred	O
in	O
a	O
kidney	O
transplant	O
recipient	O
and	O
the	O
second	O
case	O
occurred	O
in	O
a	O
liver	O
transplant	O
recipient	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
A	O
theoretical	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
is	O
also	O
considered	O
extremely	O
remote	O
.	O
	
They	O
had	O
a	O
mean	O
age	O
of	O
64	O
years	O
and	O
an	O
average	O
smoking	O
history	O
of	O
46	O
pack-years	O
,	O
with	O
44	O
%	O
identified	O
as	O
current	O
smokers	O
.	O
	
Discontinue	O
TIVICAY	O
and	O
other	O
suspect	O
agents	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
develop	O
,	O
as	O
a	O
delay	O
in	O
stopping	O
treatment	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
Neutralizing	O
antibodies	O
were	O
detected	O
in	O
3	O
patients	O
receiving	O
BENLYSTA	O
1	O
mg/kg	O
.	O
	
In	O
Virologically-Suppressed	O
HIV-1-Infected	O
Subjects	O
No	O
new	O
adverse	O
reactions	O
to	O
STRIBILD	O
through	O
Week	O
48	O
were	O
identified	O
in	O
584	O
virologically	O
stably	O
suppressed	O
subjects	O
switching	O
to	O
STRIBILD	O
from	O
a	O
regimen	O
containing	O
a	O
RTV-boosted	O
protease	O
inhibitor	O
(	O
PI	O
)	O
or	O
a	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NNRTI	O
)	O
.	O
	
The	O
mean	O
age	O
of	O
treated	O
patients	O
was	O
48	O
to	O
50	O
years	O
(	O
range	O
18	O
to	O
92	O
years	O
)	O
,	O
across	O
treatment	O
arms	O
and	O
indications	O
.	O
	
This	O
included	O
783	O
patients	O
who	O
received	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
2-year	O
placebo-controlled	O
trials	O
(	O
Studies	O
1	O
and	O
3	O
)	O
and	O
429	O
patients	O
who	O
received	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
1	O
year	O
active-controlled	O
trial	O
(	O
Study	O
2	O
)	O
.	O
	
Treatment	O
of	O
cervical	O
dystonia	O
with	O
botulinum	O
toxins	O
may	O
weaken	B
neck	I
muscles	I
that	O
serve	O
as	O
accessory	O
muscles	O
of	O
ventilation	O
.	O
	
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
Gadavist	O
were	O
usually	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
.	O
	
All	O
serious	O
adverse	O
events	O
were	O
judged	O
to	O
be	O
not	O
related	O
or	O
unlikely	O
to	O
be	O
related	O
to	O
study	O
medication	O
by	O
the	O
investigator	O
,	O
except	O
for	O
four	O
patients	O
receiving	O
Toviaz	O
who	O
reported	O
one	O
serious	O
adverse	O
event	O
each	O
:	O
angina	B
,	O
chest	B
pain	I
,	O
gastroenteritis	B
,	O
and	O
QT	B
prolongation	I
on	O
ECG	O
.	O
	
However	O
,	O
the	O
incidence	O
of	O
nonfatal	O
serious	O
infections	B
was	O
3.3	O
%	O
in	O
the	O
placebo	O
and	O
4.0	O
%	O
in	O
the	O
Prolia	O
groups	O
.	O
	
More	O
frequent	O
renal	O
function	O
monitoring	O
is	O
recommended	O
in	O
patients	O
with	O
an	O
eGFR	O
below	O
60	O
mL/min/1.73	O
m	O
2	O
.	O
	
In	O
rare	O
instances	O
severe	O
anaphylactoid	B
reactions	I
have	O
occurred	O
,	O
particularly	O
in	O
the	O
second	O
and	O
subsequent	O
cycles	O
of	O
therapy	O
.	O
	
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
in	O
an	O
open	O
label	O
clinical	O
trial	O
(	O
Study	O
1	O
)	O
that	O
included	O
48	O
patients	O
with	O
previously	O
treated	O
CLL	O
and	O
a	O
randomized	O
clinical	O
trial	O
(	O
Study	O
2	O
)	O
that	O
included	O
391	O
randomized	O
patients	O
with	O
previously	O
treated	O
CLL	O
or	O
SLL	O
.	O
	
Adverse	O
Reactions	O
Based	O
on	O
Gender	O
and	O
Race	O
No	O
significant	O
gender	O
differences	O
were	O
noted	O
in	O
the	O
incidence	O
of	O
adverse	O
reactions	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
6	O
years	O
,	O
had	O
a	O
mean	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
of	O
8.3	O
%	O
,	O
and	O
21	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
Inc.	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Because	O
trough	O
levels	O
of	O
ipilimumab	O
interfere	O
with	O
the	O
ECL	O
assay	O
results	O
,	O
a	O
subset	O
analysis	O
was	O
performed	O
in	O
the	O
dose	O
cohort	O
with	O
the	O
lowest	O
trough	O
levels	O
.	O
	
Monitor	O
patients	O
receiving	O
BLINCYTO	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
toxicities	O
,	O
and	O
interrupt	O
or	O
discontinue	O
BLINCYTO	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
PR	O
Interval	O
Prolongation	O
and	O
Adverse	O
Reactions	O
of	O
First	O
Degree	O
Atrioventricular	O
(	O
AV	O
)	O
Block	O
A	O
mean	O
increase	B
from	I
baseline	I
in	I
PR	I
interval	I
of	O
2-3	O
milliseconds	O
was	O
observed	O
in	O
TRULICITY-treated	O
patients	O
in	O
contrast	O
to	O
a	O
mean	O
decrease	O
of	O
0.9	O
millisecond	O
in	O
placebo-treated	O
patients	O
.	O
	
Urinary	B
retention	I
was	O
generally	O
reported	O
within	O
the	O
first	O
6	O
months	O
of	O
treatment	O
,	O
but	O
was	O
also	O
observed	O
later	O
.	O
	
5.12	O
Embryo-Fetal	O
Toxicity	O
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
ADCETRIS	O
in	O
pregnant	O
women	O
.	O
	
Consequently	O
,	O
to	O
provide	O
a	O
meaningful	O
estimate	O
of	O
the	O
proportion	O
of	O
individuals	O
experiencing	O
adverse	O
reactions	O
,	O
reactions	O
were	O
grouped	O
in	O
standardized	O
categories	O
using	O
MedDRA	O
terminology	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
AGRANULOCYTOSIS	B
/NEUTROPENIA	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
the	O
RE-LY	O
study	O
,	O
drug	O
hypersensitivity	B
(	O
including	O
urticaria	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
,	O
allergic	B
edema	I
,	O
anaphylactic	B
reaction	I
,	O
and	O
anaphylactic	B
shock	I
were	O
reported	O
in	O
<	O
0.1	O
%	O
of	O
patients	O
receiving	O
PRADAXA	O
.	O
	
*	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
myopathy	B
,	O
including	O
rhabdomyolysis	B
.	O
	
Significantly	O
elevated	O
serum	O
calcitonin	O
value	O
may	O
indicate	O
MTC	O
and	O
patients	O
with	O
MTC	O
usually	O
have	O
calcitonin	O
values	O
>	O
50	O
ng/L	O
.	O
	
A	O
total	O
of	O
503	O
patients	O
received	O
HALAVEN	O
,	O
and	O
247	O
patients	O
in	O
the	O
control	O
group	O
received	O
therapy	O
consisting	O
of	O
chemotherapy	O
[	O
total	O
97	O
%	O
(	O
anthracyclines	O
10	O
%	O
,	O
capecitabine	O
18	O
%	O
,	O
gemcitabine	O
19	O
%	O
,	O
taxanes	O
15	O
%	O
,	O
vinorelbine	O
25	O
%	O
,	O
other	O
chemotherapies	O
10	O
%	O
)	O
]	O
or	O
hormonal	O
therapy	O
(	O
3	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
(	O
>	O
=	O
25	O
%	O
)	O
in	O
the	O
XIAFLEX	O
clinical	O
trials	O
in	O
patients	O
with	O
Peyronie	O
's	O
disease	O
were	O
penile	B
hematoma	I
,	O
penile	B
swelling	I
,	O
and	O
penile	B
pain	I
.	O
	
HALAVEN	O
is	O
a	O
microtubule	O
inhibitor	O
;	O
therefore	O
,	O
it	O
is	O
expected	O
to	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
When	O
liver	O
function	O
tests	O
show	O
sustained	O
improvement	O
or	O
return	O
to	O
baseline	O
,	O
initiate	O
corticosteroid	O
tapering	O
and	O
continue	O
to	O
taper	O
over	O
1	O
month	O
.	O
	
Table	O
5	O
Bleeding	B
Events	O
in	O
RE-SONATE	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
Advise	O
the	O
patient	O
to	O
rinse	O
his/her	O
mouth	O
with	O
water	O
without	O
swallowing	O
following	O
inhalation	O
to	O
help	O
reduce	O
the	O
risk	O
of	O
oropharyngeal	O
candidiasis	O
.	O
	
Three	O
percent	O
(	O
3	O
%	O
)	O
of	O
255	O
patients	O
experienced	O
a	O
QTc	B
interval	I
increase	I
over	O
baseline	O
greater	O
than	O
60	O
msec	O
in	O
Study	O
1	O
.	O
	
(	O
5.1	O
)	O
*	O
Ferriprox	O
can	O
cause	O
fetal	B
harm	I
.	O
	
(	O
5.6	O
)	O
*	O
Neutropenia	B
:	O
monitor	O
blood	O
counts	O
.	O
	
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
in	O
at	O
least	O
2	O
%	O
of	O
pediatric	O
subjects	O
were	O
rash	B
and	O
diarrhea	B
.	O
	
In	O
the	O
non-Hodgkin	O
's	O
lymphoma	O
study	O
,	O
52	O
%	O
of	O
patients	O
were	O
male	O
,	O
the	O
median	O
age	O
was	O
55	O
years	O
,	O
and	O
88	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
Renal	O
function	O
should	O
be	O
evaluated	O
prior	O
to	O
initiation	O
of	O
FARXIGA	O
and	O
monitored	O
periodically	O
thereafter	O
.	O
	
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
:	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
PRADAXA	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
Non-GI	B
fistulas	I
were	O
reported	O
in	O
4	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
These	O
changes	O
were	O
not	O
associated	O
with	O
other	O
abnormal	B
thyroid	I
function	I
tests	O
suggesting	O
hypothyroidism	B
.	O
	
A	O
subset	O
of	O
patients	O
experienced	O
a	O
recurrence	O
of	O
symptoms	O
when	O
restarting	O
the	O
same	O
drug	O
or	O
a	O
different	O
DPP-4	O
inhibitor	O
.	O
	
Anaphylaxis	B
occurred	O
as	O
late	O
into	O
treatment	O
as	O
the	O
47	O
th	O
infusion	O
.	O
	
If	O
ARCAPTA	O
NEOHALER	O
no	O
longer	O
controls	O
the	O
symptoms	O
of	O
bronchoconstriction	O
,	O
or	O
the	O
patient	O
's	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
becomes	O
less	O
effective	O
or	O
the	O
patient	O
needs	O
more	O
inhalation	O
of	O
short-acting	O
beta2-agonist	O
than	O
usual	O
,	O
these	O
may	O
be	O
markers	O
of	O
deterioration	O
of	O
disease	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
11	O
years	O
,	O
had	O
a	O
mean	O
HbA1C	O
of	O
8.0	O
%	O
and	O
33	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
6.1	O
Retrospective	O
Case	O
Series	O
Experience	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
occurring	O
in	O
>	O
=	O
13	O
%	O
of	O
patients	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
are	O
:	O
Infections	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
pyrexia	B
,	O
tonsilitis	B
,	O
anemia	B
,	O
ear	B
infection	I
,	O
diarrhea	B
,	O
nasopharyngitis	B
,	O
and	O
headache	B
.	O
	
Avoid	O
co-administration	O
of	O
strong	O
CYP3A4	O
inducers	O
,	O
such	O
as	O
rifamycins	O
(	O
i.e.	O
,	O
rifampin	O
,	O
rifapentine	O
and	O
rifabutin	O
)	O
,	O
or	O
moderate	O
CYP3A4	O
inducers	O
,	O
such	O
as	O
efavirenz	O
,	O
during	O
treatment	O
with	O
SIRTURO	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Pancreatitis	O
Pancreatitis	B
was	O
reported	O
in	O
1	O
patient	O
(	O
0.8	O
%	O
)	O
in	O
the	O
placebo	O
group	O
and	O
1	O
patient	O
(	O
0.8	O
%	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
The	O
time	O
from	O
product	O
administration	O
to	O
event	O
occurrence	O
was	O
variable	O
.	O
	
Women	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	O
hormone	O
.	O
	
5.8	O
Withdrawal	O
Seizures	O
As	O
with	O
all	O
AEDs	O
,	O
when	O
POTIGA	O
is	O
discontinued	O
,	O
it	O
should	O
be	O
withdrawn	O
gradually	O
when	O
possible	O
to	O
minimize	O
the	O
potential	O
of	O
increased	O
seizure	O
frequency	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
subjects	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
depression	B
(	O
2.5	O
%	O
)	O
,	O
suicidal	B
ideation	I
(	O
2.5	O
%	O
)	O
,	O
bipolar	B
I	I
disorder	I
(	O
1.9	O
%	O
)	O
,	O
insomnia	B
(	O
1.9	O
%	O
)	O
and	O
depressive	B
symptoms	I
(	O
1.3	O
%	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
with	O
Prolia	O
in	O
men	O
with	O
osteoporosis	O
are	O
back	B
pain	I
,	O
arthralgia	B
,	O
and	O
nasopharyngitis	B
.	O
	
3Includes	O
the	O
preferred	O
terms	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
lower	I
,	O
and	O
abdominal	B
discomfort	I
.	O
	
(	O
5.1	O
)	O
*	O
When	O
treating	O
patients	O
with	O
asthma	O
,	O
only	O
prescribe	O
BREO	O
ELLIPTA	O
for	O
patients	O
not	O
adequately	O
controlled	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
ICS	O
,	O
or	O
whose	O
disease	O
severity	O
clearly	O
warrants	O
initiation	O
of	O
treatment	O
with	O
both	O
an	O
ICS	O
and	O
a	O
LABA	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
alglucosidase	O
alfa	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Table	O
8	O
:	O
Percentage	O
of	O
EPS	B
Compared	O
to	O
Placebo	O
Placebo	O
(	O
%	O
)	O
FANAPT	O
10-16	O
mg/day	O
(	O
%	O
)	O
FANAPT	O
20-24	O
mg/day	O
(	O
%	O
)	O
Adverse	O
Event	O
Term	O
(	O
N=587	O
)	O
(	O
N=483	O
)	O
(	O
N=391	O
)	O
All	O
EPS	O
events	O
11.6	O
13.5	O
15.1	O
Akathisia	B
2.7	O
1.7	O
2.3	O
Bradykinesia	B
0	O
0.6	O
0.5	O
Dyskinesia	B
1.5	O
1.7	O
1.0	O
Dystonia	B
0.7	O
1.0	O
0.8	O
Parkinsonism	B
0	O
0.2	O
0.3	O
Tremor	B
1.9	O
2.5	O
3.1	O
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
incidence	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
between	O
FANAPT-treated	O
(	O
5	O
%	O
)	O
and	O
placebo-treated	O
(	O
5	O
%	O
)	O
patients	O
.	O
	
Dizziness	B
led	O
to	O
withdrawal	O
in	O
2	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
3	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
5.7	O
Acute	O
Rejection	O
and	O
Graft	B
Loss	I
with	I
Corticosteroid	I
Minimization	I
occurred	O
in	O
patients	O
with	O
4	O
to	O
6	O
HLA	O
mismatches	O
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
with	O
drug	O
exposure	O
.	O
	
Several	O
patients	O
discontinued	O
GILENYA	O
because	O
of	O
unexplained	O
dyspnea	B
during	O
the	O
extension	O
(	O
uncontrolled	O
)	O
studies	O
.	O
	
In	O
the	O
combined	O
clinical	O
trial	O
experience	O
with	O
all	O
doses	O
of	O
fingolimod	O
,	O
the	O
rate	O
of	O
macular	B
edema	I
was	O
approximately	O
20	O
%	O
in	O
MS	O
patients	O
with	O
a	O
history	O
of	O
uveitis	O
versus	O
0.6	O
%	O
in	O
those	O
without	O
a	O
history	O
of	O
uveitis	O
.	O
	
Isolated	O
cases	O
of	O
aspergillosis	B
,	O
herpes	B
zoster	I
)	O
were	O
reported	O
during	O
ILARIS	O
treatment	O
.	O
	
Because	O
GILENYA	O
exposure	O
is	O
doubled	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
,	O
these	O
patients	O
should	O
be	O
closely	O
monitored	O
,	O
as	O
the	O
risk	O
of	O
adverse	O
reactions	O
is	O
greater	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Currently	O
available	O
data	O
are	O
inadequate	O
to	O
determine	O
whether	O
concurrent	O
use	O
of	O
inhaled	O
corticosteroids	O
or	O
other	O
long-term	O
asthma	O
control	O
drugs	O
mitigates	O
the	O
increased	O
risk	O
of	O
asthma-related	O
death	B
from	O
LABA	O
.	O
	
Rates	O
of	O
seroconversion	O
increased	O
with	O
exposure	O
to	O
KALBITOR	O
over	O
time	O
.	O
	
Specifically	O
,	O
nocturia	B
was	O
reported	O
by	O
0.4	O
%	O
,	O
0.3	O
%	O
,	O
and	O
0.8	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
MULTAQ	O
should	O
only	O
be	O
initiated	O
in	O
patients	O
in	O
sinus	O
rhythm	O
who	O
are	O
receiving	O
appropriate	O
antithrombotic	O
therapy	O
[	O
see	O
Drug	O
interactions	O
(	O
7.3	O
)	O
]	O
.	O
	
The	O
QTcF	B
was	I
increased	I
more	O
than	O
60	O
msec	O
from	O
baseline	O
in	O
13	O
%	O
(	O
7/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
In	O
a	O
placebo-controlled	O
trial	O
of	O
PROMACTA	O
in	O
patients	O
with	O
chronic	O
liver	O
diseaseand	O
thrombocytopenia	O
not	O
related	O
to	O
ITP	O
,	O
six	O
patients	O
treated	O
with	O
PROMACTA	O
and	O
one	O
patient	O
in	O
the	O
placebo	O
group	O
developed	O
portal	B
vein	I
thromboses	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Grade	O
3	O
events	O
were	O
reported	O
in	O
3	O
of	O
the	O
25	O
patients	O
treated	O
with	O
ADCETRIS	O
who	O
experienced	O
infusion-related	B
reactions	I
.	O
	
5.8	O
Hypertriglyceridemia	O
In	O
women	O
with	O
pre-existing	O
hypertriglyceridemia	O
,	O
treatment	O
with	O
estrogens	O
may	O
be	O
associated	O
with	O
elevations	B
of	I
plasma	I
triglycerides	I
leading	O
to	O
pancreatitis	B
.	O
	
In	O
the	O
extension	O
chronic	O
ITP	O
trial	O
,	O
one	O
additional	O
patient	O
had	O
PROMACTA	O
discontinued	O
due	O
to	O
liver	B
test	I
abnormalities	I
(	O
less	O
than	O
or	O
equal	O
to	O
Grade	O
3	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatic	B
Effects	I
:	O
Postmarketing	O
reports	O
of	O
hepatic	B
failure	I
,	O
sometimes	O
fatal	B
.	O
	
Delayed	O
reactions	O
can	O
occur	O
up	O
to	O
several	O
days	O
after	O
EOVIST	O
administration	O
.	O
	
These	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
no	O
history	O
of	O
prior	O
exposure	O
to	O
Vizamyl	O
.	O
	
Hematuria	O
:	O
Adverse	O
events	O
of	O
hematuria	B
,	O
including	O
those	O
requiring	O
medical	O
intervention	O
,	O
were	O
more	O
common	O
in	O
JEVTANA-treated	O
patients	O
.	O
	
Prior	O
to	O
initiating	O
immunomodulatory	O
therapies	O
,	O
including	O
ILARIS	O
,	O
patients	O
should	O
be	O
evaluated	O
for	O
active	O
and	O
latent	O
tuberculosis	O
infection	O
.	O
	
Because	O
of	O
this	O
,	O
patients	O
who	O
have	O
conditions	O
that	O
might	O
be	O
influenced	O
by	O
this	O
factor	O
,	O
such	O
as	O
cardiac	O
dysfunction	O
or	O
renal	O
impairment	O
,	O
warrant	O
careful	O
observation	O
when	O
estrogens	O
are	O
prescribed	O
.	O
	
Of	O
those	O
patients	O
who	O
developed	O
new	O
cuSCC	B
,	O
approximately	O
33	O
%	O
developed	O
one	O
or	O
more	O
cuSCC	B
with	O
continued	O
administration	O
of	O
TAFINLAR	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Exclusive	O
of	O
an	O
uncommon	O
,	O
mild	O
injection	B
site	I
reaction	I
,	O
no	O
adverse	O
reactions	O
to	O
11	O
C-choline	O
have	O
been	O
reported	O
.	O
	
Concomitant	O
administration	O
of	O
drugs	O
associated	O
with	O
ONJ	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
ONJ	O
.	O
	
Advise	O
patients	O
to	O
report	O
symptoms	O
of	O
severe	O
hyperglycemia	O
such	O
as	O
excessive	O
thirst	O
or	O
any	O
increase	O
in	O
the	O
volume	O
or	O
frequency	O
of	O
urination	O
.	O
	
Graft	B
loss	I
in	O
some	O
patients	O
.	O
	
5.4	O
Oral	O
Ulceration	O
Mouth	B
ulcers	I
,	O
stomatitis	B
,	O
and	O
oral	B
mucositis	I
have	O
occurred	O
in	O
patients	O
treated	O
with	O
AFINITOR	O
at	O
an	O
incidence	O
ranging	O
from	O
44	O
%	O
-78	O
%	O
across	O
the	O
clinical	O
trial	O
experience	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
Patients	O
ranged	O
in	O
age	O
from	O
18	O
to	O
83	O
years	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
51	O
years	O
.	O
	
Adverse	O
event	O
data	O
collected	O
from	O
those	O
trials	O
showed	O
the	O
following	O
rates	O
of	O
EPS-related	B
adverse	I
events	I
as	O
shown	O
in	O
Table	O
8	O
.	O
	
Side-by-side	O
tabulation	O
is	O
to	O
simplify	O
presentation	O
;	O
direct	O
comparisons	O
across	O
trials	O
should	O
not	O
be	O
made	O
due	O
to	O
differing	O
trial	O
designs	O
.	O
	
(	O
5.4	O
)	O
*	O
Risk	O
of	O
adverse	O
reactions	O
or	O
loss	O
of	O
virologic	O
response	O
due	O
to	O
drug	O
interactions	O
:	O
The	O
concomitant	O
use	O
of	O
STRIBILD	O
and	O
other	O
drugs	O
may	O
result	O
in	O
known	O
or	O
potentially	O
significant	O
drug	O
interactions	O
,	O
some	O
of	O
which	O
may	O
lead	O
to	O
loss	O
of	O
therapeutic	O
effect	O
of	O
STRIBILD	O
and	O
possible	O
development	O
of	O
resistance	O
;	O
and	O
possible	O
clinically	O
significant	O
adverse	O
reactions	O
from	O
greater	O
exposures	O
of	O
concomitant	O
drugs	O
.	O
	
There	O
were	O
4	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
Treatment-emergent	O
ADRs	O
in	O
VIKING-3	O
were	O
generally	O
similar	O
compared	O
with	O
observations	O
with	O
the	O
50-mg	O
once-daily	O
dose	O
in	O
adult	O
Phase	O
3	O
trials	O
.	O
	
Other	O
adverse	O
reactions	O
with	O
a	O
plausible	O
relationship	O
to	O
treatment	O
that	O
have	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=0.3	O
%	O
and	O
greater	O
than	O
placebo	O
in	O
more	O
than	O
3300	O
patients	O
treated	O
with	O
Edarbi	O
in	O
controlled	O
trials	O
are	O
listed	O
below	O
:	O
Gastrointestinal	O
Disorders	O
:	O
nausea	B
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
asthenia	B
,	O
fatigue	B
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
muscle	B
spasm	I
Nervous	O
System	O
Disorders	O
:	O
dizziness	B
,	O
dizziness	B
postural	I
Respiratory	O
,	O
Thoracic	O
,	O
and	O
Mediastinal	O
Disorders	O
:	O
cough	B
6.2	O
Clinical	O
Laboratory	O
Findings	O
In	O
controlled	O
clinical	O
trials	O
,	O
clinically	O
relevant	O
changes	O
in	O
standard	O
laboratory	O
parameters	O
were	O
uncommon	O
with	O
administration	O
of	O
Edarbi	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
these	O
infections	O
.	O
	
Estrogens	O
may	O
increase	O
the	O
chances	O
of	O
getting	O
certain	O
types	O
of	O
cancers	O
,	O
including	O
cancer	O
of	O
the	O
breast	O
or	O
uterus	O
.	O
	
``	O
When	O
the	O
estrogen	O
levels	O
begin	O
dropping	O
,	O
some	O
women	O
get	O
very	O
uncomfortable	O
symptoms	O
,	O
such	O
as	O
feelings	O
of	O
warmth	O
in	O
the	O
face	O
,	O
neck	O
,	O
and	O
chest	O
,	O
or	O
sudden	O
intense	O
episodes	O
of	O
heat	O
and	O
sweating	O
(	O
``	O
hot	O
flashes	O
''	O
or	O
``	O
hot	O
flushes	O
''	O
)	O
.	O
	
Osteonecrosis	O
of	O
the	O
Jaw	O
No	O
cases	O
of	O
ONJ	B
were	O
reported	O
.	O
	
The	O
incidence	O
of	O
diplopia	B
was	O
greater	O
with	O
the	O
concomitant	O
use	O
of	O
APTIOM	O
and	O
carbamazepine	O
compared	O
to	O
the	O
use	O
of	O
APTIOM	O
without	O
carbamazepine	O
(	O
up	O
to	O
16	O
%	O
vs.	O
6	O
%	O
,	O
respectively	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Analyses	O
of	O
17	O
placebo-controlled	O
trials	O
(	O
modal	O
duration	O
of	O
10	O
weeks	O
)	O
,	O
largely	O
in	O
patients	O
taking	O
atypical	O
antipsychotic	O
drugs	O
,	O
revealed	O
a	O
risk	O
of	O
death	B
in	O
the	O
drug-treated	O
patients	O
of	O
between	O
1.6	O
to	O
1.7	O
times	O
that	O
seen	O
in	O
placebo-treated	O
patients	O
.	O
	
5.4	O
Atrial	O
Fibrillation	O
Atrial	B
fibrillation	I
and	O
atrial	B
flutter	I
(	O
range	O
,	O
6	O
to	O
9	O
%	O
)	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
,	O
particularly	O
in	O
patients	O
with	O
cardiac	O
risk	O
factors	O
,	O
acute	O
infections	O
,	O
and	O
a	O
previous	O
history	O
of	O
atrial	O
fibrillation	O
.	O
	
The	O
population	O
was	O
31-84	O
years	O
of	O
age	O
,	O
60	O
%	O
male	O
,	O
and	O
40	O
%	O
female	O
.	O
	
The	O
incidence	O
of	O
Grade	O
>	O
=3	O
hemorrhagic	B
events	I
was	O
higher	O
in	O
COMETRIQ-treated	O
patients	O
compared	O
with	O
placebo	O
(	O
3	O
%	O
vs.	O
1	O
%	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
number	O
of	O
ERWINAZE	O
courses	O
ranged	O
from	O
1	O
to	O
9	O
.	O
	
Patients	O
who	O
fail	O
to	O
show	O
substantial	O
clinical	O
benefit	O
after	O
adequate	O
titration	O
should	O
be	O
discontinued	O
from	O
POTIGA	O
.	O
	
Women	O
with	O
a	O
tendency	O
to	O
chloasma	O
should	O
avoid	O
exposure	O
to	O
the	O
sun	O
or	O
ultraviolet	O
radiation	O
while	O
taking	O
COCs	O
.	O
	
5.12	O
Suicide	O
The	O
possibility	O
of	O
a	O
suicide	O
attempt	O
is	O
inherent	O
in	O
psychotic	O
illness	O
,	O
and	O
close	O
supervision	O
of	O
high-risk	O
patients	O
should	O
accompany	O
drug	O
therapy	O
.	O
	
Antibody	O
formation	O
was	O
associated	O
with	O
lowered	O
drug	O
plasma	O
concentration	O
and	O
reduced	O
efficacy	O
.	O
	
There	O
were	O
too	O
few	O
cases	O
to	O
determine	O
whether	O
the	O
emergence	O
of	O
these	O
events	O
is	O
related	O
to	O
FARXIGA	O
.	O
	
These	O
trials	O
included	O
832	O
patients	O
of	O
whom	O
551	O
and	O
281	O
received	O
XIAFLEX	O
and	O
placebo	O
,	O
respectively	O
.	O
	
Monitor	O
liver	O
function	O
and	O
modify	O
,	O
interrupt	O
,	O
or	O
discontinue	O
ZYTIGA	O
dosing	O
as	O
recommended	O
.	O
	
b	O
Bleeding	B
site	O
based	O
on	O
investigator	O
assessment	O
.	O
	
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
immediately	O
interrupt	O
therapy	O
and	O
report	O
to	O
their	O
physician	O
if	O
they	O
experience	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
Embryo-fetal	B
toxicity	I
and	O
teratogenicity	B
occurred	O
in	O
rats	O
that	O
received	O
eribulin	O
mesylate	O
at	O
approximately	O
half	O
of	O
the	O
recommended	O
human	O
dose	O
based	O
on	O
body	O
surface	O
area	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
has	O
occurred	O
in	O
Beleodaq-treated	O
patients	O
in	O
the	O
clinical	O
trial	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
extensive	O
or	O
intensive	O
chemotherapy	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life	O
threatening	O
infections	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.2	O
Radiation	O
Risk	O
Neuraceq	O
,	O
similar	O
to	O
other	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
RE-SONATE	O
was	O
a	O
placebo-controlled	O
study	O
in	O
which	O
684	O
patients	O
received	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
following	O
6	O
to	O
18	O
months	O
of	O
oral	O
anticoagulant	O
regimen	O
.	O
	
When	O
medically	O
feasible	O
,	O
stop	O
these	O
drugs	O
before	O
AdreView	O
administration	O
and	O
monitor	O
patients	O
for	O
withdrawal	O
signs	O
and	O
symptoms	O
.	O
	
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
grade	O
3	O
to	O
4	O
hypertension	B
occurred	O
in	O
2	O
%	O
of	O
patients	O
,	O
grade	O
3	O
to	O
4	O
hypokalemia	B
in	O
4	O
%	O
of	O
patients	O
,	O
and	O
grade	O
3	O
to	O
4	O
edema	B
in	O
1	O
%	O
of	O
patients	O
treated	O
with	O
ZYTIGA	O
[	O
seeAdverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
of	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
in	O
patients	O
with	O
RA	O
,	O
some	O
patients	O
have	O
developed	O
ANA	B
.	O
	
To	O
reduce	O
the	O
potential	O
risk	O
of	O
bleeding	O
associated	O
with	O
the	O
concurrent	O
use	O
of	O
dabigatran	O
and	O
epidural	O
or	O
spinal	O
anesthesia/analgesia	O
or	O
spinal	O
puncture	O
,	O
consider	O
the	O
pharmacokinetic	O
profile	O
of	O
dabigatran	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Aspiration	O
pneumonia	O
is	O
a	O
common	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
elderly	O
patients	O
,	O
in	O
particular	O
those	O
with	O
advanced	O
Alzheimer	O
's	O
dementia	O
.	O
	
About	O
25	O
%	O
of	O
patients	O
were	O
from	O
the	O
United	O
States	O
and	O
75	O
%	O
from	O
other	O
countries	O
.	O
	
The	O
combination	O
of	O
transaminase	B
elevations	I
and	O
elevated	B
bilirubin	I
without	O
evidence	O
of	O
obstruction	O
is	O
generally	O
recognized	O
as	O
an	O
important	O
predictor	O
of	O
severe	O
liver	B
injury	I
.	O
	
BEPREVE	O
should	O
not	O
be	O
used	O
to	O
treat	O
contact	O
lens-related	O
irritation	O
.	O
	
(	O
5.1	O
)	O
*	O
Interstitial	B
Lung	I
Disease	I
(	O
ILD	B
)	O
/Pneumonitis	O
:	O
Occurred	O
in	O
2.9	O
%	O
of	O
patients	O
.	O
	
In	O
this	O
setting	O
,	O
a	O
re-evaluation	O
of	O
the	O
patient	O
and	O
the	O
COPD	O
treatment	O
regimen	O
should	O
be	O
undertaken	O
at	O
once	O
.	O
	
Pancreatitis	O
Pancreatitis	B
was	O
reported	O
in	O
4	O
patients	O
(	O
0.1	O
%	O
)	O
in	O
the	O
placebo	O
and	O
8	O
patients	O
(	O
0.2	O
%	O
)	O
in	O
the	O
Prolia	O
groups	O
.	O
	
Record	O
the	O
specific	O
GBCA	O
and	O
the	O
dose	O
administered	O
to	O
a	O
patient	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
60	O
%	O
of	O
the	O
patients	O
in	O
the	O
KRd	O
arm	O
and	O
54	O
%	O
of	O
the	O
patients	O
in	O
the	O
Rd	O
arm	O
.	O
	
In	O
other	O
women	O
,	O
symptoms	O
can	O
be	O
more	O
severe	O
.	O
	
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
:	O
Approximately	O
16	O
%	O
(	O
25/158	O
)	O
of	O
SAPHRIS-treated	O
patients	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
,	O
compared	O
with	O
about	O
11	O
%	O
(	O
18/166	O
)	O
on	O
placebo	O
.	O
	
Prolactin	O
:	O
In	O
short-term	O
,	O
placebo-controlled	O
adult	O
schizophrenia	O
trials	O
,	O
the	O
mean	O
decreases	B
in	I
prolactin	I
levels	I
were	O
6.5	O
ng/mL	O
for	O
SAPHRIS-treated	O
patients	O
compared	O
to	O
10.7	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
*	O
Toviaz	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
with	O
clinically	O
significant	O
bladder	O
outlet	O
obstruction	O
because	O
of	O
the	O
risk	O
of	O
urinary	O
retention	O
.	O
	
Because	O
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
HORIZANT	O
also	O
increases	O
this	O
risk	O
.	O
	
Treatment	O
with	O
STRIBILD	O
should	O
be	O
suspended	O
in	O
any	O
patient	O
who	O
develops	O
clinical	O
or	O
laboratory	O
findings	O
suggestive	O
of	O
lactic	O
acidosis	O
or	O
pronounced	O
hepatotoxicity	O
(	O
which	O
may	O
include	O
hepatomegaly	O
and	O
steatosis	O
even	O
in	O
the	O
absence	O
of	O
marked	O
transaminase	O
elevations	O
)	O
.	O
	
Monitor	O
thyroid	O
function	O
tests	O
and	O
clinical	O
chemistries	O
at	O
the	O
start	O
of	O
treatment	O
,	O
before	O
each	O
dose	O
,	O
and	O
as	O
clinically	O
indicated	O
based	O
on	O
symptoms	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
in	O
GILOTRIF-treated	O
patients	O
were	O
diarrhea	B
(	O
1.3	O
%	O
)	O
,	O
ILD	B
(	O
0.9	O
%	O
)	O
,	O
and	O
paronychia	B
(	O
0.9	O
%	O
)	O
.	O
	
The	O
incidence	O
of	O
adverse	O
events	O
leading	O
to	O
study	O
drug	O
discontinuation	O
for	O
Cleviprex	O
in	O
severe	O
hypertension	O
was	O
4.8	O
%	O
.	O
	
5.5	O
Posterior	O
Reversible	O
Encephalopathy	O
Syndrome	O
There	O
have	O
been	O
rare	O
cases	O
of	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
reported	O
in	O
patients	O
receiving	O
GILENYA	O
.	O
	
5.4	O
Osteonecrosis	O
of	O
the	O
Jaw	O
Osteonecrosis	O
of	O
the	O
jaw	O
(	O
ONJ	O
)	O
,	O
which	O
can	O
occur	O
spontaneously	O
,	O
is	O
generally	O
associated	O
with	O
tooth	O
extraction	O
and/or	O
local	O
infection	O
with	O
delayed	O
healing	O
.	O
	
5.7	O
Liver	O
Injury	O
Elevations	B
of	I
liver	I
enzymes	I
may	O
occur	O
in	O
patients	O
receiving	O
GILENYA	O
.	O
	
Blood	O
Glucose	O
and	O
Lipids	O
Hyperglycemia	B
,	O
hyperlipidemia	B
,	O
and	O
hypertriglyceridemia	B
have	O
been	O
reported	O
in	O
patients	O
taking	O
AFINITOR	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
Twenty-two	O
(	O
6	O
%	O
)	O
patients	O
discontinued	O
JEVTANA	O
treatment	O
due	O
to	O
neutropenia	B
,	O
febrile	B
neutropenia	I
,	O
infection	B
,	O
or	O
sepsis	B
.	O
	
5.2	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
Acute	B
respiratory	I
distress	I
syndrome	I
(	O
ARDS	B
)	O
can	O
occur	O
in	O
patients	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
.	O
	
Ribavirin	O
therapy	O
should	O
not	O
be	O
started	O
unless	O
a	O
report	O
of	O
a	O
negative	O
pregnancy	O
test	O
has	O
been	O
obtained	O
immediately	O
prior	O
to	O
initiation	O
of	O
therapy	O
.	O
	
c	O
Includes	O
the	O
following	O
terms	O
:	O
rash	B
,	O
rash	B
generalized	I
,	O
rash	B
pruritic	I
,	O
rash	B
erythematous	I
,	O
rash	B
papular	I
,	O
rash	B
vesicular	I
,	O
rash	B
macular	I
,	O
and	O
rash	B
maculo-papular	I
.	O
	
Prescriptions	O
for	O
SAPHRIS	O
should	O
be	O
written	O
for	O
the	O
smallest	O
quantity	O
of	O
tablets	O
consistent	O
with	O
good	O
patient	O
management	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
overdose	O
.	O
	
In	O
Study	O
3	O
,	O
infusion-related	B
reactions	I
were	O
reported	O
in	O
25	O
patients	O
(	O
15	O
%	O
)	O
in	O
the	O
ADCETRIS-treated	O
arm	O
and	O
3	O
patients	O
(	O
2	O
%	O
)	O
in	O
the	O
placebo	O
arm	O
.	O
	
(	O
5.8	O
,	O
2.3	O
)	O
*	O
Hyperglycemia	B
:	O
Monitor	O
serum	O
glucose	O
levels	O
in	O
patients	O
with	O
pre-existing	O
diabetes	O
or	O
hyperglycemia	O
.	O
	
If	O
examination	O
reveals	O
papilledema	O
or	O
retinal	O
vascular	O
lesions	O
,	O
DUAVEE	O
should	O
be	O
permanently	O
discontinued	O
.	O
	
During	O
the	O
four	O
week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
,	O
28/1263	O
(	O
2	O
%	O
)	O
subjects	O
experienced	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
treatment	O
.	O
	
If	O
such	O
reactions	O
occur	O
,	O
discontinue	O
further	O
administration	O
of	O
CIMZIA	O
and	O
institute	O
appropriate	O
therapy	O
.	O
	
Adverse	O
Reactions	O
Pooled	O
Phase	O
3	O
Clinical	O
Trials	O
(	O
four	O
trials	O
,	O
two	O
in	O
ABSSSI	O
and	O
two	O
in	O
CABP	O
)	O
Teflaro	O
(	O
N=1300	O
)	O
Pooled	O
Comparators	O
a	O
(	O
N=1297	O
)	O
Gastrointestinal	O
Disorders	O
Diarrhea	B
5	O
%	O
3	O
%	O
Nausea	B
4	O
%	O
4	O
%	O
Constipation	B
2	O
%	O
2	O
%	O
Vomiting	B
2	O
%	O
2	O
%	O
Laboratory	O
Investigations	O
Increased	B
transaminases	I
2	O
%	O
3	O
%	O
Metabolism	O
and	O
Nutrition	O
disorders	O
Hypokalemia	B
2	O
%	O
3	O
%	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
Rash	B
3	O
%	O
2	O
%	O
Vascular	O
Disorders	O
Phlebitis	B
2	O
%	O
1	O
%	O
Other	O
Adverse	O
Reactions	O
Observed	O
During	O
Clinical	O
Trials	O
of	O
Teflaro	O
Following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
reported	O
by	O
the	O
1740	O
patients	O
who	O
received	O
Teflaro	O
in	O
any	O
clinical	O
trial	O
with	O
incidences	O
less	O
than	O
2	O
%	O
.	O
	
Eleven	O
patients	O
(	O
26	O
%	O
)	O
were	O
treated	O
for	O
greater	O
than	O
6	O
months	O
and	O
7	O
patients	O
(	O
16	O
%	O
)	O
were	O
treated	O
for	O
greater	O
than	O
1	O
year	O
.	O
	
In	O
Study	O
3	O
,	O
67	O
%	O
of	O
patients	O
treated	O
with	O
ADCETRIS	O
experienced	O
any	O
grade	O
of	O
neuropathy	B
.	O
	
Discontinue	O
for	O
intolerable	O
Grade	O
2	O
,	O
or	O
Grade	O
3	O
or	O
4	O
rash	O
not	O
improving	O
within	O
3	O
weeks	O
despite	O
interruption	O
of	O
TAFINLAR	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
associated	O
with	O
infusion-related	B
reactions	I
were	O
chills	B
(	O
4	O
%	O
)	O
,	O
nausea	B
(	O
3	O
%	O
)	O
,	O
dyspnea	B
(	O
3	O
%	O
)	O
,	O
pruritus	B
(	O
3	O
%	O
)	O
,	O
pyrexia	B
(	O
2	O
%	O
)	O
,	O
and	O
cough	B
(	O
2	O
%	O
)	O
.	O
	
5.2	O
Serotonin	O
Syndrome	O
The	O
development	O
of	O
a	O
potentially	O
life-threatening	O
serotonin	B
syndrome	I
has	O
been	O
reported	O
with	O
SNRIs	O
and	O
SSRIs	O
,	O
including	O
PRISTIQ	O
,	O
alone	O
but	O
particularly	O
with	O
concomitant	O
use	O
of	O
other	O
serotonergic	O
drugs	O
(	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
tryptophan	O
,	O
buspirone	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
)	O
,	O
and	O
with	O
drugs	O
that	O
impair	O
metabolism	O
of	O
serotonin	O
(	O
in	O
particular	O
,	O
MAOIs	O
,	O
both	O
those	O
intended	O
to	O
treat	O
psychiatric	O
disorders	O
and	O
also	O
others	O
,	O
such	O
as	O
linezolid	O
and	O
intravenous	O
methylene	O
blue	O
)	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
or	O
to	O
other	O
factors	O
[	O
seeAdverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
For	O
pediatric	O
patients	O
with	O
SEGA	O
that	O
do	O
not	O
require	O
immediate	O
treatment	O
,	O
complete	O
the	O
recommended	O
childhood	O
series	O
of	O
live	O
virus	O
vaccinations	O
according	O
to	O
American	O
Council	O
on	O
Immunization	O
Practices	O
(	O
ACIP	O
)	O
guidelines	O
prior	O
to	O
the	O
start	O
of	O
therapy	O
.	O
	
*	O
Serotonin	B
Syndrome	I
:	O
Serotonin	B
syndrome	I
has	O
been	O
reported	O
with	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
with	O
PRISTIQ	O
,	O
both	O
when	O
taken	O
alone	O
,	O
but	O
especially	O
when	O
co-administered	O
with	O
other	O
serotonergic	O
agents	O
(	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
tryptophan	O
,	O
buspirone	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
)	O
.	O
	
Infections	B
,	O
in	O
some	O
instances	O
serious	O
,	O
have	O
been	O
reported	O
with	O
ILARIS	O
.	O
	
Coadministration	O
of	O
ILARIS	O
with	O
TNF	O
inhibitors	O
is	O
not	O
recommended	O
because	O
this	O
may	O
increase	O
the	O
risk	O
of	O
serious	O
infections	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Monitoring	O
of	O
fasting	O
serum	O
glucose	O
and	O
lipid	O
profile	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
as	O
well	O
as	O
management	O
with	O
appropriate	O
medical	O
therapy	O
.	O
	
chemotherapy	O
,	O
corticosteroids	O
,	O
angiogenesis	O
inhibitors	O
)	O
,	O
poor	O
oral	O
hygiene	O
,	O
and	O
co-morbid	O
disorders	O
(	O
e.g	O
.	O
	
**	O
Fatal	B
bleeding	B
is	O
an	O
adjudicated	O
death	B
with	O
the	O
primary	O
cause	O
of	O
death	B
as	O
intracranial	B
bleeding	I
or	O
non-intracranial	B
bleeding	I
during	O
the	O
on-treatment	O
period	O
.	O
	
The	O
two	O
cases	O
of	O
PTLD	B
were	O
reported	O
among	O
the	O
140	O
EBV	O
seropositive	O
patients	O
(	O
1.4	O
%	O
)	O
.	O
	
There	O
is	O
limited	O
experience	O
with	O
short-duration	O
therapy	O
with	O
beta-blockers	O
as	O
a	O
treatment	O
for	O
Cleviprex-induced	O
tachycardia	O
.	O
	
(	O
5.1	O
)	O
*	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
There	O
was	O
a	O
greater	O
incidence	O
of	O
myocardial	B
infarction	I
in	O
alvimopan-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients	O
in	O
a	O
12-month	O
clinical	O
trial	O
,	O
although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
PML	O
in	O
any	O
patient	O
presenting	O
with	O
new-onset	O
or	O
deteriorating	O
neurological	O
signs	O
and	O
symptoms	O
and	O
consult	O
with	O
a	O
neurologist	O
or	O
other	O
appropriate	O
specialist	O
as	O
clinically	O
indicated	O
.	O
	
Discontinue	O
GILOTRIF	O
if	O
ILD	O
is	O
diagnosed	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
1	O
%	O
of	O
GILENYA-treated	O
patients	O
and	O
>	O
=	O
1	O
%	O
higher	O
rate	O
than	O
for	O
placebo	O
.	O
	
The	O
proportion	O
of	O
pediatric	O
patients	O
with	O
ALT	B
elevations	I
>	O
=3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
was	O
2.4	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
versus	O
none	O
for	O
the	O
other	O
SAPHRIS	O
dose	O
groups	O
and	O
placebo-treated	O
patients	O
.	O
	
Table	O
8	O
:	O
Grade	O
3-4	O
Laboratory	O
Abnormalities	O
(	O
>	O
10	O
%	O
)	O
(	O
Monotherapy	O
)	O
Adverse	O
Reaction	O
Kyprolis	O
(	O
N	O
=	O
598	O
)	O
Decreased	B
Platelets	I
184	O
(	O
31	O
%	O
)	O
Decreased	B
Lymphocytes	I
151	O
(	O
25	O
%	O
)	O
Decreased	B
Hemoglobin	I
132	O
(	O
22	O
%	O
)	O
Decreased	B
Total	I
White	I
Blood	I
Cell	I
Count	I
71	O
(	O
12	O
%	O
)	O
Decreased	B
Sodium	I
69	O
(	O
12	O
%	O
)	O
Decreased	B
Absolute	I
Neutrophil	I
Count	I
67	O
(	O
11	O
%	O
)	O
6.2	O
Post-marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
the	O
post-marketing	O
experience	O
with	O
Kyprolis	O
.	O
	
The	O
use	O
of	O
clinical	O
information	O
in	O
the	O
interpretation	O
of	O
Amyvid	O
images	O
has	O
not	O
been	O
evaluated	O
and	O
may	O
lead	O
to	O
errors	O
.	O
	
In	O
some	O
women	O
,	O
the	O
symptoms	O
are	O
mild	O
,	O
and	O
they	O
will	O
not	O
need	O
to	O
take	O
medicines	O
.	O
	
Among	O
the	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
for	O
NSF	O
are	O
repeated	O
or	O
higher	O
than	O
recommended	O
doses	O
of	O
a	O
GBCA	O
and	O
the	O
degree	O
of	O
renal	O
impairment	O
at	O
the	O
time	O
of	O
exposure	O
.	O
	
(	O
5.5	O
)	O
*	O
Potential	O
worsening	B
of	I
infections	I
)	O
.	O
	
A	O
dose	O
decrease	O
is	O
recommended	O
when	O
administering	O
INLYTA	O
to	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
B	O
)	O
.	O
	
Dermatologic	O
Reactions	O
dermal	B
adverse	I
events	I
(	O
such	O
as	O
dermatitis	B
,	O
eczema	B
,	O
and	O
rashes	B
)	O
were	O
reported	O
in	O
4	O
patients	O
(	O
3.3	O
%	O
)	O
in	O
the	O
placebo	O
group	O
and	O
5	O
patients	O
(	O
4.2	O
%	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
estradiol	B
,	I
may	I
be	I
decreased	I
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
BioMarin	O
at	O
1-866-906-6100	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Impairment	O
in	O
Renal	O
Function	O
INVOKANA	O
is	O
associated	O
with	O
a	O
dose-dependent	O
increase	B
in	I
serum	I
creatinine	I
and	O
a	O
concomitant	O
fall	B
in	I
estimated	I
GFR	I
(	O
Table	O
3	O
)	O
.	O
	
Permanently	O
discontinue	O
in	O
patients	O
with	O
ILD/pneumonitis	O
.	O
	
If	O
an	O
anaphylactic	O
or	O
other	O
clinically	O
significant	O
allergic	O
reaction	O
occurs	O
,	O
initiate	O
appropriate	O
therapy	O
and	O
discontinue	O
further	O
use	O
of	O
Prolia	O
[	O
see	O
Contraindications	O
(	O
4.3	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Monitor	O
patients	O
closely	O
and	O
take	O
appropriate	O
precautions	O
in	O
patients	O
at	O
risk	O
for	O
tumor	O
lysis	O
syndrome	O
(	O
e.g	O
.	O
	
Hypersensitivity	B
reactions	O
have	O
occurred	O
as	O
early	O
as	O
30	O
minutes	O
from	O
the	O
start	O
of	O
infusion	O
but	O
as	O
late	O
as	O
six	O
days	O
after	O
infusion	O
.	O
	
FANAPT	O
and	O
other	O
antipsychotic	O
drugs	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
at	O
risk	O
for	O
aspiration	O
pneumonia	O
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
Four	O
patients	O
out	O
of	O
2,367	O
patients	O
treated	O
with	O
CIMZIA	O
in	O
RA	O
clinical	O
studies	O
developed	O
clinical	O
signs	O
suggestive	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
Pregnancy	O
should	O
be	O
ruled	O
out	O
in	O
the	O
event	O
of	O
amenorrhea	O
occurring	O
in	O
two	O
or	O
more	O
consecutive	O
cycles	O
.	O
	
POTIGA	O
should	O
only	O
be	O
used	O
in	O
patients	O
who	O
have	O
responded	O
inadequately	O
to	O
several	O
alternative	O
treatments	O
and	O
for	O
whom	O
the	O
benefits	O
outweigh	O
the	O
potential	O
risk	O
of	O
vision	O
loss	O
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
and	O
if	O
observed	O
,	O
treat	O
urgently	O
.	O
	
Most	O
patients	O
who	O
developed	O
these	O
infections	B
were	O
taking	O
concomitant	O
immunosuppressants	O
such	O
as	O
methotrexate	O
or	O
corticosteroids	O
.	O
	
(	O
5.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Severe	O
cutaneous	B
reactions	I
:	O
Monitor	O
patients	O
for	O
the	O
development	O
of	O
severe	O
cutaneous	O
reactions	O
and	O
discontinue	O
Zydelig	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
AdreView	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Congestive	O
Heart	O
Failure	O
Many	O
commonly	O
used	O
cardiovascular	O
,	O
pulmonary	O
,	O
and	O
neuropsychiatric	O
medications	O
interfere	O
with	O
AdreView	O
imaging	O
(	O
see	O
above	O
)	O
.	O
	
In	O
patients	O
receiving	O
the	O
recommended	O
CIMZIA	O
dosage	O
of	O
200	O
mg	O
every	O
other	O
week	O
with	O
concomitant	O
MTX	O
,	O
the	O
ACR20	O
response	O
was	O
lower	O
among	O
antibody	O
positive	O
patients	O
than	O
among	O
antibody-negative	O
patients	O
(	O
Study	O
RA-I	O
,	O
48	O
%	O
versus	O
60	O
%	O
;	O
Study	O
RA-II	O
35	O
%	O
versus	O
59	O
%	O
,	O
respectively	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
EYLEA	O
were	O
conjunctival	B
hemorrhage	I
,	O
eye	B
pain	I
,	O
cataract	B
,	O
vitreous	B
floaters	I
,	O
intraocular	B
pressure	I
increased	I
,	O
and	O
vitreous	B
detachment	I
.	O
	
(	O
5.1	O
,	O
5.2	O
)	O
*	O
Withdrawal	O
:	O
Symptoms	O
may	O
occur	O
with	O
rapid	O
dose	O
reduction	O
or	O
discontinuation	O
.	O
	
In	O
pooled	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
agranulocytosis	B
was	O
1.7	O
%	O
of	O
patients	O
.	O
	
Concurrent	O
Administration	O
with	O
Vemurafenib	O
In	O
a	O
dose-finding	O
trial	O
,	O
Grade	O
3	O
increases	B
in	I
transaminases	I
with	O
or	O
without	O
concomitant	O
increases	B
in	I
total	I
bilirubin	I
occurred	O
in	O
6	O
of	O
10	O
patients	O
who	O
received	O
concurrent	O
YERVOY	O
(	O
3	O
mg/kg	O
)	O
and	O
vemurafenib	O
(	O
960	O
mg	O
BID	O
or	O
720	O
mg	O
BID	O
)	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Agranulocytosis/Neutropenia	O
Fatal	B
agranulocytosis	B
can	O
occur	O
with	O
Ferriprox	O
use	O
.	O
	
a	O
Patients	O
with	O
at	O
least	O
one	O
MBE	B
.	O
	
There	O
was	O
also	O
an	O
increased	O
incidence	O
of	O
pneumonias	B
resulting	O
in	O
hospitalization	O
.	O
	
Do	O
not	O
administer	O
Beleodaq	O
to	O
patients	O
with	O
an	O
active	O
infection	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Regeneron	O
at	O
1-855-395-3248	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Use	O
caution	O
and	O
monitor	O
for	O
symptoms	O
and	O
signs	O
of	O
adrenocortical	O
insufficiency	O
,	O
particularly	O
if	O
patients	O
are	O
withdrawn	O
from	O
prednisone	O
,	O
have	O
prednisone	O
dose	O
reductions	O
,	O
or	O
experience	O
unusual	O
stress	O
.	O
	
Avoid	O
concurrent	O
use	O
of	O
Zydelig	O
with	O
other	O
drugs	O
that	O
may	O
cause	O
liver	O
toxicity	O
.	O
	
(	O
5.1	O
)	O
*	O
Adrenocortical	B
insufficiency	I
:	O
Monitor	O
for	O
symptoms	O
and	O
signs	O
of	O
adrenocortical	O
insufficiency	O
.	O
	
In	O
general	O
,	O
in	O
clinical	O
trials	O
,	O
rash	B
was	O
mild	O
to	O
moderate	O
,	O
occurred	O
primarily	O
in	O
the	O
second	O
week	O
of	O
therapy	O
,	O
and	O
was	O
infrequent	O
after	O
Week	O
4	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
moderate	O
,	O
severe	O
,	O
or	O
life-threatening	O
immune-mediated	B
dermatitis	I
was	O
3.1	O
weeks	O
and	O
ranged	O
up	O
to	O
17.3	O
weeks	O
from	O
the	O
initiation	O
of	O
YERVOY	O
.	O
	
An	O
additional	O
13	O
(	O
2.5	O
%	O
)	O
patients	O
experienced	O
moderate	O
hepatotoxicity	B
manifested	O
by	O
liver	B
function	I
test	I
abnormalities	I
(	O
ALT	B
elevations	I
of	O
more	O
than	O
2.5	O
times	O
but	O
not	O
more	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
total	B
bilirubin	I
elevation	I
of	O
more	O
than	O
1.5	O
times	O
but	O
not	O
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
;	O
Grade	O
2	O
)	O
.	O
	
For	O
neutropenia	O
(	O
ANC	O
<	O
1.5	O
x	O
10	O
9	O
/L	O
and	O
>	O
0.5	O
x	O
10	O
9	O
/L	O
)	O
:	O
Instruct	O
the	O
patient	O
to	O
immediately	O
discontinue	O
Ferriprox	O
and	O
all	O
other	O
medications	O
with	O
a	O
potential	O
to	O
cause	O
neutropenia	O
.	O
	
Discontinue	O
for	O
nephrotic	O
syndrome	O
.	O
	
5.11	O
Dysphagia	O
Esophageal	B
dysmotility	I
and	O
aspiration	B
have	O
been	O
associated	O
with	O
antipsychotic	O
drug	O
use	O
.	O
	
Symptomatic	B
hypotension	I
can	O
occur	O
after	O
initiating	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
particularly	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
eGFR	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
elderly	O
patients	O
,	O
or	O
patients	O
on	O
loop	O
diuretics	O
.	O
	
5.7	O
Palmar-Plantar	O
Erythrodysesthesia	O
Syndrome	O
Palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
occurred	O
in	O
50	O
%	O
of	O
patients	O
treated	O
with	O
COMETRIQ	O
and	O
was	O
severe	O
(	O
>	O
=	O
Grade	O
3	O
)	O
in	O
13	O
%	O
of	O
patients	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
13	O
%	O
for	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
19	O
%	O
for	O
the	O
cyclosporine	O
control	O
arm	O
through	O
three	O
years	O
of	O
treatment	O
.	O
	
Drugs	O
with	O
alpha-adrenergic	O
blocking	O
effects	O
have	O
been	O
reported	O
to	O
induce	O
priapism	B
.	O
	
The	O
overall	O
safety	O
profile	O
of	O
KALYDECO	O
is	O
based	O
on	O
pooled	O
data	O
from	O
three	O
placebo-controlled	O
clinical	O
trials	O
conducted	O
in	O
353	O
patients	O
6	O
years	O
of	O
age	O
and	O
older	O
with	O
CF	O
who	O
had	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
(	O
Trials	O
1	O
and	O
2	O
)	O
or	O
were	O
homozygous	O
for	O
the	O
F508del	O
mutation	O
(	O
Trial	O
3	O
)	O
.	O
	
If	O
atrial	O
fibrillation	O
persists	O
,	O
consider	O
the	O
risks	O
and	O
benefits	O
of	O
IMBRUVICA	O
treatment	O
and	O
dose	O
modification	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
preservative	O
in	O
BEPREVE	O
,	O
benzalkonium	O
chloride	O
,	O
may	O
be	O
absorbed	O
by	O
soft	O
contact	O
lenses	O
.	O
	
New	O
malignancies	B
related	I
to	I
the	I
breast	I
(	O
0.6	O
%	O
placebo	O
vs.	O
0.9	O
%	O
Prolia	O
)	O
were	O
reported	O
.	O
	
5.10	O
Immunizations	O
Patients	O
treated	O
with	O
CIMZIA	O
may	O
receive	O
vaccinations	O
,	O
except	O
for	O
live	O
or	O
live	O
attenuated	O
vaccines	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
)	O
were	O
pneumonia	B
,	O
pyrexia	B
,	O
infection	B
,	O
anemia	B
,	O
increased	B
creatinine	I
,	O
thrombocytopenia	B
,	O
and	O
multi-organ	B
failure	I
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
56	O
years	O
and	O
3	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
nausea	B
,	O
anemia	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
diarrhea	B
,	O
pyrexia	B
,	O
rash	B
,	O
thrombocytopenia	B
,	O
cough	B
,	O
and	O
vomiting	B
.	O
	
If	O
any	O
bleeding	O
requires	O
medical	O
intervention	O
,	O
temporarily	O
interrupt	O
the	O
INLYTA	O
dose	O
.	O
	
Table	O
11	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
In	O
Any	O
SAPHRIS-Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
at	O
3	O
Weeks	O
in	O
Adjunctive	O
Bipolar	O
Mania	O
Trials	O
*	O
SAPHRIS	O
5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
with	O
flexible	O
dosing	O
.	O
	
DUAVEE	O
is	O
not	O
for	O
use	O
in	O
children	O
.	O
	
Pain	B
in	I
extremity	I
and	O
musculoskeletal	B
pain	I
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
(	O
5.7	O
)	O
*	O
Immune	B
reconstitution	I
syndrome	I
:	O
May	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
In	O
ATHENA	O
,	O
the	O
maximum	O
follow-up	O
was	O
30	O
months	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
in	O
Advanced	O
Hormone	O
Receptor-Positive	O
,	O
HER2-Negative	O
Breast	O
Cancer	O
The	O
efficacy	O
and	O
safety	O
of	O
AFINITOR	O
(	O
10	O
mg/day	O
)	O
plus	O
exemestane	O
(	O
25	O
mg/day	O
)	O
(	O
n=485	O
)	O
versus	O
placebo	O
plus	O
exemestane	O
(	O
25	O
mg/day	O
)	O
(	O
n=239	O
)	O
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
controlled	O
trial	O
in	O
patients	O
with	O
advanced	O
or	O
metastatic	O
hormone	O
receptor-positive	O
,	O
HER2-negative	O
breast	O
cancer	O
.	O
	
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Treatment-emergent	O
ADRs	O
of	O
moderate	O
to	O
severe	O
intensity	O
observed	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
in	O
either	O
treatment	O
arm	O
in	O
SPRING-2	O
and	O
SINGLE	O
trials	O
are	O
provided	O
in	O
Table	O
2	O
.	O
	
In	O
a	O
long-term	O
(	O
52-week	O
)	O
,	O
double-blind	O
,	O
comparator-controlled	O
adult	O
trial	O
that	O
included	O
primarily	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
decrease	B
in	I
prolactin	I
from	O
baseline	O
for	O
SAPHRIS-treated	O
patients	O
was	O
26.9	O
ng/mL	O
.	O
	
(	O
2.3,5.4	O
)	O
*	O
Keratitis	B
:	O
Occurs	O
in	O
0.8	O
%	O
of	O
patients	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
5.3	O
Decreased	O
Gastrointestinal	O
Motility	O
Toviaz	O
,	O
like	O
other	O
antimuscarinic	O
drugs	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
decreased	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
those	O
with	O
severe	O
constipation	O
.	O
	
Of	O
the	O
586	O
subjects	O
,	O
59	O
%	O
were	O
female	O
and	O
84	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
46	O
years	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Interruption	O
of	O
Prolia	O
therapy	O
should	O
be	O
considered	O
,	O
pending	O
a	O
risk/benefit	O
assessment	O
,	O
on	O
an	O
individual	O
basis	O
.	O
	
*	O
Increased	O
risk	O
of	O
suicidal	B
thinking	I
in	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
taking	O
antidepressants	O
(	O
5.1	O
)	O
.	O
	
Discontinue	O
GRANIX	O
if	O
suspected	O
(	O
5.2	O
)	O
*	O
Allergic	B
reactions	I
(	O
angioneurotic	B
edema	I
,	O
dermatitis	B
allergic	I
,	O
drug	B
hypersensitivity	I
,	O
hypersensitivity	B
,	O
rash	B
,	O
pruritic	B
rash	I
and	O
urticaria	B
)	O
(	O
5.3	O
)	O
*	O
Sickle	B
cell	I
crisis	I
:	O
Severe	O
and	O
sometimes	O
fatal	B
crisis	O
can	O
occur	O
.	O
	
Nephrotic	B
syndrome	I
secondary	O
to	O
membranous	B
glomerulonephritis	I
was	O
observed	O
in	O
some	O
Pompe	O
disease	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
who	O
had	O
persistently	O
positive	B
anti-rhGAA	I
IgG	I
antibody	I
titers	I
.	O
	
Coartem	O
Tablets	O
should	O
be	O
avoided	O
in	O
patients	O
:	O
*	O
with	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
(	O
e.g.	O
,	O
long	O
QT	O
syndrome	O
)	O
or	O
any	O
other	O
clinical	O
condition	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
such	O
as	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
cardiac	O
arrhythmias	O
,	O
with	O
clinically	O
relevant	O
bradycardia	O
or	O
with	O
severe	O
cardiac	O
disease	O
.	O
	
In	O
the	O
pooled	O
Phase	O
3	O
CABP	O
trials	O
,	O
51/520	O
(	O
9.8	O
%	O
)	O
of	O
Teflaro-treated	O
patients	O
compared	O
to	O
24/534	O
(	O
4.5	O
%	O
)	O
of	O
ceftriaxone-treated	O
patients	O
seroconverted	B
from	I
a	I
negative	I
to	I
a	I
positive	I
direct	I
Coombs	I
'	I
test	I
result	I
.	O
	
In	O
this	O
clinical	O
context	O
,	O
if	O
the	O
patient	O
is	O
found	O
to	O
have	O
abnormal	O
liver	O
tests	O
(	O
ALT	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
the	O
reference	O
range	O
)	O
,	O
ULORIC	O
treatment	O
should	O
be	O
interrupted	O
and	O
investigation	O
done	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
Treatment-related	O
Adverse	O
Reactions	O
(	O
>	O
=3	O
%	O
)	O
from	O
Extension	O
Trial	O
in	O
Adults	O
with	O
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
Adverse	O
Reaction	O
PROMACTA	O
50	O
mg	O
n	O
=	O
299	O
(	O
%	O
)	O
Headache	B
10	O
Hyperbilirubinemia	B
6	O
ALT	B
increased	I
6	O
Cataract	B
5	O
AST	B
increased	I
4	O
Fatigue	B
4	O
Nausea	B
4	O
In	O
the	O
three	O
controlled	O
chronic	O
ITP	O
trials	O
,	O
serum	B
liver	I
test	I
abnormalities	I
(	O
predominantly	O
Grade	O
2	O
or	O
less	O
in	O
severity	O
)	O
were	O
reported	O
in	O
11	O
%	O
and	O
7	O
%	O
of	O
patients	O
for	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
such	O
combinations	O
is	O
not	O
recommended	O
.	O
	
If	O
the	O
decision	O
has	O
been	O
made	O
to	O
discontinue	O
treatment	O
,	O
medication	O
should	O
be	O
tapered	O
,	O
as	O
rapidly	O
as	O
is	O
feasible	O
,	O
but	O
with	O
recognition	O
that	O
abrupt	O
discontinuation	O
can	O
be	O
associated	O
with	O
certain	O
symptoms	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
for	O
a	O
description	O
of	O
the	O
risks	O
of	O
discontinuation	O
of	O
PRISTIQ	O
]	O
.	O
	
It	O
is	O
uncertain	O
whether	O
the	O
occurrence	O
of	O
HSTCL	O
is	O
related	O
to	O
use	O
of	O
a	O
TNF	O
blocker	O
or	O
a	O
TNF	O
blocker	O
in	O
combination	O
with	O
these	O
other	O
immunosuppressants	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
EOVIST	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
any	O
re-administration	O
.	O
	
The	O
range	O
of	O
time	O
to	O
diagnosis	O
of	O
cuSCC	B
was	O
136	O
to197	O
days	O
in	O
the	O
combination	O
arm	O
and	O
was	O
9	O
to	O
197	O
days	O
in	O
the	O
arm	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.1	O
Imaging	O
Errors	O
Imaging	O
errors	O
have	O
been	O
reported	O
with	O
11	O
C-choline	O
PET	O
and	O
PET/CT	O
imaging	O
.	O
	
Discontinue	O
GRANIX	O
if	O
suspected	O
(	O
5.4	O
)	O
*	O
Capillary	B
Leak	I
Syndrome	I
:	O
Monitor	O
if	O
symptoms	O
develop	O
and	O
administer	O
standard	O
symptomatic	O
treatment	O
(	O
5.5	O
)	O
5.1	O
Splenic	O
Rupture	O
Splenic	B
rupture	I
,	O
including	O
fatal	B
cases	O
,	O
can	O
occur	O
following	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
Patients	O
who	O
are	O
suspected	O
of	O
having	O
or	O
who	O
develop	O
ONJ	O
while	O
on	O
Prolia	O
should	O
receive	O
care	O
by	O
a	O
dentist	O
or	O
an	O
oral	O
surgeon	O
.	O
	
Anti-ecallantide	O
IgE	O
antibodies	O
were	O
detected	O
at	O
a	O
rate	O
of	O
4.7	O
%	O
for	O
tested	O
patients	O
,	O
and	O
anti-	O
P.	O
pastoris	O
IgE	O
antibodies	O
were	O
also	O
detected	O
at	O
a	O
rate	O
of	O
20.2	O
%	O
.	O
	
If	O
PRES	O
is	O
suspected	O
,	O
GILENYA	O
should	O
be	O
discontinued	O
.	O
	
In	O
addition	O
,	O
two	O
cases	O
of	O
PTLD	B
involving	O
the	O
liver	O
allograft	O
(	O
one	O
fatal	B
)	O
and	O
one	O
fatal	B
case	O
of	O
PML	B
were	O
observed	O
among	O
the	O
147	O
patients	O
randomized	O
to	O
NULOJIX	O
.	O
	
5.6	O
Serious	O
Infections	O
In	O
a	O
clinical	O
trial	O
of	O
over	O
7800	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
serious	O
infections	B
leading	O
to	O
hospitalization	O
were	O
reported	O
more	O
frequently	O
in	O
the	O
Prolia	O
group	O
than	O
in	O
the	O
placebo	O
group	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Hematologic	O
Parameters	O
Decreased	B
hemoglobin	I
have	O
been	O
reported	O
in	O
patients	O
taking	O
AFINITOR	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
TANZEUM	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
.	O
	
(	O
5.3	O
)	O
*	O
Do	O
not	O
administer	O
leucovorin	O
within	O
2	O
hours	O
before	O
or	O
after	O
a	O
dose	O
of	O
VORAXAZE	O
.	O
	
5.2	O
E.A.S.E	O
.	O
	
In	O
postmarketing	O
experience	O
with	O
alglucosidase	O
alfa	O
,	O
serious	O
adverse	O
reactions	O
have	O
been	O
reported	O
,	O
including	O
anaphylaxis	B
[	O
seeBoxed	O
WarningandWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
[	O
See	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
.	O
]	O
	
Grade	O
1-4	O
elevations	B
in	I
bilirubin	I
occurred	O
in	O
3	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.1	O
%	O
Grade	O
3-4	O
)	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
no	O
Grade	O
3-4	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
Prolia	O
in	O
patients	O
with	O
postmenopausal	O
osteoporosis	O
are	O
back	B
pain	I
and	O
constipation	B
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
of	O
Treatment	O
:	O
A	O
total	O
of	O
6.7	O
%	O
(	O
7/104	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5.1	O
%	O
(	O
5/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
5.1	O
%	O
(	O
5/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
compared	O
to	O
4	O
%	O
(	O
4/101	O
)	O
on	O
placebo	O
.	O
	
5.3	O
Venous	O
Thromboembolic	O
Events	O
In	O
clinical	O
trials	O
,	O
venous	B
thromboembolic	I
events	I
have	O
been	O
reported	O
,	O
including	O
deaths	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
negatives	O
)	O
have	O
been	O
observed	O
(	O
5.1	O
)	O
.	O
	
XEOMIN-treated	O
patients	O
were	O
22	O
to	O
79	O
years	O
of	O
age	O
(	O
mean	O
62	O
years	O
)	O
,	O
predominantly	O
female	O
(	O
65	O
%	O
)	O
,	O
Caucasian	O
(	O
79	O
%	O
)	O
,	O
and	O
had	O
a	O
mean	O
time	O
since	O
diagnosis	O
of	O
approximately	O
5	O
years	O
.	O
	
Patients	O
received	O
placebo	O
(	O
N=995	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=999	O
)	O
,	O
or	O
JARDIANCE	O
25	O
mg	O
(	O
N=977	O
)	O
once	O
daily	O
.	O
	
In	O
cases	O
of	O
symptomatic	O
bradycardia	O
that	O
is	O
not	O
life-threatening	O
,	O
hold	O
XALKORI	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
re-evaluate	O
the	O
use	O
of	O
concomitant	O
medications	O
,	O
and	O
adjust	O
the	O
dose	O
of	O
XALKORI	O
.	O
	
Because	O
of	O
the	O
potential	O
for	O
hypersensitivity	O
reactions	O
,	O
administer	O
antihistamines	O
with	O
or	O
without	O
antipyretics	O
prior	O
to	O
infusion	O
.	O
	
5.4	O
Use	O
with	O
Medications	O
Known	O
to	O
Cause	O
Hypoglycemia	O
Insulin	O
and	O
insulin	O
secretagogues	O
,	O
such	O
as	O
sulfonylureas	O
,	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
The	O
majority	O
of	O
these	O
immune-mediated	O
reactions	O
initially	O
manifested	O
during	O
treatment	O
;	O
however	O
,	O
a	O
minority	O
occurred	O
weeks	O
to	O
months	O
after	O
discontinuation	O
of	O
YERVOY	O
.	O
	
5.9	O
COC	O
Use	O
Before	O
or	O
During	O
Early	O
Pregnancy	O
Extensive	O
epidemiological	O
studies	O
have	O
revealed	O
no	O
increased	O
risk	O
of	O
birth	B
defects	I
in	O
women	O
who	O
have	O
used	O
oral	O
contraceptives	O
prior	O
to	O
pregnancy	O
.	O
	
For	O
invasive	O
dental	O
procedures	O
,	O
withhold	O
COMETRIQ	O
treatment	O
for	O
at	O
least	O
28	O
days	O
prior	O
to	O
scheduled	O
surgery	O
,	O
if	O
possible	O
.	O
	
Women	O
on	O
thyroid	O
hormone	O
replacement	O
therapy	O
may	O
need	O
increased	O
doses	O
of	O
thyroid	O
hormone	O
because	O
serum	O
concentrations	O
of	O
thyroid-binding	B
globulin	I
increase	I
with	O
use	O
of	O
COCs	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
If	O
contraceptive	O
methods	O
are	O
being	O
considered	O
,	O
use	O
effective	O
contraception	O
during	O
treatment	O
,	O
and	O
for	O
at	O
least	O
1	O
month	O
after	O
the	O
last	O
dose	O
of	O
Zydelig	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
At	O
baseline	O
,	O
2.5	O
%	O
of	O
the	O
population	O
reported	O
retinopathy	O
.	O
	
5.2	O
Carcinoma	O
of	O
the	O
Breasts	O
and	O
Reproductive	O
Organs	O
Women	O
who	O
currently	O
have	O
or	O
have	O
had	O
breast	O
cancer	O
should	O
not	O
use	O
Natazia	O
because	O
breast	O
cancer	O
is	O
a	O
hormonally-sensitive	O
tumor	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Increased	O
dosage	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
before	O
,	O
during	O
and	O
after	O
stressful	O
situations	O
.	O
	
5.3	O
Nutritional	O
Management	O
Since	O
hyperammonemia	O
is	O
the	O
result	O
of	O
protein	O
catabolism	O
,	O
complete	O
protein	O
restriction	O
is	O
recommended	O
to	O
be	O
maintained	O
for	O
24	O
to	O
48	O
hours	O
and	O
caloric	O
supplementation	O
should	O
be	O
maximized	O
to	O
reverse	O
catabolism	O
and	O
nitrogen	O
turnover	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
CIMZIA	O
.	O
	
Women	O
who	O
are	O
not	O
pregnant	O
and	O
use	O
Natazia	O
,	O
may	O
experience	O
amenorrhea	B
.	O
	
Monitor	O
plasma	O
zinc	O
,	O
and	O
supplement	O
in	O
the	O
event	O
of	O
a	O
deficiency	O
.	O
	
Patients	O
using	O
BREO	O
ELLIPTA	O
should	O
not	O
use	O
another	O
medicine	O
containing	O
a	O
LABA	O
(	O
e.g.	O
,	O
salmeterol	O
,	O
formoterol	O
fumarate	O
,	O
arformoterol	O
tartrate	O
,	O
indacaterol	O
)	O
for	O
any	O
reason	O
.	O
	
(	O
5.8	O
)	O
*	O
Reversible	B
posterior	I
leukoencephalopathy	I
syndrome	I
(	O
RPLS	B
)	O
:	O
Discontinue	O
COMETRIQ	O
.	O
	
Documented	O
symptomatic	B
hypoglycemia	I
occurred	O
in	O
39	O
%	O
and	O
40	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
a	O
sulfonylurea	O
.	O
	
In	O
addition	O
,	O
it	O
is	O
recommended	O
to	O
avoid	O
use	O
of	O
XIAFLEX	O
in	O
patients	O
with	O
coagulation	O
disorders	O
,	O
including	O
patients	O
receiving	O
concomitant	O
anticoagulants	O
(	O
except	O
for	O
low-dose	O
aspirin	O
)	O
.	O
	
Reversal	O
of	O
Anticoagulant	O
Effect	O
:	O
A	O
specific	O
reversal	O
agent	O
for	O
dabigatran	O
is	O
not	O
available	O
.	O
	
FANAPT	O
shares	O
this	O
pharmacologic	O
activity	O
.	O
	
(	O
5.4	O
)	O
*	O
Increased	B
LDL-C	I
:	O
Monitor	O
and	O
treat	O
per	O
standard	O
of	O
care	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
In	O
the	O
controlled	O
portions	O
of	O
the	O
clinical	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
a	O
greater	O
proportion	O
of	O
XIAFLEX-treated	O
patients	O
(	O
15	O
%	O
)	O
compared	O
to	O
placebo-treated	O
patients	O
(	O
1	O
%	O
)	O
had	O
mild	O
allergic	B
reactions	I
(	O
pruritus	B
)	O
after	O
up	O
to	O
3	O
injections	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
ZYKADIA	O
and	O
for	O
at	O
least	O
2	O
weeks	O
following	O
completion	O
of	O
therapy	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
Post-Transplant	O
Lymphoproliferative	O
Disorder	O
Reported	O
cases	O
of	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
up	O
to	O
36	O
months	O
post	O
transplant	O
were	O
obtained	O
for	O
NULOJIX	O
by	O
pooling	O
both	O
dosage	O
regimens	O
of	O
NULOJIX	O
in	O
Studies	O
1	O
and	O
2	O
(	O
804	O
patients	O
)	O
with	O
data	O
from	O
a	O
third	O
study	O
in	O
kidney	O
transplantation	O
(	O
Study	O
3	O
,	O
145	O
patients	O
)	O
which	O
evaluated	O
two	O
NULOJIX	O
dosage	O
regimens	O
similar	O
,	O
but	O
slightly	O
different	O
,	O
from	O
those	O
of	O
Studies	O
1	O
and	O
2	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
YERVOY	O
can	O
result	O
in	O
severe	O
and	O
fatal	B
immune-mediated	B
adverse	I
reactions	I
due	O
to	O
T-cell	O
activation	O
and	O
proliferation	O
.	O
	
Before	O
initiating	O
FARXIGA	O
in	O
patients	O
with	O
one	O
or	O
more	O
of	O
these	O
characteristics	O
,	O
volume	O
status	O
should	O
be	O
assessed	O
and	O
corrected	O
.	O
	
Patients	O
who	O
develop	O
arrhythmic	O
symptoms	O
(	O
e.g.	O
,	O
palpitations	O
,	O
lightheadedness	O
)	O
or	O
new	O
onset	O
dyspnea	O
should	O
have	O
an	O
ECG	O
performed	O
.	O
	
The	O
reporting	O
rate	O
of	O
these	O
reactions	O
associated	O
with	O
oxcarbazepine	O
use	O
exceeds	O
the	O
background	O
incidence	O
rate	O
estimates	O
by	O
a	O
factor	O
of	O
3-	O
to	O
10-fold	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
INLYTA	O
.	O
	
Appropriate	O
clinical	O
monitoring	O
for	O
SIRTURO-related	O
adverse	O
reactions	O
is	O
recommended	O
.	O
	
A	O
causal	O
relationship	O
to	O
drug	O
exposure	O
has	O
not	O
been	O
established	O
.	O
	
Additional	O
signs	O
may	O
include	O
elevated	B
creatine	I
phosphokinase	I
,	O
myoglobinuria	B
(	O
rhabdomyolysis	B
)	O
,	O
and	O
acute	B
renal	I
failure	I
.	O
	
*	O
Record	O
the	O
date	O
you	O
open	O
the	O
foil	O
pouch	O
in	O
the	O
space	O
provided	O
on	O
the	O
blister	O
package	O
label	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
.	O
	
Common	O
adverse	O
events	O
(	O
>	O
=5	O
%	O
in	O
any	O
XEOMIN	O
treatment	O
group	O
)	O
observed	O
in	O
patients	O
who	O
received	O
XEOMIN	O
(	O
120	O
Units	O
or	O
240	O
Units	O
)	O
included	O
dysphagia	B
,	O
neck	B
pain	I
,	O
muscle	B
weakness	I
,	O
injection	B
site	I
pain	I
,	O
and	O
musculoskeletal	B
pain	I
.	O
	
Hemoglobin/Hematocrit	O
Low	B
hemoglobin	I
were	O
observed	O
in	O
0.2	O
%	O
,	O
0.4	O
%	O
,	O
and	O
0.3	O
%	O
of	O
Edarbi-treated	O
subjects	O
,	O
respectively	O
.	O
	
The	O
data	O
below	O
reflect	O
exposure	O
to	O
ADCETRIS	O
as	O
monotherapy	O
in	O
327	O
patients	O
with	O
classical	O
Hodgkin	O
lymphoma	O
(	O
HL	O
)	O
and	O
systemic	O
anaplastic	O
large	O
cell	O
lymphoma	O
(	O
sALCL	O
)	O
,	O
including	O
160	O
patients	O
in	O
two	O
uncontrolled	O
single-arm	O
trials	O
(	O
Studies	O
1	O
and	O
2	O
)	O
and	O
167	O
patients	O
in	O
one	O
placebo-controlled	O
randomized	O
trial	O
(	O
Study	O
3	O
)	O
.	O
	
These	O
consisted	O
mainly	O
of	O
dyspnea	B
.	O
	
No	O
data	O
are	O
available	O
on	O
the	O
secondary	O
transmission	O
of	O
infection	O
from	O
persons	O
receiving	O
live	O
vaccines	O
to	O
patients	O
receiving	O
BENLYSTA	O
or	O
the	O
effect	O
of	O
BENLYSTA	O
on	O
new	O
immunizations	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
with	O
SAPHRIS	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
in	O
SAPHRIS-treated	O
Bipolar	O
Patients	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
>	O
=2	O
%	O
in	O
any	O
SAPHRIS	O
dose	O
group	O
and	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
therapy	O
are	O
shown	O
in	O
Table	O
10	O
.	O
	
*	O
have	O
unusual	O
vaginal	O
bleeding	O
.	O
	
The	O
majority	O
of	O
the	O
reports	O
of	O
eyelid	B
ptosis	I
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
over	O
several	O
weeks	O
.	O
	
(	O
r	O
)	O
)	O
Program	O
.	O
	
Through	O
96	O
weeks	O
,	O
the	O
rate	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
was	O
2	O
%	O
in	O
both	O
treatment	O
arms	O
.	O
	
In	O
those	O
patients	O
treated	O
with	O
HORIZANT	O
who	O
reported	O
dizziness	B
,	O
symptoms	O
persisted	O
during	O
treatment	O
in	O
about	O
20	O
%	O
.	O
	
Dizziness	B
,	O
tachycardia	B
,	O
and	O
weight	B
increased	I
were	O
at	O
least	O
twice	O
as	O
common	O
on	O
20	O
to	O
24	O
mg/day	O
as	O
on	O
10	O
to	O
16	O
mg/day	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
alglucosidase	O
alfa	O
.	O
	
Infections	B
resulting	O
in	O
death	B
occurred	O
in	O
0.3	O
%	O
(	O
4/1,458	O
)	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
and	O
in	O
0.1	O
%	O
(	O
1/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
keratitis	O
evaluation	O
.	O
	
Following	O
resolution	O
of	O
transaminase	O
elevations	O
,	O
consider	O
the	O
benefits	O
and	O
risks	O
of	O
resuming	O
KALYDECO	O
dosing	O
.	O
	
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
and	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
See	O
Table	O
3	O
and	O
Table	O
4	O
for	O
other	O
potentially	O
significant	O
drug	O
interactions	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
An	O
increase	O
in	O
the	O
AFINITOR	O
dose	O
is	O
recommended	O
when	O
co-administered	O
with	O
a	O
strong	O
CYP3A4/PgP	O
inducer	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
The	O
population	O
had	O
a	O
mean	O
age	O
of	O
39	O
(	O
range	O
:	O
18	O
to	O
75	O
)	O
,	O
94	O
%	O
were	O
female	O
,	O
and	O
52	O
%	O
were	O
Caucasian	O
.	O
	
Administration	O
of	O
ILARIS	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
.	O
	
The	O
rate	O
of	O
treatment	O
discontinuation	O
due	O
to	O
urinary	B
tract	I
infections	I
was	O
0.1	O
%	O
,	O
0.2	O
%	O
,	O
and	O
0.1	O
%	O
for	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
Serious	O
Adverse	O
Events	O
and	O
Discontinuation	O
-	O
Perioperative	O
Hypertension	O
Studies	O
The	O
incidence	O
of	O
adverse	O
events	O
leading	O
to	O
study	O
drug	O
discontinuation	O
in	O
patients	O
with	O
perioperative	O
hypertension	O
receiving	O
Cleviprex	O
was	O
5.9	O
%	O
versus	O
3.2	O
%	O
for	O
all	O
active	O
comparators	O
.	O
	
(	O
5.3	O
)	O
*	O
Continue	O
hydration	O
and	O
alkalinization	O
of	O
the	O
urine	O
as	O
indicated	O
.	O
	
Episodes	O
vary	O
in	O
frequency	O
,	O
severity	O
and	O
may	O
be	O
life-threatening	O
if	O
treatment	O
is	O
delayed	O
.	O
	
Healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
the	O
similarity	O
of	O
symptoms	O
between	O
hypersensitivity	O
reactions	O
and	O
hereditary	O
angioedema	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
.	O
	
Spinal/epidural	O
anesthesia	O
or	O
puncture	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
1	O
%	O
)	O
are	O
related	O
to	O
bleeding	B
.	O
	
*	O
Worsening	B
Renal	I
Impairment	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
through	O
approximately	O
92	O
weeks	O
,	O
the	O
incidence	O
of	O
malignancies	B
per	O
100	O
patient-years	O
,	O
other	O
than	O
lymphoma	B
and	O
NMSC	B
,	O
in	O
SIMPONI	O
ARIA-treated	O
patients	O
was	O
0.31	O
(	O
CI	O
:	O
0.06	O
,	O
0.92	O
)	O
and	O
the	O
incidence	O
of	O
NMSC	B
was	O
0.1	O
(	O
95	O
%	O
CI	O
:	O
0.00	O
,	O
0.58	O
)	O
.	O
	
In	O
vitro	O
studies	O
with	O
human	O
platelets	O
indicate	O
that	O
STENDRA	O
potentiates	B
the	I
anti-aggregatory	I
effect	I
of	I
sodium	I
nitroprusside	I
(	O
a	O
nitric	O
oxide	O
[	O
NO	O
]	O
donor	O
)	O
.	O
	
(	O
5.3,7.2,7.3	O
)	O
5.1	O
Prolongation	O
of	O
the	O
QT	O
Interval	O
Some	O
antimalarials	O
(	O
e.g.	O
,	O
halofantrine	O
,	O
quinine	O
,	O
quinidine	O
)	O
including	O
Coartem	O
Tablets	O
have	O
been	O
associated	O
with	O
prolongation	B
of	I
the	I
QT	I
interval	I
on	O
the	O
electrocardiogram	O
.	O
	
*	O
Hypersensitivity	O
reactions	O
:	O
anaphylaxis	B
,	O
urticaria	B
,	O
angioedema	B
,	O
and	O
serious	O
skin	B
reactions	I
(	O
bullous	B
eruption	I
)	O
have	O
been	O
reported	O
.	O
	
The	O
small	O
number	O
of	O
patients	O
positive	O
for	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
limits	O
the	O
ability	O
to	O
draw	O
definitive	O
conclusions	O
regarding	O
the	O
relationship	O
between	O
antibodies	O
to	O
golimumab	O
and	O
clinical	O
efficacy	O
or	O
safety	O
measures	O
.	O
	
5.5	O
Liver	O
Injury	O
*	O
Hepatocellular	B
liver	I
injury	I
,	O
including	O
acute	B
liver	I
failure	I
requiring	O
transplant	O
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
MULTAQ	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
The	O
data	O
above	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
in	O
an	O
ELISA	O
assay	O
.	O
	
5.2	O
Risk	O
for	O
Image	O
Misinterpretation	O
and	O
Other	O
Errors	O
Errors	O
may	O
occur	O
while	O
using	O
Vizamyl	O
PET	O
images	O
to	O
estimate	O
brain	O
neuritic	O
plaque	O
density	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Administration	O
Reactions	O
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
,	O
1.1	O
%	O
of	O
SIMPONI	O
ARIA	O
infusions	O
were	O
associated	O
with	O
an	O
infusion	B
reaction	I
compared	O
with	O
0.2	O
%	O
of	O
infusions	O
in	O
the	O
control	O
group	O
.	O
	
Discontinue	O
medication	O
pending	O
examination	O
if	O
there	O
is	O
sudden	O
partial	O
or	O
complete	O
loss	O
of	O
vision	O
,	O
or	O
a	O
sudden	O
onset	O
of	O
proptosis	O
,	O
diplopia	O
,	O
or	O
migraine	O
.	O
	
*	O
receiving	O
medications	O
that	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
enzyme	O
CYP2D6	O
which	O
also	O
have	O
cardiac	O
effects	O
(	O
e.g.	O
,	O
flecainide	O
,	O
imipramine	O
,	O
amitriptyline	O
,	O
clomipramine	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.6	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Postmarketing	O
cases	O
of	O
hepatosplenic	B
T-cell	I
lymphoma	I
(	O
HSTCL	B
)	O
,	O
a	O
rare	O
type	O
of	O
T-cell	O
lymphoma	O
that	O
has	O
a	O
very	O
aggressive	O
disease	O
course	O
and	O
is	O
usually	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
.	O
	
There	O
are	O
no	O
data	O
on	O
the	O
risks	O
of	O
using	O
CIMZIA	O
in	O
patients	O
who	O
have	O
experienced	O
a	O
severe	O
hypersensitivity	O
reaction	O
towards	O
another	O
TNF	O
blocker	O
;	O
in	O
these	O
patients	O
caution	O
is	O
needed	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Bleeding	B
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
?	O
	
Table	O
4	O
lists	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
in	O
the	O
pooled	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
Symptoms	O
reported	O
included	O
sudden	O
onset	O
of	O
severe	O
headache	B
,	O
altered	B
mental	I
status	I
,	O
visual	B
disturbances	I
,	O
and	O
seizure	B
.	O
	
The	O
incidence	O
of	O
Grade	O
3	O
hyperglycemia	B
based	O
on	O
laboratory	O
values	O
was	O
6	O
%	O
(	O
12/187	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
compared	O
with	O
none	O
of	O
the	O
dacarbazine-treated	O
patients	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Serious	O
Allergic	O
Reactions	O
Serious	O
allergic	B
reactions	I
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
EXCERPT	O
:	O
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
prolactin	I
levels	I
was	O
4.9	O
ng/mL	O
for	O
SAPHRIS-treated	O
patients	O
compared	O
to	O
a	O
decrease	O
of	O
0.2	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
*	O
Life-threatening	O
anaphylactic	B
reactions	I
and	O
severe	O
hypersensitivity	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
and	O
after	O
alglucosidase	O
alfa	O
infusions	O
.	O
	
5.4	O
Immune-mediated	O
Neuropathies	O
In	O
Study	O
1	O
,	O
1	O
case	O
of	O
fatal	B
Guillain-Barre	B
syndrome	I
and	O
1	O
case	O
of	O
severe	O
(	O
Grade	O
3	O
)	O
peripheral	B
motor	I
neuropathy	I
were	O
reported	O
.	O
	
Do	O
not	O
place	O
DUAVEE	O
in	O
pill	O
boxes	O
or	O
pill	O
organizers	O
.	O
	
Extrapyramidal	O
Symptoms	O
(	O
EPS	O
)	O
in	O
Clinical	O
Trials	O
Pooled	O
data	O
from	O
the	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
provided	O
information	O
regarding	O
treatment-emergent	O
EPS	B
.	O
	
(	O
6.4	O
)	O
SEGA	O
with	O
TSC	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
are	O
stomatitis	B
and	O
respiratory	B
tract	I
infection	I
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
below	O
is	O
based	O
upon	O
two	O
double-blind	O
,	O
placebo-controlled	O
,	O
48-week	O
clinical	O
trials	O
(	O
Trials	O
1	O
and	O
2	O
)	O
in	O
a	O
total	O
of	O
213	O
patients	O
with	O
CF	O
ages	O
6	O
to	O
53	O
who	O
have	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
and	O
who	O
were	O
treated	O
with	O
KALYDECO	O
150	O
mg	O
orally	O
or	O
placebo	O
twice	O
daily	O
.	O
	
Administer	O
corticosteroid	O
eye	O
drops	O
to	O
patients	O
who	O
develop	O
uveitis	O
,	O
iritis	O
,	O
or	O
episcleritis	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
moderate	O
to	O
severe	O
immune-mediated	B
endocrinopathy	I
was	O
11	O
weeks	O
and	O
ranged	O
up	O
to	O
19.3	O
weeks	O
after	O
the	O
initiation	O
of	O
YERVOY	O
.	O
	
*	O
help	O
reduce	O
your	O
chances	O
of	O
developing	O
osteoporosis	O
(	O
thin	O
,	O
weak	O
bones	O
)	O
If	O
you	O
use	O
DUAVEE	O
only	O
to	O
prevent	O
osteoporosis	O
due	O
to	O
menopause	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
about	O
whether	O
a	O
different	O
treatment	O
or	O
medicine	O
without	O
estrogens	O
might	O
be	O
better	O
for	O
you.DUAVEE	O
should	O
be	O
taken	O
for	O
the	O
shortest	O
time	O
possible	O
and	O
only	O
for	O
as	O
long	O
as	O
treatment	O
is	O
needed	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
from	O
last	O
dose	O
of	O
DYSPORT	O
(	O
r	O
)	O
was	O
approximately	O
one	O
week	O
,	O
and	O
the	O
median	O
duration	O
was	O
approximately	O
three	O
weeks	O
.	O
	
5.7	O
Immunization	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
for	O
30	O
days	O
before	O
or	O
concurrently	O
with	O
BENLYSTA	O
as	O
clinical	O
safety	O
has	O
not	O
been	O
established	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
These	O
reactions	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
ARCAPTA	O
NEOHALER	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
acutely	O
deteriorating	O
COPD	O
.	O
	
In	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
,	O
the	O
incidence	O
rate	O
of	O
pancreatitis	B
(	I
acute	I
)	O
was	O
0.9	O
,	O
2.7	O
,	O
and	O
0.9	O
per	O
1000	O
patient-years	O
of	O
exposure	O
to	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Obtain	O
serum	O
potassium	O
,	O
calcium	O
,	O
and	O
magnesium	O
at	O
baseline	O
and	O
correct	O
if	O
abnormal	O
.	O
	
*	O
A	O
24-week	O
placebo-controlled	O
trial	O
(	O
Trial	O
5	O
)	O
involving	O
69	O
patients	O
between	O
the	O
ages	O
of	O
6	O
and	O
68	O
years	O
with	O
an	O
R117H	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
At	O
the	O
recommended	O
dose	O
of	O
50	O
mg	O
,	O
the	O
discontinuation	O
rate	O
due	O
to	O
an	O
adverse	O
reaction	O
for	O
PRISTIQ	O
(	O
4.1	O
%	O
)	O
was	O
similar	O
to	O
the	O
rate	O
for	O
placebo	O
(	O
3.8	O
%	O
)	O
.	O
	
(	O
5.1	O
,	O
5.2	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
YERVOY	O
can	O
result	O
in	O
severe	O
and	O
fatal	B
immune-mediated	B
reactions	I
due	O
to	O
T-cell	O
activation	O
and	O
proliferation	O
.	O
	
Information	O
on	O
selected	O
significant	O
adverse	O
reactions	O
observed	O
during	O
clinical	O
trials	O
is	O
summarized	O
below	O
.	O
	
The	O
administration	O
of	O
oral	O
contraceptives	O
to	O
induce	O
withdrawal	O
bleeding	O
should	O
not	O
be	O
used	O
as	O
a	O
test	O
for	O
pregnancy	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
XIAFLEX-associated	O
pruritus	B
increased	O
after	O
more	O
XIAFLEX	O
injections	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
.	O
	
There	O
is	O
no	O
evidence	O
of	O
increased	O
risk	O
of	O
infections	O
with	O
continued	O
exposure	O
over	O
time	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Conduct	O
periodic	O
monitoring	O
with	O
electrocardiograms	O
(	O
ECGs	O
)	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
those	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
.	O
	
c	O
Confidence	O
interval	O
Patients	O
Major	O
bleeding	B
event	O
a	O
Bleeding	B
sites	O
for	O
MBE	B
b	O
Clinically	O
relevant	O
non-major	O
bleeding	B
Any	O
bleeding	B
In	O
the	O
RE-MEDY	O
study	O
,	O
the	O
rate	O
of	O
any	O
gastrointestinal	B
bleeds	I
in	O
patients	O
receiving	O
PRADAXA	O
150	O
mg	O
was	O
3.1	O
%	O
(	O
2.2	O
%	O
on	O
warfarin	O
)	O
.	O
	
There	O
were	O
insufficient	O
numbers	O
of	O
patients	O
with	O
biopsy-proven	O
hepatitis	O
to	O
characterize	O
the	O
clinical	O
course	O
of	O
this	O
event	O
.	O
	
Increased	O
dosage	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
before	O
,	O
during	O
and	O
after	O
stressful	O
situations	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
One	O
patient	O
with	O
baseline	O
hyperuricemia	O
and	O
bulky	O
disease	O
experienced	O
Grade	O
4	O
tumor	B
lysis	I
syndrome	I
during	O
the	O
first	O
cycle	O
of	O
treatment	O
and	O
died	B
due	O
to	O
multi-organ	B
failure	I
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
receiving	O
HALAVEN	O
were	O
febrile	B
neutropenia	I
(	O
4	O
%	O
)	O
and	O
neutropenia	B
(	O
2	O
%	O
)	O
.	O
	
Although	O
some	O
past	O
studies	O
have	O
suggested	O
that	O
COCs	O
might	O
increase	O
the	O
incidence	O
of	O
breast	B
cancer	I
,	O
more	O
recent	O
studies	O
have	O
not	O
confirmed	O
such	O
findings	O
.	O
	
The	O
adverse	O
reactions	O
were	O
predominantly	O
of	O
mild	O
to	O
moderate	O
intensity	O
.	O
	
Do	O
not	O
resume	O
Ferriprox	O
in	O
patients	O
who	O
have	O
developed	O
agranulocytosis	O
unless	O
potential	O
benefits	O
outweigh	O
potential	O
risks	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Exelixis	O
,	O
Inc.	O
at	O
1-855-500-3935	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Other	O
adverse	O
reactions	O
seen	O
frequently	O
in	O
one	O
or	O
more	O
studies	O
included	O
asthenia	B
,	O
fatigue	B
,	O
malaise	B
,	O
and	O
weakness	B
;	O
dry	B
mouth	I
;	O
somnolence	B
;	O
cough	B
;	O
constipation	B
;	O
headache	B
;	O
mucosal	B
inflammation	I
and	O
stomatitis	B
.	O
	
Across	O
clinical	O
trials	O
(	O
n=1669	O
)	O
,	O
49	O
XALKORI-treated	O
patients	O
(	O
2.9	O
%	O
)	O
had	O
ILD	B
of	O
any	O
grade	O
,	O
18	O
patients	O
(	O
1.1	O
%	O
)	O
had	O
Grade	O
3	O
or	O
4	O
ILD	B
,	O
and	O
8	O
patients	O
(	O
0.5	O
%	O
)	O
had	O
fatal	B
ILD	B
.	O
	
Of	O
the	O
total	O
8,394	O
patients	O
exposed	O
to	O
at	O
least	O
one	O
dose	O
of	O
PRISTIQ	O
;	O
2,116	O
were	O
exposed	O
to	O
PRISTIQ	O
for	O
6	O
months	O
,	O
representing	O
1,658	O
patient-years	O
of	O
exposure	O
,	O
and	O
421	O
were	O
exposed	O
for	O
one	O
year	O
,	O
representing	O
416	O
patient-years	O
of	O
exposure	O
.	O
	
Advise	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
taking	O
the	O
drug	O
(	O
5.7	O
)	O
.	O
	
(	O
5.8	O
)	O
*	O
QT	B
Prolongation	I
:	O
Increases	B
in	I
QT	I
interval	I
;	O
avoid	O
use	O
with	O
drugs	O
that	O
also	O
increase	O
the	O
QT	O
interval	O
and	O
in	O
patients	O
with	O
risk	O
factors	O
for	O
prolonged	O
QT	O
interval	O
.	O
	
5.4	O
Immediate	O
Hypersensitivity	O
Reactions	O
Immediate	O
hypersensitivity	B
reactions	I
may	O
occur	O
after	O
administration	O
of	O
ARCAPTA	O
NEOHALER	O
.	O
	
Table	O
1	O
Summary	O
of	O
Treatment	O
Exposure	O
in	O
RE-LY	O
PRADAXA	O
110	O
mg	O
twice	O
daily	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
Warfarin	O
Total	O
number	O
treated	O
5983	O
6059	O
5998	O
Exposure	O
>	O
12	O
months	O
4936	O
4939	O
5193	O
>	O
24	O
months	O
2387	O
2405	O
2470	O
Mean	O
exposure	O
(	O
months	O
)	O
20.5	O
20.3	O
21.3	O
Total	O
patient-years	O
10,242	O
10,261	O
10,659	O
Drug	O
Discontinuation	O
in	O
RE-LY	O
The	O
rates	O
of	O
adverse	O
reactions	O
leading	O
to	O
treatment	O
discontinuation	O
were	O
21	O
%	O
for	O
PRADAXA	O
150	O
mg	O
and	O
16	O
%	O
for	O
warfarin	O
.	O
	
as	O
rescue	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.6	O
Discontinuation	O
of	O
HORIZANT	O
When	O
discontinuing	O
HORIZANT	O
,	O
patients	O
with	O
RLS	O
receiving	O
600	O
mg	O
or	O
less	O
once	O
daily	O
can	O
discontinue	O
the	O
drug	O
without	O
tapering	O
.	O
	
DRESS	B
typically	O
,	O
although	O
not	O
exclusively	O
,	O
presents	O
with	O
fever	B
,	O
rash	B
,	O
and/or	O
lymphadenopathy	B
,	O
in	O
association	O
with	O
other	O
organ	O
system	O
involvement	O
,	O
such	O
as	O
hepatitis	B
,	O
nephritis	B
,	O
hematological	B
abnormalities	I
,	O
myocarditis	B
,	O
or	O
myositis	B
sometimes	O
resembling	O
an	O
acute	O
viral	O
infection	O
.	O
	
All	O
serious	O
adverse	O
events	O
were	O
assessed	O
as	O
unrelated	O
to	O
study	O
drug	O
.	O
	
Patients	O
receiving	O
BENLYSTA	O
should	O
be	O
instructed	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
experience	O
new	O
or	O
worsening	O
depression	O
,	O
suicidal	O
thoughts	O
,	O
or	O
other	O
mood	O
changes	O
.	O
	
Report	O
any	O
diagnosis	O
of	O
NSF	O
following	O
DOTAREM	O
administration	O
to	O
Guerbet	O
LLC	O
(	O
1-877-729-6679	O
)	O
or	O
FDA	O
(	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
)	O
.	O
	
On	O
Day	O
1	O
,	O
the	O
maximum	O
decline	B
in	I
heart	I
rate	I
generally	O
occurs	O
within	O
6	O
hours	O
and	O
recovers	O
,	O
although	O
not	O
to	O
baseline	O
levels	O
,	O
by	O
8	O
to	O
10	O
hours	O
postdose	O
.	O
	
Falls	B
were	O
not	O
associated	O
with	O
loss	B
of	I
consciousness	I
or	O
seizure	B
.	O
	
If	O
an	O
anaphylactic	O
or	O
other	O
serious	O
allergic	O
reaction	O
occurs	O
,	O
administration	O
of	O
SIMPONI	O
ARIA	O
should	O
be	O
discontinued	O
immediately	O
and	O
appropriate	O
therapy	O
instituted	O
.	O
	
(	O
5.6	O
)	O
*	O
Liver	B
injury	I
:	O
liver	O
enzyme	O
results	O
should	O
be	O
available	O
before	O
initiation	O
.	O
	
The	O
incidence	O
of	O
Grade	O
1-4	O
thrombocytopenia	B
was	O
6	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.3	O
%	O
Grade	O
3-4	O
)	O
and	O
5	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
0.5	O
%	O
Grade	O
3-4	O
)	O
.	O
	
5.7	O
Thyroid	O
Dysfunction	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
hypothyroidism	B
was	O
reported	O
in	O
69/359	O
patients	O
(	O
19	O
%	O
)	O
receiving	O
INLYTA	O
and	O
29/355	O
patients	O
(	O
8	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Serious	O
infusion	B
reactions	I
(	O
excluding	O
hypersensitivity	B
reactions	I
)	O
were	O
reported	O
in	O
0.5	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
and	O
included	O
bradycardia	B
,	O
myalgia	B
,	O
headache	B
,	O
rash	B
,	O
urticaria	B
,	O
and	O
hypotension	B
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
trial	O
that	O
compared	O
the	O
safety	O
of	O
another	O
LABA	O
(	O
salmeterol	O
)	O
with	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
subjects	O
receiving	O
salmeterol	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
INLYTA	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
RPLS	O
is	O
not	O
known	O
.	O
	
Cardiac	O
Disorders	O
Palpitations	B
,	O
tachycardia	B
.	O
	
If	O
appropriate	O
,	O
initiation	O
of	O
anti-hepatitis	O
B	O
therapy	O
may	O
be	O
warranted	O
.	O
	
A	O
causal	O
relationship	O
with	O
alvimopan	O
with	O
long-term	O
use	O
has	O
not	O
been	O
established	O
.	O
	
Because	O
patients	O
with	O
moderate	O
to	O
severe	O
renal	O
impairment	O
(	O
CrCl	O
<	O
=50mL/min	O
)	O
would	O
require	O
a	O
dose	O
lower	O
than	O
10	O
mg	O
twice	O
daily	O
and	O
no	O
strength	O
smaller	O
than	O
10	O
mg	O
is	O
available	O
,	O
AMPYRA	O
is	O
contraindicated	O
in	O
these	O
patients	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Consultation	O
with	O
a	O
specialist	O
(	O
e.g.	O
,	O
neurologist	O
and/or	O
infectious	O
disease	O
)	O
should	O
be	O
considered	O
for	O
any	O
suspected	O
or	O
confirmed	O
cases	O
of	O
PML	O
.	O
	
Bleeding	B
events	O
were	O
counted	O
during	O
treatment	O
or	O
within	O
2	O
days	O
of	O
stopping	O
study	O
treatment	O
(	O
on-treatment	O
period	O
)	O
.	O
	
These	O
wound-related	O
complications	O
may	O
require	O
surgical	O
intervention	O
.	O
	
There	O
has	O
been	O
a	O
long-standing	O
concern	O
,	O
however	O
,	O
that	O
antidepressants	O
may	O
have	O
a	O
role	O
in	O
inducing	O
worsening	B
of	I
depression	I
and	O
the	O
emergence	O
of	O
suicidality	B
in	O
certain	O
patients	O
during	O
the	O
early	O
phases	O
of	O
treatment	O
.	O
	
Complete	O
treatment	O
of	O
pre-existing	O
invasive	O
fungal	O
infections	O
prior	O
to	O
starting	O
treatment	O
with	O
AFINITOR	O
.	O
	
(	O
5.3	O
)	O
*	O
Venous	B
Thromboembolism	I
:	O
Deep	B
vein	I
thrombosis	I
and	O
pulmonary	B
embolism	I
can	O
occur	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
types	O
of	O
AR	O
resulting	O
in	O
withdrawal	O
from	O
the	O
study	O
varied	O
considerably	O
.	O
	
In	O
Trial	O
1	O
,	O
cutaneous	B
squamous	I
cell	I
carcinomas	I
and	O
keratoacanthomas	B
(	O
cuSCC	B
)	O
occurred	O
in	O
7	O
%	O
(	O
14/187	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
in	O
none	O
of	O
the	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
Three	O
percent	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
had	O
platelet	B
counts	I
of	I
less	I
than	I
50	I
*	I
10	I
9	I
per	I
L	I
compared	O
to	O
1	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Classical	O
HL	O
Post-auto-HSCT	O
Consolidation	O
(	O
Study	O
3	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
329	O
patients	O
with	O
classical	O
HL	O
at	O
high	O
risk	O
of	O
relapse	O
or	O
progression	O
post-auto-HSCT	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
of	O
ADCETRIS	O
administered	O
intravenously	O
over	O
30	O
minutes	O
every	O
3	O
weeks	O
or	O
placebo	O
for	O
up	O
to	O
16	O
cycles	O
.	O
	
Clinical	O
surveillance	O
of	O
all	O
women	O
taking	O
DUAVEE	O
is	O
important	O
.	O
	
Immunogenicity	O
Antibodies	O
to	O
SIMPONI	O
ARIA	O
were	O
detected	O
in	O
13	O
(	O
3	O
%	O
)	O
golimumab-treated	O
patients	O
following	O
IV	O
administration	O
of	O
SIMPONI	O
ARIA	O
in	O
combination	O
with	O
MTX	O
through	O
Week	O
24	O
of	O
Trial	O
1	O
.	O
	
(	O
5.2	O
)	O
*	O
Direct	B
Coombs	I
'	I
test	I
seroconversion	I
has	O
been	O
reported	O
with	O
Teflaro	O
.	O
	
The	O
size	O
of	O
the	O
control	O
group	O
and	O
limited	O
duration	O
of	O
the	O
controlled	O
portions	O
of	O
the	O
studies	O
precludes	O
the	O
ability	O
to	O
draw	O
firm	O
conclusions	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
,	O
did	O
not	O
lead	O
to	O
discontinuation	O
of	O
study	O
medication	O
,	O
and	O
resolved	O
.	O
	
5.5	O
Macrophage	O
Activation	O
Syndrome	O
Macrophage	O
activation	O
syndrome	O
(	O
MAS	O
)	O
is	O
a	O
known	O
,	O
life-threatening	O
disorder	O
that	O
may	O
develop	O
in	O
patients	O
with	O
rheumatic	O
conditions	O
,	O
in	O
particular	O
SJIA	O
,	O
and	O
should	O
be	O
aggressively	O
treated	O
.	O
	
Appropriate	O
fluid	O
and	O
electrolyte	O
management	O
,	O
protein	O
supplementation	O
,	O
antibiotic	O
treatment	O
of	O
C.	O
difficile	O
,	O
and	O
surgical	O
evaluation	O
should	O
be	O
instituted	O
as	O
clinically	O
indicated	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
rarely	O
during	O
the	O
post-marketing	O
use	O
of	O
BEPREVE	O
.	O
	
Test	O
patients	O
for	O
HBV	O
infection	O
before	O
initiating	O
treatment	O
with	O
CIMZIA	O
.	O
	
In	O
patients	O
with	O
end-stage	O
renal	O
failure	O
,	O
hepatic	O
contrast	O
was	O
markedly	O
reduced	O
and	O
was	O
attributed	O
to	O
elevated	O
serum	O
ferritin	O
levels	O
.	O
	
*	O
with	O
known	O
disturbances	O
of	O
electrolyte	O
balance	O
,	O
e.g.	O
,	O
hypokalemia	O
or	O
hypomagnesemia	O
.	O
	
Percentages	O
calculated	O
with	O
the	O
number	O
of	O
male	O
subjects	O
in	O
each	O
group	O
as	O
denominator	O
:	O
placebo	O
(	O
N=514	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=556	O
)	O
,	O
JARDIANCE	O
25	O
mg	O
(	O
N=557	O
)	O
.	O
	
One	O
case	O
of	O
ANC	B
less	I
than	I
0.5x10	I
9	I
/L	I
was	O
observed	O
in	O
the	O
ILARIS	O
group	O
and	O
none	O
in	O
the	O
placebo	O
group	O
.	O
	
Elevations	O
5-fold	O
the	O
ULN	O
or	O
greater	O
occurred	O
in	O
4.5	O
%	O
of	O
patients	O
on	O
GILENYA	O
and	O
1	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
in	O
Patients	O
with	O
Dupuytren	O
's	O
Contracture	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
received	O
BENLYSTA	O
at	O
doses	O
of	O
1	O
mg/kg	O
(	O
N	O
=	O
673	O
)	O
,	O
4	O
mg/kg	O
(	O
N	O
=	O
111	O
;	O
Trial	O
1	O
only	O
)	O
,	O
or	O
10	O
mg/kg	O
(	O
N	O
=	O
674	O
)	O
or	O
placebo	O
(	O
N	O
=	O
675	O
)	O
intravenously	O
over	O
a	O
1-hour	O
period	O
on	O
Days	O
0	O
,	O
14	O
,	O
28	O
,	O
and	O
then	O
every	O
28	O
days	O
.	O
	
Physicians	O
should	O
also	O
consider	O
the	O
risk	O
that	O
reduced	O
immunosuppression	O
represents	O
to	O
the	O
functioning	O
allograft	O
.	O
	
The	O
pooled	O
mean	O
maximum	O
dose	O
in	O
these	O
studies	O
was	O
10	O
mg/hour	O
and	O
the	O
mean	O
duration	O
of	O
treatment	O
was	O
8	O
hours	O
.	O
	
In	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
,	O
the	O
median	O
time	O
to	O
initial	O
onset	O
of	O
fever	B
was	O
30	O
days	O
compared	O
with	O
19	O
days	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
;	O
the	O
median	O
duration	O
of	O
fever	B
was	O
6	O
days	O
with	O
the	O
combination	O
compared	O
with	O
4	O
days	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.2	O
Renal	O
Impairment	O
AMPYRA	O
is	O
eliminated	O
through	O
the	O
kidneys	O
primarily	O
as	O
unchanged	O
drug	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.4	O
)	O
]	O
.	O
	
Use	O
cautiously	O
in	O
patients	O
with	O
seizure	O
disorder	O
(	O
5.8	O
)	O
.	O
	
The	O
incidence	O
of	O
opportunistic	B
infections	I
was	O
similar	O
between	O
placebo	O
and	O
Prolia	O
groups	O
,	O
and	O
the	O
overall	O
incidence	O
of	O
infections	B
was	O
similar	O
between	O
the	O
treatment	O
groups	O
.	O
	
There	O
was	O
one	O
death	B
due	O
to	O
pulmonary	B
embolism	I
on	O
the	O
placebo	O
arm	O
.	O
	
Hepatic	O
function	O
should	O
be	O
monitored	O
closely	O
in	O
these	O
patients	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
signs	O
and	O
symptoms	O
.	O
	
*	O
Infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	B
exacerbation	I
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
due	O
to	O
fluid	B
overload	I
,	O
and	O
require	O
additional	O
monitoring	O
(	O
5.3	O
)	O
.	O
	
These	O
events	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness	O
,	O
frequency	O
of	O
reporting	O
,	O
or	O
causal	O
connection	O
to	O
BREO	O
ELLIPTA	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O
	
In	O
those	O
patients	O
treated	O
with	O
HORIZANT	O
who	O
reported	O
somnolence	B
,	O
the	O
somnolence	B
persisted	O
during	O
treatment	O
in	O
about	O
30	O
%	O
.	O
	
5.10	O
Proteinuria	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
proteinuria	B
was	O
reported	O
in	O
39/359	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
INLYTA	O
and	O
26/355	O
patients	O
(	O
7	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
treated	O
with	O
GILOTRIF	O
were	O
diarrhea	B
(	O
6.6	O
%	O
)	O
;	O
vomiting	B
(	O
4.8	O
%	O
)	O
;	O
and	O
dyspnea	B
,	O
fatigue	B
,	O
and	O
hypokalemia	B
(	O
1.7	O
%	O
each	O
)	O
.	O
	
Two	O
patients	O
(	O
2	O
%	O
)	O
on	O
placebo	O
and	O
1	O
patient	O
(	O
0.5	O
%	O
)	O
on	O
KALYDECO	O
permanently	O
discontinued	O
treatment	O
for	O
elevated	B
transaminases	I
,	O
all	O
>	O
8	O
*	O
ULN	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
59	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Edarbi	O
as	O
soon	O
as	O
possible	O
[	O
seeUse	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
Postmarketing	O
reports	O
indicate	O
that	O
the	O
effects	O
of	O
XEOMIN	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	O
produce	O
symptoms	O
consistent	O
with	O
botulinum	O
toxin	B
effects	I
.	O
	
(	O
5.5	O
)	O
*	O
Decrease	B
in	I
pulmonary	I
function	I
tests	I
)	O
:	O
Obtain	O
PFT	O
when	O
clinically	O
indicated	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
In	O
a	O
pooled	O
analysis	O
of	O
clinical	O
studies	O
,	O
adverse	O
reactions	O
with	O
an	O
incidence	O
of	O
less	O
than	O
2	O
%	O
reported	O
in	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
groups	O
included	O
dysphagia	B
0.5	O
%	O
,	O
gait	B
disturbance	I
0.5	O
%	O
,	O
hypertonia	B
0.5	O
%	O
,	O
and	O
sensation	B
of	I
heaviness	I
0.3	O
%	O
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
discontinue	O
administration	O
of	O
alglucosidase	O
alfa	O
,	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
.	O
	
Other	O
than	O
injection	B
site	I
reactions	I
,	O
most	O
adverse	O
reactions	O
became	O
noticeable	O
about	O
one	O
week	O
after	O
treatment	O
and	O
lasted	O
several	O
weeks	O
.	O
	
Monitor	O
glucose	O
levels	O
in	O
patients	O
at	O
baseline	O
and	O
periodically	O
during	O
treatment	O
.	O
	
At	O
baseline	O
,	O
57	O
%	O
of	O
the	O
population	O
had	O
diabetes	O
more	O
than	O
5	O
years	O
and	O
had	O
a	O
mean	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
of	O
8	O
%	O
.	O
	
Table	O
2	O
summarizes	O
the	O
adverse	O
reactions	O
regardless	O
of	O
causality	O
from	O
the	O
trial	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
.	O
	
Tables	O
5	O
and	O
6	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
in	O
XALKORI-treated	O
patients	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
or	O
a	O
history	O
of	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
SAPHRIS	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
a	O
patient	O
becomes	O
pregnant	O
while	O
receiving	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
seeUse	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
If	O
signs	O
suggesting	O
allergic	O
reactions	O
(	O
in	O
particular	O
,	O
difficulties	O
in	O
breathing	O
or	O
swallowing	O
,	O
swelling	O
of	O
tongue	O
,	O
lips	O
and	O
face	O
,	O
urticaria	O
,	O
skin	O
rash	O
)	O
occur	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
be	O
discontinued	O
immediately	O
and	O
alternative	O
therapy	O
instituted	O
.	O
	
Withholding	O
treatment	O
should	O
be	O
considered	O
in	O
patients	O
with	O
serious	O
infections	O
until	O
the	O
infection	O
(	O
s	O
)	O
is	O
resolved	O
.	O
	
Events	O
related	O
to	O
dizziness	B
and	O
disturbance	B
in	I
gait	I
were	O
more	O
often	O
serious	O
in	O
APTIOM-treated	O
patients	O
than	O
in	O
placebo-treated	O
patients	O
(	O
2	O
%	O
vs.	O
0	O
%	O
)	O
,	O
and	O
more	O
often	O
led	O
to	O
study	O
withdrawal	O
in	O
APTIOM-treated	O
patients	O
than	O
in	O
placebo-treated	O
patients	O
(	O
9	O
%	O
vs.	O
0.7	O
%	O
)	O
.	O
	
Management	O
of	O
hypersensitivity	O
reactions	O
should	O
be	O
based	O
on	O
the	O
severity	O
of	O
the	O
reaction	O
and	O
include	O
slowing	O
or	O
temporary	O
interruption	O
of	O
the	O
infusion	O
and/or	O
administration	O
of	O
additional	O
antihistamines	O
,	O
antipyretics	O
,	O
and/or	O
corticosteroids	O
for	O
mild	O
reactions	O
.	O
	
Evaluate	O
patients	O
with	O
thigh	O
or	O
groin	O
pain	O
to	O
rule	O
out	O
a	O
femoral	O
fracture	O
(	O
5.5	O
)	O
*	O
Serious	O
infections	B
including	O
skin	B
infections	I
:	O
May	O
occur	O
,	O
including	O
those	O
leading	O
to	O
hospitalization	O
.	O
	
(	O
5.1	O
)	O
*	O
BEPREVE	O
should	O
not	O
be	O
used	O
to	O
treat	O
contact	O
lens-related	O
irritation	O
.	O
	
d	O
Includes	O
fatigue	B
,	O
asthenia	B
,	O
malaise	B
.	O
	
Discontinue	O
PRADAXA	O
in	O
patients	O
with	O
active	O
pathological	O
bleeding	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Increase	O
in	O
Serum	O
Inorganic	O
Phosphorus	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
increases	B
from	I
baseline	I
in	I
mean	I
serum	I
phosphorus	I
levels	I
were	O
reported	O
at	O
Week	O
24	O
in	O
FARXIGA-treated	O
patients	O
compared	O
with	O
placebo-treated	O
patients	O
(	O
mean	O
increase	O
of	O
0.13	O
versus	O
-0.04	O
mg/dL	O
,	O
respectively	O
)	O
.	O
	
Institute	O
hormone	O
replacement	O
therapy	O
as	O
needed	O
.	O
	
Prescribers	O
should	O
monitor	O
patients	O
for	O
somnolence	O
and	O
sedation	O
,	O
particularly	O
with	O
concomitant	O
use	O
of	O
other	O
central	O
nervous	O
system	O
depressants	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
resulting	O
in	O
discontinuation	O
of	O
HALAVEN	O
was	O
peripheral	B
neuropathy	I
(	O
5	O
%	O
)	O
.	O
	
There	O
is	O
substantial	O
evidence	O
that	O
COCs	O
do	O
not	O
increase	O
the	O
incidence	O
of	O
breast	B
cancer	I
.	O
	
Patients	O
with	O
pneumonitis	O
thought	O
to	O
be	O
caused	O
by	O
Zydelig	O
have	O
been	O
treated	O
with	O
discontinuation	O
of	O
Zydelig	O
and	O
administration	O
of	O
corticosteroids	O
.	O
	
5.2	O
Deterioration	O
of	O
Disease	O
and	O
Acute	O
Episodes	O
BREO	O
ELLIPTA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
during	O
rapidly	O
deteriorating	O
or	O
potentially	O
life-threatening	O
episodes	O
of	O
COPD	O
or	O
asthma	O
.	O
	
(	O
5.12	O
)	O
*	O
Assess	O
for	O
decrease	O
in	O
bone	O
mineral	O
density	O
initially	O
and	O
periodically	O
thereafter	O
.	O
	
If	O
neurological	O
compromise	O
is	O
noted	O
,	O
urgent	O
treatment	O
is	O
necessary	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.Consider	O
the	O
benefits	O
and	O
risks	O
before	O
neuraxial	O
intervention	O
in	O
patients	O
anticoagulated	O
or	O
to	O
be	O
anticoagulated	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
5.2	O
Therapeutic	O
Monitoring	O
Plasma	O
ammonia	O
levels	O
should	O
be	O
maintained	O
within	O
normal	O
range	O
for	O
age	O
via	O
individual	O
dose	O
adjustment	O
.	O
	
c	O
Confidence	O
interval	O
Patients	O
Major	O
bleeding	B
event	O
a	O
Clinically	O
relevant	O
non-major	O
bleeding	B
Any	O
bleeding	B
In	O
the	O
RE-SONATE	O
study	O
,	O
the	O
rate	O
of	O
any	O
gastrointestinal	B
bleeds	I
in	O
patients	O
receiving	O
PRADAXA	O
150	O
mg	O
was	O
0.7	O
%	O
(	O
0.3	O
%	O
on	O
placebo	O
)	O
.	O
	
Factors	O
that	O
can	O
increase	O
the	O
risk	O
of	O
developing	O
epidural	O
or	O
spinal	O
hematomas	O
in	O
these	O
patients	O
include	O
:	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
,	O
such	O
as	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
platelet	O
inhibitors	O
,	O
other	O
anticoagulants	O
a	O
history	O
of	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
punctures	O
a	O
history	O
of	O
spinal	O
deformity	O
or	O
spinal	O
surgery	O
optimal	O
timing	O
between	O
the	O
administration	O
of	O
PRADAXA	O
and	O
neuraxial	O
procedures	O
is	O
not	O
known	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
until	O
hyperglycemia	O
is	O
adequately	O
controlled	O
,	O
then	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
.	O
	
Discontinue	O
Zydelig	O
permanently	O
in	O
patients	O
who	O
experience	O
intestinal	O
perforation	O
.	O
	
Patients	O
taking	O
Zydelig	O
who	O
present	O
with	O
pulmonary	O
symptoms	O
such	O
as	O
cough	O
,	O
dyspnea	O
,	O
hypoxia	O
,	O
interstitial	O
infiltrates	O
on	O
a	O
radiologic	O
exam	O
,	O
or	O
a	O
decline	O
by	O
more	O
than	O
5	O
%	O
in	O
oxygen	O
saturation	O
should	O
be	O
evaluated	O
for	O
pneumonitis	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
.	O
]	O
	
For	O
patients	O
whose	O
sera	O
tested	O
positive	O
in	O
the	O
screening	O
immunoassay	O
,	O
an	O
in	O
vitro	O
biological	O
assay	O
was	O
performed	O
to	O
detect	O
neutralizing	O
antibodies	O
.	O
	
Among	O
the	O
28	O
patients	O
with	O
Grade	O
2	O
enterocolitis	B
,	O
79	O
%	O
experienced	O
complete	O
resolution	O
,	O
11	O
%	O
improved	O
,	O
and	O
11	O
%	O
did	O
not	O
improve	O
.	O
	
The	O
detection	O
of	O
anti-blinatumomab	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
At	O
baseline	O
,	O
5.2	O
%	O
of	O
the	O
population	O
reported	O
retinopathy	O
.	O
	
5.6	O
Neurological	O
Adverse	O
Reactions	O
Dizziness	O
and	O
Disturbance	O
in	O
Gait	O
and	O
Coordination	O
APTIOM	O
causes	O
dose-related	O
increases	O
in	O
adverse	O
reactions	O
related	O
to	O
dizziness	B
and	O
disturbance	B
in	I
gait	I
(	O
dizziness	B
,	O
ataxia	B
,	O
vertigo	B
,	O
balance	B
disorder	I
,	O
gait	B
disturbance	I
,	O
nystagmus	B
,	O
and	O
abnormal	B
coordination	I
)	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.1	O
Hemorrhage	O
Fatal	B
bleeding	B
events	I
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
5.3	O
Spinal	O
or	O
Cervical	O
Cord	O
Compression	O
Spinal	O
or	O
cervical	O
cord	O
compression	O
(	O
SCC	O
)	O
is	O
a	O
known	O
and	O
serious	O
complication	O
of	O
MPS	O
IVA	O
and	O
may	O
occur	O
as	O
part	O
of	O
the	O
natural	O
history	O
of	O
the	O
disease	O
.	O
	
The	O
mean	O
duration	O
of	O
exposure	O
to	O
INVOKANA	O
was	O
38	O
weeks	O
with	O
1832	O
individuals	O
exposed	O
to	O
INVOKANA	O
for	O
greater	O
than	O
50	O
weeks	O
.	O
	
All	O
men	O
were	O
instructed	O
to	O
take	O
at	O
least	O
1000	O
mg	O
of	O
calcium	O
and	O
800	O
IU	O
of	O
vitamin	O
D	O
supplementation	O
per	O
day	O
.	O
	
It	O
is	O
not	O
known	O
if	O
DUAVEE	O
passes	O
into	O
your	O
breast	O
milk	O
.	O
	
Laboratory	O
Abnormalities	O
Table	O
6	O
describes	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
reported	O
at	O
a	O
rate	O
of	O
>	O
=10	O
%	O
in	O
the	O
KRd	O
arm	O
for	O
patients	O
who	O
received	O
combination	O
therapy	O
.	O
	
It	O
is	O
recommended	O
that	O
therapeutic	O
infectious	O
agents	O
not	O
be	O
given	O
concurrently	O
with	O
SIMPONI	O
ARIA	O
.	O
	
(	O
5.10	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
disorders	O
because	O
of	O
beta-adrenergic	O
stimulation	O
.	O
	
(	O
5.8	O
)	O
*	O
Blood	O
pressure	O
(	O
BP	O
)	O
:	O
Monitor	O
BP	O
during	O
treatment	O
.	O
	
Infections	O
In	O
Study	O
1	O
,	O
1	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
compared	O
to	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
died	B
from	O
infections	B
or	O
sepsis	B
.	O
	
Testing	O
was	O
performed	O
in	O
patients	O
who	O
experienced	O
moderate	O
to	O
severe	O
or	O
hypersensitivity	B
reactions	I
,	O
for	O
which	O
mast-cell	O
activation	O
was	O
suspected	O
.	O
	
5.2	O
Weight	O
Decrease	O
During	O
the	O
controlled	O
period	O
of	O
the	O
studies	O
in	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
weight	B
decrease	I
between	O
5	O
%	O
-10	O
%	O
of	O
body	O
weight	O
was	O
reported	O
in	O
10	O
%	O
(	O
49/497	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
compared	O
to	O
3.3	O
%	O
(	O
16/495	O
)	O
treated	O
with	O
placebo	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
LACTIC	B
ACIDOSIS/SEVERE	O
HEPATOMEGALY	B
WITH	O
STEATOSIS	B
and	O
POST	O
TREATMENT	O
ACUTE	B
EXACERBATION	I
OF	I
HEPATITIS	I
B	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
prednisone	O
)	O
at	O
the	O
time	O
of	O
fracture	O
.	O
	
5.16	O
Laboratory	O
Tests	O
Serum	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
estradiol	O
levels	O
have	O
not	O
been	O
shown	O
to	O
be	O
useful	O
in	O
the	O
management	O
of	O
moderate	O
to	O
severe	O
vasomotor	O
symptoms	O
.	O
	
SAPHRIS	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
dementia-related	O
psychosis	O
,	O
and	O
should	O
not	O
be	O
used	O
in	O
patients	O
at	O
risk	O
for	O
aspiration	O
pneumonia	O
[	O
see	O
also	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
These	O
events	O
are	O
notable	O
because	O
of	O
their	O
seriousness	O
,	O
severity	O
,	O
or	O
increased	O
frequency	O
in	O
subjects	O
who	O
received	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
compared	O
with	O
subjects	O
who	O
received	O
only	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
PRISTIQ	O
should	O
be	O
discontinued	O
before	O
initiating	O
treatment	O
with	O
the	O
MAOI	O
[	O
see	O
Contraindications	O
(	O
4.2	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2.6	O
)	O
]	O
.	O
	
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
additional	O
estrogens	O
as	O
this	O
may	O
increase	O
the	O
risk	O
of	O
endometrial	O
hyperplasia	O
.	O
	
In	O
the	O
event	O
of	O
an	O
erection	O
that	O
persists	O
longer	O
than	O
4	O
hours	O
,	O
the	O
patient	O
should	O
seek	O
immediate	O
medical	O
assistance	O
.	O
	
There	O
is	O
evidence	O
to	O
suggest	O
that	O
some	O
patients	O
who	O
develop	O
high	O
and	O
sustained	O
IgG	O
antibody	O
titers	O
may	O
experience	O
reduced	B
clinical	I
efficacy	I
to	O
alglucosidase	O
alfa	O
treatment	O
,	O
such	O
as	O
loss	B
of	I
motor	I
function	I
,	O
ventilator	O
dependence	O
,	O
or	O
death	B
.	O
	
In	O
addition	O
,	O
because	O
ILARIS	O
may	O
interfere	B
with	I
normal	I
immune	I
response	I
to	O
new	O
antigens	O
,	O
vaccinations	O
may	O
not	O
be	O
effective	O
in	O
patients	O
receiving	O
ILARIS	O
.	O
	
Subgroup	O
analyses	O
of	O
women	O
50	O
to	O
59	O
years	O
of	O
age	O
suggest	O
a	O
statistically	O
non-significant	O
reduction	O
in	O
CHD	B
events	O
(	O
CE	O
[	O
0.625	O
mg	O
]	O
-alone	O
compared	O
to	O
placebo	O
)	O
in	O
women	O
with	O
less	O
than	O
10	O
years	O
since	O
menopause	O
(	O
8	O
versus	O
16	O
per	O
10,000	O
women-years	O
)	O
.	O
	
In	O
controlled	O
studies	O
of	O
CIMZIA	O
for	O
Crohn	O
's	O
disease	O
and	O
other	O
investigational	O
uses	O
,	O
there	O
was	O
one	O
case	O
of	O
lymphoma	B
among	O
2,657	O
Cimzia-treated	O
patients	O
and	O
one	O
case	O
of	O
Hodgkin	B
's	I
lymphoma	I
among	O
1,319	O
placebo-treated	O
patients	O
.	O
	
Coronary	O
Heart	O
Disease	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
no	O
overall	O
effect	O
on	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
events	O
(	O
defined	O
as	O
nonfatal	O
myocardial	B
infarction	I
,	O
silent	B
myocardial	I
infarction	I
,	O
or	O
CHD	B
death	I
)	O
was	O
reported	O
in	O
women	O
receiving	O
estrogen-alone	O
compared	O
to	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
Physicians	O
should	O
be	O
attentive	O
to	O
symptoms	O
of	O
infection	O
or	O
worsening	O
of	O
SJIA	O
,	O
as	O
these	O
are	O
known	O
triggers	O
for	O
MAS	O
.	O
	
If	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
other	O
serotonergic	O
drugs	O
,	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
buspirone	O
,	O
tryptophan	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
is	O
clinically	O
warranted	O
,	O
patients	O
should	O
be	O
made	O
aware	O
of	O
a	O
potential	O
increased	O
risk	O
for	O
serotonin	O
syndrome	O
,	O
particularly	O
during	O
treatment	O
initiation	O
and	O
dose	O
increases	O
.	O
	
The	O
concomitant	O
use	O
of	O
ADCETRIS	O
with	O
bleomycin	O
is	O
contraindicated	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
After	O
an	O
average	O
follow-up	O
of	O
5.2	O
years	O
,	O
28	O
women	O
in	O
the	O
estrogen-alone	O
group	O
and	O
19	O
women	O
in	O
the	O
placebo	O
group	O
were	O
diagnosed	O
with	O
probable	O
dementia	B
.	O
	
The	O
safety	O
of	O
DIFICID	O
200	O
mg	O
tablets	O
taken	O
twice	O
a	O
day	O
for	O
10	O
days	O
was	O
evaluated	O
in	O
564	O
patients	O
with	O
CDAD	O
in	O
two	O
active-comparator	O
controlled	O
trials	O
with	O
86.7	O
%	O
of	O
patients	O
receiving	O
a	O
full	O
course	O
of	O
treatment	O
.	O
	
Short-term	O
studies	O
did	O
not	O
show	O
an	O
increase	O
in	O
the	O
risk	O
of	O
suicidality	B
with	O
antidepressants	O
compared	O
to	O
placebo	O
in	O
adults	O
beyond	O
age	O
24	O
;	O
there	O
was	O
a	O
reduction	O
with	O
antidepressants	O
compared	O
to	O
placebo	O
in	O
adults	O
aged	O
65	O
and	O
older	O
.	O
	
The	O
safety	O
of	O
VORAXAZE	O
is	O
based	O
on	O
data	O
from	O
290	O
patients	O
who	O
were	O
treated	O
in	O
2	O
single-arm	O
,	O
open-label	O
,	O
multicenter	O
trials	O
enrolling	O
patients	O
who	O
had	O
markedly	O
delayed	O
methotrexate	O
clearance	O
secondary	O
to	O
renal	O
dysfunction	O
.	O
	
In	O
addition	O
to	O
the	O
term	O
injection	B
site	I
reaction	I
(	O
see	O
Table	O
1	O
)	O
,	O
the	O
following	O
other	O
types	O
of	O
injection	B
site	I
reactions	I
also	O
occurred	O
more	O
frequently	O
on	O
TANZEUM	O
:	O
injection	B
site	I
hematoma	I
(	O
1.9	O
%	O
versus	O
2.1	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
erythema	I
(	O
0.4	O
%	O
versus	O
1.7	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
rash	I
(	O
0	O
%	O
versus	O
1.4	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
hypersensitivity	I
(	O
0	O
%	O
versus	O
0.8	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
and	O
injection	B
site	I
hemorrhage	I
(	O
0.6	O
%	O
versus	O
0.7	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
5.2	O
Immunosuppression	O
The	O
impact	O
of	O
treatment	O
with	O
anti-interleukin-1	O
(	O
IL-1	O
)	O
therapy	O
on	O
the	O
development	O
of	O
malignancies	O
is	O
not	O
known	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
ENTEREG	O
REMS	O
Program	O
that	O
restricts	O
use	O
to	O
enrolled	O
hospitals	O
because	O
of	O
the	O
potential	O
risk	O
of	O
myocardial	O
infarction	O
with	O
long-term	O
use	O
of	O
ENTEREG	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
*	O
If	O
you	O
miss	O
a	O
dose	O
of	O
DUAVEE	O
,	O
take	O
it	O
as	O
soon	O
as	O
you	O
remember	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
severe	O
neuropathy	O
(	O
interfering	O
with	O
daily	O
activities	O
)	O
such	O
as	O
Guillain-Barre-like	O
syndromes	O
.	O
	
The	O
ADRs	O
observed	O
in	O
FLAMINGO	O
were	O
generally	O
consistent	O
with	O
those	O
seen	O
in	O
SPRING-2	O
and	O
SINGLE	O
.	O
	
Adverse	O
laboratory	O
and	O
ECG	O
effects	O
are	O
presented	O
separately	O
in	O
Table	O
2	O
.	O
	
A	O
total	O
of	O
64	O
%	O
of	O
patients	O
on	O
GILOTRIF	O
and	O
67	O
%	O
of	O
pemetrexed/cisplatin	O
patients	O
were	O
female	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
are	O
adverse	O
events	O
in	O
which	O
there	O
is	O
some	O
basis	O
to	O
believe	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
the	O
drug	O
and	O
the	O
occurrence	O
of	O
the	O
adverse	O
event	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
who	O
have	O
evidence	O
of	O
untreated	O
brain	O
metastasis	O
or	O
recent	O
active	O
gastrointestinal	O
bleeding	O
and	O
should	O
not	O
be	O
used	O
in	O
those	O
patients	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
alglucosidase	O
alfa	O
to	O
patients	O
susceptible	O
to	O
fluid	O
volume	O
overload	O
.	O
	
Administer	O
insulin	O
therapy	O
as	O
necessary	O
in	O
patients	O
with	O
hyperglycemia	O
.	O
	
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
.	O
	
The	O
risk	O
of	O
suicidal	B
thoughts	I
was	O
generally	O
consistent	O
among	O
drugs	O
in	O
the	O
data	O
analyzed	O
.	O
	
Patients	O
treated	O
with	O
any	O
AED	O
for	O
any	O
indication	O
should	O
be	O
monitored	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
depression	O
,	O
suicidal	O
thoughts	O
or	O
behavior	O
,	O
and/or	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
.	O
	
Obtain	O
an	O
ECG	O
before	O
initiation	O
of	O
treatment	O
,	O
and	O
at	O
least	O
2	O
,	O
12	O
,	O
and	O
24	O
weeks	O
after	O
starting	O
treatment	O
with	O
SIRTURO	O
.	O
	
Most	O
of	O
these	O
reactions	O
may	O
have	O
been	O
the	O
consequence	O
of	O
the	O
surgical	O
procedure	O
.	O
	
5.5	O
Paradoxical	O
Bronchospasm	O
As	O
with	O
other	O
inhaled	O
beta2-agonists	O
,	O
ARCAPTA	O
NEOHALER	O
may	O
produce	O
paradoxical	B
bronchospasm	I
that	O
may	O
be	O
life-threatening	O
.	O
	
Table	O
5	O
.	O
	
If	O
a	O
patient	O
develops	O
a	O
dermatologic	O
reaction	O
while	O
taking	O
APTIOM	O
,	O
discontinue	O
APTIOM	O
use	O
,	O
unless	O
the	O
reaction	O
is	O
clearly	O
not	O
drug-related	O
.	O
	
A	O
total	O
of	O
1,867	O
subjects	O
were	O
included	O
in	O
two	O
clinical	O
phase	O
3	O
studies	O
with	O
a	O
treatment	O
duration	O
up	O
to	O
28	O
cycles	O
with	O
Natazia	O
as	O
an	O
oral	O
contraceptive	O
and	O
264	O
subjects	O
in	O
the	O
two	O
phase	O
3	O
clinical	O
trials	O
with	O
a	O
treatment	O
duration	O
of	O
7	O
cycles	O
evaluating	O
Natazia	O
in	O
the	O
treatment	O
of	O
heavy	O
,	O
prolonged	O
,	O
and/or	O
frequent	O
menstrual	O
bleeding	O
in	O
women	O
without	O
organic	O
pathology	O
.	O
	
The	O
hypersensitivity	B
reactions	I
include	O
itching	B
,	O
body	B
rash	I
,	O
and	O
swelling	B
of	I
lips	I
.	O
	
Consider	O
as	O
a	O
possible	O
cause	O
for	O
severe	O
joint	O
pain	O
and	O
discontinue	O
drug	O
if	O
appropriate	O
.	O
	
Patients	O
treated	O
with	O
concomitant	O
immunosuppressants	O
had	O
a	O
lower	O
rate	O
of	O
antibody	O
development	O
than	O
patients	O
not	O
taking	O
immunosuppressants	O
at	O
baseline	O
(	O
3	O
%	O
and	O
11	O
%	O
,	O
respectively	O
)	O
.	O
	
The	O
immunogenicity	O
of	O
BLINCYTO	O
has	O
been	O
evaluated	O
using	O
either	O
an	O
electrochemiluminescence	O
detection	O
technology	O
(	O
ECL	O
)	O
or	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
screening	O
immunoassay	O
for	O
the	O
detection	O
of	O
binding	O
anti-blinatumomab	O
antibodies	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
1	O
%	O
or	O
greater	O
)	O
are	O
:	O
systemic	B
hypersensitivity	I
,	O
hyperglycemia	B
,	O
transaminases	B
abnormal	I
,	O
fever	B
,	O
pancreatitis	B
,	O
local	B
reactions	I
,	O
vomiting	B
,	O
nausea	B
,	O
thrombosis	B
,	O
hyperbilirubinemia	B
,	O
abdominal	B
pain	I
,	O
and	O
diarrhea	B
.	O
	
Table	O
4	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
study	O
.	O
	
Neuropathy	B
lasting	O
more	O
than	O
one	O
year	O
occurred	O
in	O
5	O
%	O
(	O
26/503	O
)	O
of	O
patients	O
.	O
	
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
>	O
1	O
%	O
were	O
associated	O
with	O
the	O
injection	B
site	I
(	I
1.3	I
%	I
)	I
,	I
problems	I
.	O
	
If	O
signs	O
or	O
symptoms	O
suggest	O
SJS/TEN	O
,	O
use	O
of	O
this	O
drug	O
should	O
not	O
be	O
resumed	O
and	O
alternative	O
therapy	O
should	O
be	O
considered	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Withhold	O
Zydelig	O
if	O
the	O
ALT	O
or	O
AST	O
is	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
continue	O
to	O
monitor	O
AST	O
,	O
ALT	O
and	O
total	O
bilirubin	O
weekly	O
until	O
the	O
abnormality	O
is	O
resolved	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Women	O
with	O
a	O
history	O
of	O
COC-related	O
cholestasis	B
may	O
have	O
the	O
condition	O
recur	O
with	O
subsequent	O
COC	O
use	O
.	O
	
Withdrawal	O
symptoms	O
(	O
e.g.	O
,	O
convulsions	O
,	O
psychosis	O
,	O
hallucinations	O
,	O
behavioral	O
disorder	O
,	O
tremor	O
,	O
and	O
anxiety	O
)	O
have	O
been	O
reported	O
following	O
abrupt	O
discontinuance	O
of	O
benzodiazepines	O
.	O
	
Hypersensitivity	B
reactions	I
have	O
uncommonly	O
been	O
reported	O
during	O
the	O
postmarketing	O
use	O
of	O
AdreView	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
safety	O
profile	O
for	O
subjects	O
who	O
completed	O
48	O
weeks	O
of	O
treatment	O
was	O
similar	O
to	O
the	O
safety	O
profile	O
for	O
subjects	O
who	O
completed	O
24	O
weeks	O
of	O
treatment	O
.	O
	
Women	O
with	O
hypertriglyceridemia	O
,	O
or	O
a	O
family	O
history	O
thereof	O
,	O
may	O
be	O
at	O
an	O
increased	O
risk	O
of	O
pancreatitis	B
when	O
using	O
COCs	O
.	O
	
The	O
incidence	O
of	O
hypertension	B
increases	O
with	O
increasing	O
concentration	O
of	O
progestin	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
have	O
a	O
genital	B
mycotic	I
infection	I
during	O
the	O
study	O
than	O
those	O
with	O
no	O
prior	O
history	O
(	O
10.0	O
%	O
,	O
23.1	O
%	O
,	O
and	O
25.0	O
%	O
versus	O
0.8	O
%	O
,	O
5.9	O
%	O
,	O
and	O
5.0	O
%	O
on	O
placebo	O
,	O
FARXIGA	O
5	O
mg	O
,	O
and	O
FARXIGA	O
10	O
mg	O
,	O
respectively	O
)	O
.	O
	
Two	O
(	O
1	O
%	O
)	O
of	O
these	O
were	O
fatal	B
.	O
	
Non-melanoma	B
skin	I
cancer	I
was	O
reported	O
in	O
1.5	O
%	O
(	O
6/401	O
)	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
in	O
3.7	O
%	O
(	O
15/405	O
)	O
of	O
patients	O
treated	O
with	O
cyclosporine	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Evaluate	O
at	O
each	O
visit	O
for	O
signs	O
and	O
symptoms	O
of	O
endocrinopathy	O
.	O
	
POTIGA	O
was	O
associated	O
with	O
dose-related	O
weight	B
gain	I
,	O
with	O
mean	O
weight	B
increasing	I
by	O
0.2	O
kg	O
,	O
1.2	O
kg	O
,	O
1.6	O
kg	O
,	O
and	O
2.7	O
kg	O
in	O
the	O
placebo	O
,	O
600	O
mg	O
per	O
day	O
,	O
900	O
mg	O
per	O
day	O
,	O
and	O
1,200	O
mg	O
per	O
day	O
groups	O
,	O
respectively	O
.	O
	
5.3	O
Cytopenias	O
Treatment-emergent	O
Grade	O
3	O
or	O
4	O
cytopenias	B
including	O
neutropenia	B
(	O
range	O
,	O
19	O
to	O
29	O
%	O
)	O
,	O
thrombocytopenia	B
(	O
range	O
,	O
5	O
to	O
17	O
%	O
)	O
,	O
and	O
anemia	B
(	O
range	O
,	O
0	O
to	O
9	O
%	O
)	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
5.3	O
Hepatic	O
Effects	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
fatal	B
and	O
nonfatal	O
hepatic	B
failure	I
in	O
patients	O
taking	O
NESINA	O
,	O
although	O
some	O
of	O
the	O
reports	O
contain	O
insufficient	O
information	O
necessary	O
to	O
establish	O
the	O
probable	O
cause	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Permanently	O
discontinue	O
XALKORI	O
in	O
patients	O
who	O
develop	O
QTc	O
greater	O
than	O
500	O
ms	O
or	O
greater	O
than	O
or	O
equal	O
to	O
60	O
ms	O
change	O
from	O
baseline	O
with	O
Torsade	O
de	O
pointes	O
or	O
polymorphic	O
ventricular	O
tachycardia	O
or	O
signs/symptoms	O
of	O
serious	O
arrhythmia	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
ophthalmic	O
steroids	O
include	O
elevated	B
intraocular	I
pressure	I
,	O
which	O
may	O
be	O
associated	O
with	O
optic	B
nerve	I
damage	I
,	O
visual	B
acuity	I
and	I
field	I
defects	I
,	O
posterior	B
subcapsular	I
cataract	I
formation	I
;	O
secondary	B
ocular	I
infection	I
,	O
and	O
perforation	B
of	I
the	I
globe	I
where	O
there	O
is	O
thinning	O
of	O
the	O
cornea	O
or	O
sclera	O
.	O
	
Table	O
3	O
.	O
	
In	O
addition	O
,	O
beta-agonists	O
have	O
been	O
reported	O
to	O
produce	O
ECG	B
changes	I
,	O
such	O
as	O
flattening	B
of	I
the	I
T	I
wave	I
,	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
and	O
ST	B
segment	I
depression	I
,	O
although	O
the	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
PRADAXA	O
were	O
related	O
to	O
bleeding	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
emtricitabine	O
and	O
tenofovir	O
DF	O
components	O
of	O
STRIBILD	O
are	O
primarily	O
excreted	O
by	O
the	O
kidney	O
.	O
	
Appropriate	O
medical	O
support	O
,	O
including	O
cardiopulmonary	O
resuscitation	O
equipment	O
,	O
should	O
be	O
readily	O
available	O
when	O
alglucosidase	O
alfa	O
is	O
administered	O
.	O
	
The	O
median	O
onset	O
time	O
for	O
hypertension	B
(	O
systolic	B
blood	I
pressure	I
>	I
150	I
mmHg	I
or	O
diastolic	B
blood	I
pressure	I
>	I
100	I
mmHg	I
)	O
was	O
within	O
the	O
first	O
month	O
of	O
the	O
start	O
of	O
INLYTA	O
treatment	O
and	O
blood	B
pressure	I
increases	I
have	O
been	O
observed	O
as	O
early	O
as	O
4	O
days	O
after	O
starting	O
INLYTA	O
.	O
	
b	O
Peripheral	B
neuropathies	I
NEC	I
includes	O
the	O
preferred	O
terms	O
under	O
HLT	O
peripheral	B
neuropathies	I
NEC	I
.	O
	
Severe	O
acute	B
exacerbations	I
of	I
hepatitis	I
B	I
have	O
been	O
reported	O
in	O
patients	O
who	O
are	O
coinfected	O
with	O
HBV	O
and	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
and	O
have	O
discontinued	O
EMTRIVA	O
or	O
VIREAD	O
,	O
which	O
are	O
components	O
of	O
STRIBILD	O
.	O
	
Causes	O
of	O
death	B
on	O
the	O
AFINITOR	O
arm	O
included	O
one	O
case	O
of	O
each	O
of	O
the	O
following	O
:	O
acute	B
renal	I
failure	I
,	O
acute	B
respiratory	I
distress	I
,	O
cardiac	B
arrest	I
,	O
death	B
(	O
cause	O
unknown	O
)	O
,	O
hepatic	B
failure	I
,	O
pneumonia	B
,	O
and	O
sepsis	B
.	O
	
(	O
5.9	O
)	O
5.1	O
Angioedema	O
Angioedema	B
of	I
the	I
face	I
has	O
been	O
reported	O
with	O
fesoterodine	O
.	O
	
Patients	O
on	O
the	O
placebo	O
arm	O
could	O
cross	O
over	O
to	O
open-label	O
AFINITOR	O
upon	O
disease	O
progression	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
Stevens-Johnson	O
syndrome	O
,	O
toxic	O
epidermal	O
necrolysis	O
,	O
or	O
rash	O
complicated	O
by	O
full	O
thickness	O
dermal	O
ulceration	O
,	O
or	O
necrotic	O
,	O
bullous	O
,	O
or	O
hemorrhagic	O
manifestations	O
.	O
	
Four	O
placebo-controlled	O
add-on	O
combination	O
therapy	O
trials	O
of	O
26	O
weeks	O
duration	O
were	O
also	O
conducted	O
:	O
with	O
metformin	O
,	O
with	O
a	O
sulfonylurea	O
,	O
with	O
a	O
thiazolidinedione	O
and	O
with	O
insulin	O
.	O
	
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
TREANDA	O
in	O
153	O
patients	O
with	O
CLL	O
studied	O
in	O
an	O
active-controlled	O
,	O
randomized	O
trial	O
.	O
	
Adequate	O
data	O
are	O
not	O
available	O
on	O
the	O
safety	O
or	O
efficacy	O
of	O
treating	O
patients	O
who	O
are	O
carriers	O
of	O
HBV	O
with	O
anti-viral	O
therapy	O
in	O
conjunction	O
with	O
TNF	O
blocker	O
therapy	O
to	O
prevent	O
HBV	O
reactivation	O
.	O
	
At	O
baseline	O
,	O
21	O
%	O
of	O
the	O
population	O
reported	O
peripheral	O
neuropathy	O
and	O
5	O
%	O
reported	O
retinopathy	O
.	O
	
The	O
risk	O
of	O
seizures	O
in	O
patients	O
with	O
epileptiform	O
activity	O
on	O
an	O
EEG	O
is	O
unknown	O
,	O
and	O
could	O
be	O
substantially	O
higher	O
than	O
that	O
observed	O
in	O
AMPYRA	O
clinical	O
studies	O
.	O
	
5.8	O
Use	O
with	O
Biological	O
Disease-Modifying	O
Antirheumatic	O
Drugs	O
(	O
Biological	O
DMARDs	O
)	O
Serious	O
infections	B
were	O
seen	O
in	O
clinical	O
studies	O
with	O
concurrent	O
use	O
of	O
anakinra	O
(	O
an	O
interleukin-1	O
antagonist	O
)	O
and	O
another	O
TNF	O
blocker	O
,	O
etanercept	O
,	O
with	O
no	O
added	O
benefit	O
compared	O
to	O
etanercept	O
alone	O
.	O
	
During	O
its	O
development	O
for	O
the	O
adjunctive	O
treatment	O
of	O
seizures	O
associated	O
with	O
LGS	O
,	O
ONFI	O
was	O
administered	O
to	O
333	O
healthy	O
volunteers	O
and	O
300	O
patients	O
with	O
a	O
current	O
or	O
prior	O
diagnosis	O
of	O
LGS	O
,	O
including	O
197	O
patients	O
treated	O
for	O
12	O
months	O
or	O
more	O
.	O
	
The	O
range	O
of	O
mean	O
baseline	O
LDL-C	O
levels	O
was	O
90.3	O
to	O
90.6	O
mg/dL	O
across	O
treatment	O
groups	O
.	O
	
Each	O
ECLIPSE	O
study	O
compared	O
Cleviprex	O
(	O
n=752	O
)	O
to	O
an	O
active	O
comparator	O
:	O
nitroglycerin	O
(	O
NTG	O
,	O
n=278	O
)	O
,	O
sodium	O
nitroprusside	O
(	O
SNP	O
,	O
n=283	O
)	O
,	O
or	O
nicardipine	O
(	O
NIC	O
,	O
n=193	O
)	O
.	O
	
5.3	O
Continuation	O
and	O
Timing	O
of	O
Leucovorin	O
Rescue	O
Continue	O
to	O
administer	O
leucovorin	O
after	O
VORAXAZE	O
.	O
	
Other	O
factors	O
associated	O
with	O
hematuria	B
were	O
well-balanced	O
between	O
arms	O
and	O
do	O
not	O
account	O
for	O
the	O
increased	O
rate	O
of	O
hematuria	B
on	O
the	O
JEVTANA	O
arm	O
.	O
	
The	O
greatest	O
risk	O
appears	O
associated	O
with	O
prolonged	O
use	O
,	O
with	O
increased	O
risks	O
of	O
15-	O
to	O
24-fold	O
for	O
5	O
to	O
10	O
years	O
or	O
more	O
of	O
treatment	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Serious	O
and	O
occasionally	O
fatal	B
anaphylactic	B
)	I
reactions	I
and	O
serious	O
skin	B
reactions	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
During	O
clinical	O
trials	O
,	O
no	O
anaphylactic	B
reactions	I
have	O
been	O
reported	O
.	O
	
Gastrointestinal	O
Disorders	O
Dysgeusia	B
(	O
alteration	B
of	I
taste	I
)	O
was	O
an	O
adverse	O
event	O
reported	O
at	O
an	O
increased	O
frequency	O
in	O
subjects	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
compared	O
with	O
subjects	O
receiving	O
peginterferon	O
alfa	O
and	O
ribavirin	O
alone	O
(	O
Table	O
3	O
)	O
.	O
	
It	O
should	O
be	O
noted	O
that	O
PRISTIQ	O
is	O
not	O
approved	O
for	O
use	O
in	O
treating	O
bipolar	O
depression	O
.	O
	
In	O
HIV-1-Infected	O
Subjects	O
With	O
No	O
Antiretroviral	O
Treatment	O
History	O
The	O
safety	O
assessment	O
of	O
STRIBILD	O
is	O
based	O
on	O
the	O
Week	O
144	O
pooled	O
data	O
from	O
1408	O
subjects	O
in	O
two	O
randomized	O
,	O
double-blind	O
,	O
active-controlled	O
clinical	O
trials	O
,	O
Study	O
102	O
and	O
Study	O
103	O
,	O
in	O
antiretroviral	O
treatment-naive	O
HIV-1	O
infected	O
adult	O
subjects	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
with	O
beta-lactam	O
antibacterial	O
drugs	O
,	O
including	O
Teflaro	O
.	O
	
*	O
In	O
those	O
patients	O
already	O
taking	O
an	O
optimized	O
dose	O
of	O
a	O
PDE5	O
inhibitor	O
,	O
alpha-blocker	O
therapy	O
should	O
be	O
initiated	O
at	O
the	O
lowest	O
dose	O
.	O
	
(	O
5.4	O
,	O
2.3	O
)	O
*	O
Cardiomyopathy	B
:	O
Assess	O
LVEF	O
before	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
,	O
after	O
one	O
month	O
of	O
treatment	O
,	O
then	O
every	O
2	O
to	O
3	O
months	O
thereafter	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
an	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
(	O
5.9	O
)	O
*	O
Glucose-6-Phosphate	B
Dehydrogenase	I
Deficiency	I
:	O
Closely	O
monitor	O
for	O
hemolytic	O
anemia	O
.	O
	
It	O
should	O
be	O
recognized	O
that	O
symptoms	O
of	O
the	O
underlying	O
disease	O
being	O
treated	O
may	O
be	O
similar	O
to	O
symptoms	O
of	O
hypersensitivity	O
.	O
	
Individuals	O
who	O
have	O
already	O
experienced	O
NAION	O
are	O
at	O
increased	O
risk	O
of	O
NAION	O
recurrence	O
.	O
	
Patients	O
who	O
experience	O
reduced	O
clinical	O
response	O
may	O
also	O
be	O
tested	O
for	O
inhibitory	O
antibody	O
activity	O
.	O
	
This	O
risk	O
has	O
been	O
shown	O
to	O
persist	O
for	O
at	O
least	O
8	O
to	O
15	O
years	O
after	O
estrogen	O
therapy	O
is	O
discontinued	O
.	O
	
Of	O
the	O
329	O
enrolled	O
patients	O
,	O
327	O
(	O
167	O
brentuximab	O
vedotin	O
,	O
160	O
placebo	O
)	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
treatment	O
.	O
	
If	O
PML	O
is	O
diagnosed	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
or	O
withdrawal	O
of	O
immunosuppression	O
taking	O
into	O
account	O
the	O
risk	O
to	O
the	O
allograft	O
.	O
	
Patients	O
on	O
concomitant	O
immunosuppressant	O
agents	O
or	O
with	O
impaired	O
immune	O
systems	O
may	O
be	O
at	O
increased	O
risk	O
for	O
serious	O
infections	B
.	O
	
Patients	O
should	O
be	O
evaluated	O
for	O
tuberculosis	O
and	O
tested	O
for	O
latent	O
infection	O
prior	O
to	O
initiating	O
NULOJIX	O
.	O
	
Withhold	O
TAFINLAR	O
,	O
and	O
trametinib	O
if	O
used	O
in	O
combination	O
,	O
for	O
intolerable	O
or	O
severe	O
skin	O
toxicity	O
.	O
	
Established	O
microvascular	O
complications	O
of	O
diabetes	O
at	O
baseline	O
included	O
diabetic	O
nephropathy	O
(	O
7	O
%	O
)	O
,	O
retinopathy	O
(	O
8	O
%	O
)	O
,	O
or	O
neuropathy	O
(	O
16	O
%	O
)	O
.	O
	
Suicide	O
is	O
a	O
known	O
risk	O
of	O
depression	O
and	O
certain	O
other	O
psychiatric	O
disorders	O
,	O
and	O
these	O
disorders	O
themselves	O
are	O
the	O
strongest	O
predictors	O
of	O
suicide	O
.	O
	
5.6	O
Impaired	O
Wound	O
Healing	O
Everolimus	O
delays	B
wound	I
healing	I
and	O
increases	O
the	O
occurrence	O
of	O
wound-related	B
complications	I
like	O
wound	B
dehiscence	I
,	O
wound	B
infection	I
,	O
incisional	B
hernia	I
,	O
lymphocele	B
,	O
and	O
seroma	B
.	O
	
Bone	B
pain	I
was	O
the	O
most	O
frequent	O
treatment-emergent	O
adverse	O
reaction	O
that	O
occurred	O
in	O
at	O
least	O
1	O
%	O
or	O
greater	O
in	O
patients	O
treated	O
with	O
GRANIX	O
at	O
the	O
recommended	O
dose	O
and	O
was	O
numerically	O
two	O
times	O
more	O
frequent	O
than	O
in	O
the	O
placebo	O
group	O
.	O
	
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
they	O
know	O
how	O
Toviaz	O
affects	O
them	O
(	O
5.5	O
)	O
*	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
,	O
a	O
disease	O
characterized	O
by	O
decreased	O
cholinergic	O
activity	O
at	O
the	O
neuromuscular	O
junction	O
.	O
	
Two	O
placebo-controlled	O
monotherapy	O
trials	O
of	O
12	O
and	O
26	O
weeks	O
of	O
duration	O
were	O
conducted	O
in	O
patients	O
treated	O
with	O
NESINA	O
12.5	O
mg	O
daily	O
,	O
NESINA	O
25	O
mg	O
daily	O
and	O
placebo	O
.	O
	
Musculoskeletal	O
Disorders	O
:	O
Myositis	B
.	O
	
All	O
5	O
patients	O
had	O
maximum	O
AST	B
levels	I
>	I
8	I
*	I
ULN	I
,	O
which	O
returned	O
to	O
baseline	O
levels	O
following	O
interruption	O
of	O
KALYDECO	O
dosing	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
among	O
FANAPT	O
-Treated	O
Patients	O
and	O
More	O
Frequent	O
than	O
Placebo	O
Table	O
7	O
enumerates	O
the	O
pooled	O
incidences	O
of	O
treatment-emergent	O
adverse	O
reactions	O
that	O
were	O
spontaneously	O
reported	O
in	O
four	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
listing	O
those	O
reactions	O
that	O
occurred	O
in	O
2	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
FANAPT	O
in	O
any	O
of	O
the	O
dose	O
groups	O
,	O
and	O
for	O
which	O
the	O
incidence	O
in	O
FANAPT-treated	O
patients	O
in	O
any	O
dose	O
group	O
was	O
greater	O
than	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
placebo	O
.	O
	
If	O
unexplained	O
or	O
clinically	O
significant	O
weight	O
loss	O
occurs	O
,	O
weight	O
loss	O
should	O
be	O
evaluated	O
,	O
and	O
discontinuation	O
of	O
OTEZLA	O
should	O
be	O
considered	O
.	O
	
In	O
some	O
cases	O
of	O
anaphylaxis	O
,	O
epinephrine	O
has	O
been	O
administered	O
.	O
	
Dystonic	B
symptoms	I
include	O
:	O
spasm	B
of	I
the	I
neck	I
muscles	I
,	O
sometimes	O
progressing	O
to	O
tightness	B
of	I
the	I
throat	I
,	O
swallowing	B
difficulty	I
,	O
difficulty	B
breathing	I
,	O
and/or	O
protrusion	B
of	I
the	I
tongue	I
.	O
	
In	O
addition	O
to	O
cases	O
of	O
gastrointestinal	B
perforation	I
were	O
reported	O
in	O
4/715	O
patients	O
(	O
1	O
%	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
in	O
patients	O
receiving	O
POTIGA	O
were	O
dizziness	B
(	O
6	O
%	O
)	O
,	O
confusional	B
state	I
(	O
4	O
%	O
)	O
,	O
fatigue	B
(	O
3	O
%	O
)	O
,	O
and	O
somnolence	B
(	O
3	O
%	O
)	O
.	O
	
Treatment	O
of	O
Bone	O
Loss	O
in	O
Patients	O
Receiving	O
Androgen	O
Deprivation	O
Therapy	O
for	O
Prostate	O
Cancer	O
or	O
Adjuvant	O
Aromatase	O
Inhibitor	O
Therapy	O
for	O
Breast	O
Cancer	O
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
bone	O
loss	O
in	O
men	O
with	O
nonmetastatic	O
prostate	O
cancer	O
receiving	O
androgen	O
deprivation	O
therapy	O
(	O
ADT	O
)	O
was	O
assessed	O
in	O
a	O
3-year	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multinational	O
study	O
of	O
1468	O
men	O
aged	O
48	O
to	O
97	O
years	O
.	O
	
A	O
total	O
of	O
120	O
women	O
were	O
exposed	O
to	O
placebo	O
and	O
129	O
women	O
were	O
exposed	O
to	O
Prolia	O
administered	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
subcutaneous	O
dose	O
.	O
	
In	O
randomized	O
controlled	O
studies	O
,	O
ALT	B
)	I
elevations	I
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
observed	O
:	O
1.3	O
%	O
in	O
alogliptin-treated	O
patients	O
and	O
1.5	O
%	O
in	O
all	O
comparator-treated	O
patients	O
.	O
	
5.5	O
Hyponatremia	O
Clinically	O
significant	O
hyponatremia	B
(	O
sodium	O
<	O
125	O
mEq/L	O
)	O
can	O
develop	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Contamination	O
of	O
Tip	O
and	O
Solution	O
To	O
minimize	O
contaminating	O
the	O
dropper	O
tip	O
and	O
solution	O
,	O
care	O
should	O
be	O
taken	O
not	O
to	O
touch	O
the	O
eyelids	O
or	O
surrounding	O
areas	O
with	O
the	O
dropper	O
tip	O
of	O
the	O
bottle	O
.	O
	
Monitor	O
patients	O
for	O
fever	O
and	O
infections	O
and	O
evaluate	O
promptly	O
.	O
	
Immune-mediated	B
endocrinopathies	I
:	O
Monitor	O
thyroid	O
function	O
tests	O
and	O
clinical	O
chemistries	O
prior	O
to	O
each	O
dose	O
.	O
	
Other	O
Malignancies	O
Malignancies	B
,	O
excluding	O
non-melanoma	B
skin	I
cancer	I
and	O
PTLD	B
,	O
were	O
reported	O
in	O
Study	O
1	O
and	O
Study	O
2	O
in	O
3.5	O
%	O
(	O
14/401	O
)	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
3.7	O
%	O
(	O
15/405	O
)	O
of	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Mammary	B
gland	I
proliferative	I
changes	I
and	O
increases	B
in	I
serum	I
prolactin	I
were	O
seen	O
in	O
mice	O
and	O
rats	O
treated	O
with	O
FANAPT	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Rare	O
cases	O
of	O
opportunistic	B
infections	I
have	O
also	O
been	O
reported	O
in	O
these	O
clinical	O
trials	O
.	O
	
FARXIGA	O
can	O
increase	O
the	O
risk	O
of	O
hypoglycemia	B
when	O
combined	O
with	O
insulin	O
or	O
an	O
insulin	O
secretagogue	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
A	O
penile	O
modeling	O
procedure	O
was	O
performed	O
at	O
the	O
study	O
site	O
on	O
patients	O
1	O
to	O
3	O
days	O
after	O
the	O
second	O
injection	O
of	O
the	O
cycle	O
.	O
	
If	O
anticoagulation	O
with	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Pheochromocytoma	O
and	O
Neuroblastoma	O
Drugs	O
which	O
interfere	O
with	O
norepinephrine	O
uptake	O
in	O
neuroendocrine	O
tumors	O
may	O
lead	O
to	O
false	O
negative	O
imaging	O
results	O
.	O
	
Over	O
95	O
%	O
of	O
XIAFLEX-treated	O
patients	O
had	O
an	O
adverse	B
reaction	I
of	I
the	I
injected	I
extremity	I
after	O
up	O
to	O
3	O
injections	O
.	O
	
5.3	O
Hepatotoxicity	O
Beleodaq	O
can	O
cause	O
fatal	B
hepatotoxicity	B
and	O
liver	B
function	I
test	I
abnormalities	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
An	O
estimate	O
of	O
the	O
attributable	O
risk	O
is	O
3.3	O
cases/100,000	O
COC	O
users	O
.	O
	
(	O
5.1	O
)	O
*	O
Drugs	O
which	O
block	O
norepinephrine	O
uptake	O
or	O
deplete	O
norepinephrine	O
stores	O
may	O
decrease	O
AdreView	O
uptake	O
.	O
	
Discontinuations	O
due	O
to	O
Adverse	O
Reactions	O
Twenty-five	O
patients	O
(	O
19.4	O
%	O
)	O
discontinued	O
treatment	O
with	O
Beleodaq	O
due	O
to	O
adverse	O
reactions	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
.	O
	
Do	O
not	O
rechallenge	O
patients	O
who	O
develop	O
neutropenia	O
with	O
Ferriprox	O
unless	O
potential	O
benefits	O
outweigh	O
potential	O
risks	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
laboratory	O
abnormalities	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.2	O
Potentiation	O
of	O
Sedation	O
from	O
Concomitant	O
Use	O
with	O
Central	O
Nervous	O
System	O
Depressants	O
Since	O
ONFI	O
has	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depressant	O
effect	O
,	O
patients	O
or	O
their	O
caregivers	O
should	O
be	O
cautioned	O
against	O
simultaneous	O
use	O
with	O
other	O
CNS	O
depressant	O
drugs	O
or	O
alcohol	O
,	O
and	O
cautioned	O
that	O
the	O
effects	O
of	O
other	O
CNS	O
depressant	O
drugs	O
or	O
alcohol	O
may	O
be	O
potentiated	O
.	O
	
There	O
are	O
insufficient	O
data	O
to	O
determine	O
whether	O
FARXIGA	O
has	O
an	O
effect	O
on	O
pre-existing	O
bladder	O
tumors	O
.	O
	
Rash	B
(	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
2	O
)	O
occurred	O
in	O
15	O
%	O
of	O
pediatric	O
subjects	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PRADAXA	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
XEOMIN-treated	O
patients	O
were	O
18	O
to	O
79	O
years	O
old	O
(	O
mean	O
53	O
years	O
)	O
,	O
and	O
were	O
predominantly	O
female	O
(	O
66	O
%	O
)	O
and	O
Caucasian	O
(	O
91	O
%	O
)	O
.	O
	
This	O
,	O
in	O
turn	O
,	O
may	O
inhibit	B
reproductive	I
function	I
by	O
impairing	B
gonadalsteroidogenesis	I
in	O
both	O
female	O
and	O
male	O
patients	O
.	O
	
Discontinuation	O
from	O
study	O
due	O
to	O
genital	B
infection	I
occurred	O
in	O
0	O
%	O
of	O
placebo-treated	O
patients	O
and	O
0.2	O
%	O
of	O
patients	O
treated	O
with	O
FARXIGA	O
10	O
mg	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Eli	O
Lilly	O
and	O
Company	O
at	O
1-800-LillyRx	O
(	O
1-800-545-5979	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
re-administering	O
Vimizim	O
following	O
a	O
severe	O
reaction	O
.	O
	
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
3	O
%	O
.	O
	
5.2	O
Contact	O
Lens	O
Use	O
Patients	O
should	O
be	O
advised	O
not	O
to	O
wear	O
a	O
contact	O
lens	O
if	O
their	O
eye	O
is	O
red	O
.	O
	
A	O
higher	O
percentage	O
of	O
APTIOM-treated	O
patients	O
(	O
5.1	O
%	O
)	O
than	O
placebo-treated	O
patients	O
(	O
0.7	O
%	O
)	O
experienced	O
decreases	B
in	I
sodium	I
values	I
of	O
more	O
than	O
10	O
mEq/L	O
.	O
	
These	O
18	O
patients	O
experienced	O
26	O
anaphylactic	B
reactions	I
during	O
infusion	O
with	O
signs	O
and	O
symptoms	O
including	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
retching	B
,	O
and	O
vomiting	B
)	O
in	O
conjunction	O
with	O
urticaria	B
.	O
	
Exclude	O
other	O
potential	O
causes	O
of	O
ILD/pneumonitis	O
,	O
and	O
permanently	O
discontinue	O
XALKORI	O
in	O
patients	O
diagnosed	O
with	O
drug-related	O
ILD/pneumonitis	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.7	O
Embryo-Fetal	O
Toxicity	O
Based	O
on	O
findings	O
in	O
animals	O
,	O
IMBRUVICA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Because	O
postmarketing	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
25	O
%	O
)	O
are	O
nausea	B
,	O
fatigue	B
,	O
pyrexia	B
,	O
anemia	B
,	O
and	O
vomiting	B
.	O
	
Alcohol	O
and	O
other	O
hepatotoxic	O
drugs	O
should	O
be	O
avoided	O
while	O
on	O
SIRTURO	O
,	O
especially	O
in	O
patients	O
with	O
impaired	O
hepatic	O
function	O
.	O
	
Discontinue	O
if	O
evidence	O
of	O
liver	O
injury	O
.	O
	
Transaminase	B
elevations	I
generally	O
occurred	O
within	O
the	O
first	O
2	O
months	O
of	O
treatment	O
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
9.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
14.7	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
.	O
	
In	O
the	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
in	O
546	O
patients	O
with	O
CML	O
treated	O
with	O
prior	O
therapy	O
,	O
severe	O
fluid	B
retention	I
was	O
reported	O
in	O
14	O
patients	O
(	O
3	O
%	O
)	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
mean	O
eGFR	O
88	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
The	O
usefulness	O
of	O
hemodialysis	O
in	O
the	O
prevention	O
of	O
NSF	O
is	O
unknown	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12	O
)	O
]	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
HORIZANT	O
increases	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
,	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
,	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
In	O
the	O
case	O
of	O
mild	O
pancreatitis	O
,	O
hold	O
ERWINAZE	O
until	O
the	O
signs	O
and	O
symptoms	O
subside	O
and	O
amylase	O
levels	O
return	O
to	O
normal	O
.	O
	
Approximately	O
57	O
%	O
of	O
the	O
patients	O
were	O
male	O
.	O
	
Transaminase	O
elevations	O
were	O
more	O
common	O
in	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
To	O
enroll	O
in	O
the	O
E.A.S.E	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Transaminase	O
(	O
ALT	O
or	O
AST	O
)	O
Elevations	O
Elevated	B
transaminases	I
have	O
been	O
reported	O
in	O
patients	O
with	O
CF	O
receiving	O
KALYDECO	O
.	O
	
Alglucosidase	O
alfa-treated	O
patients	O
who	O
experience	O
a	O
decrease	O
in	O
motor	O
function	O
should	O
be	O
tested	O
for	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
that	O
neutralize	O
enzyme	O
uptake	O
or	O
activity	O
.	O
	
Discontinuation	O
of	O
therapy	O
in	O
GILOTRIF-treated	O
patients	O
for	O
adverse	O
reactions	O
was	O
14.0	O
%	O
.	O
	
Antifungal	O
agents	O
should	O
not	O
be	O
used	O
unless	O
fungal	O
infection	O
has	O
been	O
diagnosed	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
More	O
patients	O
on	O
TANZEUM	O
than	O
on	O
placebo	O
:	O
discontinued	O
due	O
to	O
an	O
injection	B
site	I
reaction	I
(	O
2	O
%	O
versus	O
0.2	O
%	O
)	O
,	O
experienced	O
more	O
than	O
2	O
reactions	O
(	O
38	O
%	O
versus	O
20	O
%	O
)	O
,	O
had	O
a	O
reaction	O
judged	O
by	O
investigators	O
to	O
be	O
``	O
moderate	O
''	O
or	O
``	O
severe	O
''	O
(	O
27	O
%	O
versus	O
6	O
%	O
)	O
and	O
required	O
local	O
or	O
systemic	O
treatment	O
for	O
the	O
reactions	O
(	O
36	O
%	O
versus	O
11	O
%	O
)	O
.	O
	
5.3	O
Lipid	O
Intake	O
Cleviprex	O
contains	O
approximately	O
0.2	O
g	O
of	O
lipid	O
per	O
mL	O
(	O
2.0	O
kcal	O
)	O
.	O
	
It	O
is	O
unknown	O
whether	O
the	O
suicidality	B
risk	O
extends	O
to	O
longer-term	O
use	O
,	O
i.e.	O
,	O
beyond	O
several	O
months	O
.	O
	
Prophylaxis	O
for	O
PJP	O
should	O
be	O
considered	O
when	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
other	O
immunosuppressive	O
agents	O
are	O
required	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
at	O
>	O
=3	O
%	O
and	O
Higher	O
than	O
Placebo	O
in	O
2	O
Placebo	O
Controlled	O
Clinical	O
Trials	O
in	O
Patients	O
with	O
HAE	O
Treated	O
with	O
KALBITOR	O
a	O
Patients	O
experiencing	O
more	O
than	O
1	O
event	O
with	O
the	O
same	O
preferred	O
term	O
are	O
counted	O
only	O
once	O
for	O
that	O
preferred	O
term	O
.	O
	
These	O
infections	B
may	O
lead	O
to	O
serious	O
,	O
including	O
fatal	B
,	O
outcomes	O
[	O
see	O
Boxed	O
Warning	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Polyoma	O
Virus	O
Nephropathy	O
In	O
addition	O
to	O
cases	O
of	O
JC	B
virus-associated	O
PML	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
,	O
cases	O
of	O
polyoma	B
virus-associated	I
nephropathy	I
(	O
PVAN	B
)	O
,	O
mostly	O
due	O
to	O
BK	B
virus	I
infection	I
,	O
have	O
been	O
reported	O
.	O
	
They	O
may	O
be	O
bilateral	O
and	O
many	O
patients	O
report	O
prodromal	O
pain	O
in	O
the	O
affected	O
area	O
,	O
usually	O
presenting	O
as	O
dull	O
,	O
aching	O
thigh	B
pain	I
,	O
weeks	O
to	O
months	O
before	O
a	O
complete	O
fracture	O
occurs	O
.	O
	
In	O
the	O
CIMZIA	O
RA	O
clinical	O
trials	O
(	O
placebo-controlled	O
and	O
open	O
label	O
)	O
a	O
total	O
of	O
three	O
cases	O
of	O
lymphoma	B
were	O
observed	O
among	O
2,367	O
patients	O
.	O
	
Individuals	O
with	O
``	O
crowded	O
''	O
optic	O
disc	O
are	O
also	O
considered	O
at	O
greater	O
risk	O
for	O
NAION	O
compared	O
to	O
the	O
general	O
population	O
,	O
however	O
,	O
evidence	O
is	O
insufficient	O
to	O
support	O
screening	O
of	O
prospective	O
users	O
of	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
for	O
this	O
uncommon	O
condition	O
.	O
	
Hypertoxin-producing	O
strains	O
of	O
C.	O
difficile	O
cause	O
increased	O
morbidity	O
and	O
mortality	O
,	O
as	O
these	O
infections	O
can	O
be	O
refractory	O
to	O
antimicrobial	O
therapy	O
and	O
may	O
require	O
colectomy	O
.	O
	
This	O
component	O
reduces	O
the	O
risk	O
of	O
endometrial	O
hyperplasia	O
that	O
can	O
occur	O
with	O
the	O
conjugated	O
estrogens	O
component	O
.	O
	
When	O
Coartem	O
Tablets	O
are	O
coadministered	O
with	O
inducers	O
of	O
CYP3A4	O
it	O
may	O
result	O
in	O
decreased	O
concentrations	O
of	O
artemether	O
and/or	O
lumefantrine	O
and	O
loss	O
of	O
antimalarial	O
efficacy	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
Cases	O
of	O
TB	B
included	O
extrapulmonary	B
TB	I
.	O
	
SAPHRIS	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
recent	O
history	O
of	O
myocardial	O
infarction	O
or	O
unstable	O
heart	O
disease	O
.	O
	
Hepatic	O
:	O
Liver	B
Injury	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
Respiratory	O
:	O
Interstitial	B
lung	I
disease	I
including	O
pneumonitis	B
and	O
pulmonary	B
fibrosis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
Immune	O
:	O
Anaphylactic	B
reactions	I
including	O
angioedema	B
Vascular	O
:	O
Vasculitis	B
,	O
including	O
leukocytoclastic	B
vasculitis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
In	O
patients	O
with	O
symptomatic	O
heart	O
failure	O
and	O
recent	O
decompensation	O
requiring	O
hospitalization	O
or	O
NYHA	O
Class	O
IV	O
heart	O
failure	O
;	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
.	O
	
Patients	O
with	O
these	O
diagnoses	O
were	O
excluded	O
from	O
pre-marketing	O
clinical	O
trials	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
TAFINLAR	O
may	O
render	O
hormonal	O
contraceptives	O
less	O
effective	O
and	O
an	O
alternative	O
method	O
of	O
contraception	O
should	O
be	O
used	O
.	O
	
Based	O
on	O
the	O
clinical	O
trial	O
experience	O
,	O
ILARIS	O
does	O
not	O
appear	O
to	O
increase	O
the	O
incidence	O
of	O
MAS	B
in	O
SJIA	O
patients	O
,	O
but	O
no	O
definitive	O
conclusion	O
can	O
be	O
made	O
.	O
	
However	O
,	O
treatment	O
with	O
immunosuppressants	O
,	O
including	O
ILARIS	O
,	O
may	O
result	O
in	O
an	O
increase	O
in	O
the	O
risk	O
of	O
malignancies	B
.	O
	
Liver	O
enzymes	O
should	O
be	O
monitored	O
in	O
patients	O
who	O
develop	O
symptoms	O
suggestive	O
of	O
hepatic	O
dysfunction	O
,	O
such	O
as	O
unexplained	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
fatigue	O
,	O
anorexia	O
,	O
or	O
jaundice	O
and/or	O
dark	O
urine	O
.	O
	
PVAN	B
is	O
associated	O
with	O
serious	O
outcomes	O
;	O
including	O
deteriorating	B
renal	I
function	I
and	O
kidney	B
graft	I
loss	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
An	O
accelerated	O
vaccination	O
schedule	O
may	O
be	O
appropriate	O
.	O
	
In	O
patients	O
treated	O
with	O
TAFINLAR	O
,	O
the	O
median	O
time	O
to	O
initial	O
onset	O
of	O
fever	B
(	O
any	O
severity	O
)	O
was	O
11	O
days	O
(	O
range	O
:	O
1	O
to	O
202	O
days	O
)	O
and	O
the	O
median	O
duration	O
of	O
fever	B
was	O
3	O
days	O
(	O
range	O
:	O
1	O
to	O
129	O
days	O
)	O
.	O
	
Do	O
not	O
administer	O
ILARIS	O
to	O
patients	O
during	O
an	O
active	O
infection	O
requiring	O
medical	O
intervention	O
.	O
	
Some	O
of	O
the	O
patients	O
who	O
tested	O
positive	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
experienced	O
anaphylactic	B
reactions	I
[	O
seeBoxed	O
WarningandWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Observational	O
studies	O
suggest	O
that	O
,	O
similar	O
to	O
atypical	O
antipsychotic	O
drugs	O
,	O
treatment	O
with	O
conventional	O
antipsychotic	O
drugs	O
may	O
increase	O
mortality	O
.	O
	
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
HBV	O
infection	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
STRIBILD	O
have	O
not	O
been	O
established	O
in	O
patients	O
coinfected	O
with	O
HBV	O
and	O
HIV-1	O
.	O
	
Monitor	O
serum	O
phosphorus	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
impairment	O
.	O
	
These	O
events	O
have	O
been	O
included	O
because	O
of	O
their	O
seriousness	O
and	O
assessment	O
of	O
potential	O
causal	O
relationship	O
.	O
	
Program	O
,	O
an	O
authorized	O
hospital	O
representative	O
must	O
acknowledge	O
that	O
:	O
*	O
hospital	O
staff	O
who	O
prescribe	O
,	O
dispense	O
,	O
or	O
administer	O
ENTEREG	O
have	O
been	O
provided	O
the	O
educational	O
materials	O
on	O
the	O
need	O
to	O
limit	O
use	O
of	O
ENTEREG	O
to	O
short-term	O
,	O
inpatient	O
use	O
;	O
*	O
patients	O
will	O
not	O
receive	O
more	O
than	O
15	O
doses	O
of	O
ENTEREG	O
;	O
and	O
*	O
ENTEREG	O
will	O
not	O
be	O
dispensed	O
to	O
patients	O
after	O
they	O
have	O
been	O
discharged	O
from	O
the	O
hospital	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
dermatitis	O
such	O
as	O
rash	O
and	O
pruritus	O
.	O
	
Severe	O
pancreatitis	O
is	O
a	O
contraindication	O
to	O
additional	O
asparaginase	O
administration	O
.	O
	
One	O
patient	O
experienced	O
disturbance	B
in	I
attention	I
,	O
eyelid	B
disorder	I
,	O
feeling	B
abnormal	I
and	O
headache	B
,	O
and	O
one	O
patient	O
experienced	O
dysphagia	B
.	O
	
Discontinuation	O
of	O
INLYTA	O
treatment	O
due	O
to	O
hypertension	B
occurred	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Immune-mediated	B
neuropathies	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Four	O
serious	O
adverse	O
events	O
occurred	O
in	O
two	O
placebo-treated	O
subjects	O
.	O
	
(	O
5.3	O
)	O
*	O
Macular	B
edema	I
:	O
Perform	O
an	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
before	O
and	O
3-4	O
months	O
after	O
treatment	O
initiation	O
.	O
	
Table	O
5	O
reflects	O
exposure	O
to	O
DYSPORT	O
(	O
r	O
)	O
in	O
398	O
patients	O
19	O
to	O
75	O
years	O
of	O
age	O
who	O
were	O
evaluated	O
in	O
the	O
randomized	O
,	O
placebo-	O
controlled	O
clinical	O
studies	O
that	O
assessed	O
the	O
use	O
of	O
DYSPORT	O
(	O
r	O
)	O
for	O
the	O
temporary	O
improvement	O
in	O
the	O
appearance	O
of	O
glabellar	O
lines	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
If	O
you	O
think	O
you	O
may	O
be	O
pregnant	O
,	O
you	O
should	O
have	O
a	O
pregnancy	O
test	O
and	O
know	O
the	O
results	O
.	O
	
*	O
Drugs	O
that	O
act	O
directly	O
on	O
the	O
renin-angiotensin	O
system	O
can	O
cause	O
death	B
to	I
the	I
developing	I
fetus	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Most	O
of	O
these	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
and	O
occurred	O
during	O
the	O
titration	O
phase	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
A	O
24-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
of	O
Vimizim	O
was	O
conducted	O
in	O
176	O
patients	O
with	O
MPS	O
IVA	O
,	O
ages	O
5	O
to	O
57	O
years	O
old	O
.	O
	
The	O
risk	O
did	O
not	O
vary	O
substantially	O
by	O
age	O
(	O
5	O
to	O
100	O
years	O
)	O
in	O
the	O
clinical	O
trials	O
analyzed	O
.	O
	
In	O
patients	O
predisposed	O
to	O
hypocalcemia	O
and	O
disturbances	O
of	O
mineral	O
metabolism	O
(	O
e.g	O
.	O
	
5.3	O
QT	O
Interval	O
Prolongation	O
QTc	B
prolongation	I
can	O
occur	O
in	O
patients	O
treated	O
with	O
XALKORI	O
.	O
	
The	O
data	O
presented	O
below	O
are	O
based	O
on	O
information	O
collected	O
from	O
Study	O
1	O
,	O
a	O
single-arm	O
,	O
multi-center	O
,	O
open-label	O
,	O
safety	O
and	O
clinical	O
pharmacology	O
trial	O
(	O
intramuscular	O
administration	O
)	O
,	O
the	O
ERWINAZE	O
Master	O
Treatment	O
Protocol	O
(	O
EMTP	O
)	O
,	O
an	O
expanded	O
access	O
program	O
(	O
both	O
intramuscular	O
,	O
intravenous	O
,	O
and	O
other	O
or	O
unknown	O
administration	O
)	O
,	O
and	O
Study	O
2	O
,	O
a	O
single-arm	O
,	O
multi-center	O
,	O
open-label	O
,	O
pharmacokinetic	O
(	O
PK	O
)	O
study	O
trial	O
of	O
intravenous	O
administration	O
of	O
ERWINAZE.Study	O
1	O
enrolled	O
58	O
patients	O
treated	O
on	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
-sponsored	O
cooperative	O
group	O
ALL	O
protocols	O
who	O
were	O
unable	O
to	O
continue	O
to	O
receive	O
pegaspargase	O
due	O
to	O
hypersensitivity	O
reactions	O
.	O
	
Neither	O
clinical	O
studies	O
nor	O
epidemiologic	O
studies	O
conducted	O
to	O
date	O
have	O
shown	O
an	O
association	O
between	O
chronic	O
administration	O
of	O
this	O
class	O
of	O
drugs	O
and	O
tumorigenesis	O
in	O
humans	O
;	O
the	O
available	O
evidence	O
is	O
considered	O
too	O
limited	O
to	O
be	O
conclusive	O
at	O
this	O
time	O
.	O
	
Hyperprolactinemia	B
may	O
suppress	B
hypothalamic	I
GnRH	I
,	O
resulting	O
in	O
reduced	B
pituitary	I
gonadotropin	I
secretion	I
.	O
	
No	O
cases	O
of	O
PML	B
were	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
or	O
the	O
control	O
regimen	O
in	O
these	O
trials	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Some	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
developed	O
IgE-anti-drug	O
antibodies	O
in	O
greater	O
proportions	O
and	O
higher	O
titers	O
with	O
successive	O
XIAFLEX	O
injections	O
.	O
	
5.2	O
genotoxicity	B
in	O
animal	O
studies	O
,	O
Ferriprox	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
The	O
increased	O
risk	O
of	O
asthma-related	O
death	B
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
.	O
	
Patients	O
with	O
tuberculosis	B
have	I
frequently	I
presented	I
with	I
disseminated	I
disease	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
the	O
4	O
pivotal	O
studies	O
,	O
drug	O
hypersensitivity	B
(	O
including	O
urticaria	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
,	O
allergic	B
edema	I
,	O
anaphylactic	B
reaction	I
,	O
and	O
anaphylactic	B
shock	I
were	O
reported	O
in	O
0.1	O
%	O
of	O
patients	O
receiving	O
PRADAXA	O
.	O
	
Consequently	O
,	O
FARXIGA	O
should	O
not	O
be	O
used	O
in	O
patients	O
with	O
active	O
bladder	O
cancer	O
.	O
	
Prescribers	O
should	O
caution	O
patients	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
mental	O
alertness	O
,	O
such	O
as	O
operating	O
dangerous	O
machinery	O
or	O
motor	O
vehicles	O
,	O
until	O
the	O
effect	O
of	O
ONFI	O
is	O
known	O
.	O
	
Monitor	O
LDL-C	O
and	O
treat	O
per	O
standard	O
of	O
care	O
after	O
initiating	O
FARXIGA	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
AdreView	O
administration	O
.	O
	
Rupture	B
of	I
hepatic	I
adenomas	I
may	O
cause	O
death	B
through	O
intra-abdominal	B
hemorrhage	I
.	O
	
5.4	O
QT	O
Prolongation	O
In	O
an	O
uncontrolled	O
open-label	O
ECG	O
study	O
in	O
26	O
patients	O
,	O
QT	B
prolongation	I
was	O
observed	O
on	O
Day	O
8	O
,	O
independent	O
of	O
eribulin	O
concentration	O
,	O
with	O
no	O
QT	B
prolongation	I
observed	O
on	O
Day	O
1	O
.	O
	
Patients	O
whose	O
baseline	O
ALT	O
or	O
AST	O
were	O
elevated	O
were	O
more	O
likely	O
to	O
experience	O
liver	B
test	I
elevation	I
than	O
those	O
beginning	O
with	O
normal	O
values	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CIGARETTE	O
SMOKING	O
AND	O
SERIOUS	O
CARDIOVASCULAR	B
EVENTS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
The	O
desired	O
therapeutic	O
response	O
was	O
achieved	O
at	O
doses	O
of	O
4-6	O
mg/hour	O
.	O
	
The	O
mean	O
time	O
to	O
nadir	O
was	O
13	O
days	O
and	O
the	O
mean	O
time	O
to	O
recovery	O
from	O
severe	O
neutropenia	B
(	O
<	O
500/mm	O
3	O
)	O
was	O
8	O
days	O
.	O
	
5.4	O
Bacterial	O
Infections	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
suppress	B
the	I
host	I
response	I
and	O
thus	O
increase	O
the	O
hazard	O
of	O
secondary	B
ocular	I
infections	I
.	O
	
New-Onset	O
Diabetes	O
After	O
Transplantation	O
The	O
incidence	O
of	O
new-onset	B
diabetes	I
after	I
transplantation	I
(	O
NODAT	B
)	O
was	O
defined	O
in	O
Studies	O
1	O
and	O
2	O
as	O
use	O
of	O
an	O
antidiabetic	O
agent	O
for	O
>	O
=30	O
days	O
or	O
>	O
=2	O
fasting	O
plasma	O
glucose	O
values	O
>	O
=126	O
mg/dL	O
(	O
7.0	O
mmol/L	O
)	O
post-transplantation	O
.	O
	
Because	O
of	O
the	O
observed	O
ophthalmologic	O
adverse	O
reactions	O
,	O
POTIGA	O
should	O
only	O
be	O
used	O
in	O
patients	O
who	O
have	O
responded	O
inadequately	O
to	O
several	O
alternative	O
treatments	O
and	O
for	O
whom	O
the	O
benefits	O
outweigh	O
the	O
risk	O
of	O
retinal	O
abnormalities	O
and	O
potential	O
vision	O
loss	O
.	O
	
Causality	O
can	O
not	O
be	O
excluded	O
.	O
	
Adjunctive	O
Therapy	O
Controlled	O
Trials	O
In	O
the	O
controlled	O
adjunctive	O
therapy	O
epilepsy	O
trials	O
(	O
Study	O
3	O
,	O
Study	O
4	O
,	O
and	O
Study	O
5	O
)	O
,	O
the	O
rate	O
of	O
discontinuation	O
as	O
a	O
result	O
of	O
any	O
adverse	O
reaction	O
was	O
14	O
%	O
for	O
the	O
800	O
mg	O
dose	O
,	O
25	O
%	O
for	O
the	O
1200	O
mg	O
dose	O
,	O
and	O
7	O
%	O
in	O
subjects	O
randomized	O
to	O
placebo	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Anaphylaxis	O
and	O
Angioedema	O
TECFIDERA	O
can	O
cause	O
anaphylaxis	B
and	O
angioedema	B
after	O
the	O
first	O
dose	O
or	O
at	O
any	O
time	O
during	O
treatment	O
.	O
	
Gastrointestinal	O
disorders	O
Diarrhea	B
37	O
0	O
Nausea	B
21	O
0	O
Stomatitis	B
16	O
0	O
Gastroesophageal	B
reflux	I
disease	I
13	O
0	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
Rash	B
22	O
0	O
Bruising	B
16	O
0	O
Pruritus	B
11	O
0	O
General	O
disorders	O
and	O
administrative	O
site	O
conditions	O
Fatigue	B
21	O
0	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Muscle	B
spasms	I
21	O
0	O
Arthropathy	B
13	O
0	O
Infections	O
and	O
infestations	O
Upper	B
respiratory	I
tract	I
infection	I
19	O
0	O
Sinusitis	B
19	O
0	O
Pneumonia	B
14	O
6	O
Skin	B
infection	I
14	O
2	O
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
Epistaxis	B
19	O
0	O
Cough	B
13	O
0	O
Nervous	O
system	O
disorders	O
Dizziness	B
14	O
0	O
Headache	B
13	O
0	O
Neoplasms	O
benign	O
,	O
malignant	O
,	O
and	O
unspecified	O
(	O
including	O
cysts	O
and	O
polyps	O
)	O
Skin	B
cancer	I
11	O
0	O
Table	O
8	O
:	O
Treatment-EmergentBased	O
on	O
laboratory	O
measurements	O
.	O
	
The	O
safety	O
of	O
INLYTA	O
has	O
been	O
evaluated	O
in	O
715	O
patients	O
in	O
monotherapy	O
studies	O
,	O
which	O
included	O
537	O
patients	O
with	O
advanced	O
RCC	O
.	O
	
Renal	B
function	I
abnormalities	I
can	O
occur	O
after	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Antipsychotic	O
treatment	O
,	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
This	O
rare	B
type	I
of	I
T-cell	I
lymphoma	I
has	O
a	O
very	O
aggressive	O
disease	O
course	O
and	O
is	O
usually	O
fatal	B
.	O
	
Table	O
1	O
Table	O
2	O
6.2	O
Immunogenicity	O
As	O
with	O
most	O
therapeutic	O
proteins	O
,	O
patients	O
may	O
develop	O
anti-drug	O
antibodies	O
(	O
ADA	O
)	O
to	O
ERWINAZE.In	O
a	O
study	O
with	O
ERWINAZE	O
treatment	O
by	O
intramuscular	O
administration	O
(	O
Study	O
1	O
)	O
,	O
6	O
of	O
56	O
(	O
11	O
%	O
)	O
patients	O
treated	O
with	O
ERWINAZE	O
developed	O
antibodies	O
to	O
ERWINAZE	O
.	O
	
Merkel	B
cell	I
carcinoma	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
.	O
	
Cases	O
of	O
syncope	B
were	O
also	O
reported	O
after	O
the	O
first	O
dose	O
of	O
GILENYA	O
.	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
withhold	O
Kyprolis	O
and	O
evaluate	O
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
GILOTRIF	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
(	O
5.2	O
)	O
*	O
HORIZANT	O
is	O
not	O
interchangeable	O
with	O
other	O
gabapentin	O
products	O
.	O
	
Inform	O
patients	O
of	O
the	O
risk	O
and	O
of	O
symptoms	O
and	O
to	O
contact	O
a	O
physician	O
immediately	O
if	O
symptoms	O
of	O
an	O
infusion	O
reaction	O
occur	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
Although	O
the	O
overall	O
incidence	O
of	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
DOTAREM	O
exposure	O
in	O
2813	O
patients	O
,	O
representing	O
2672	O
adults	O
and	O
141	O
pediatric	O
patients	O
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
2	O
subjects	O
who	O
received	O
placebo	O
committed	O
suicide	B
compared	O
to	O
none	O
in	O
OTEZLA-treated	O
subjects	O
.	O
	
Patients	O
with	O
neuromuscular	O
disorders	O
may	O
be	O
at	O
increased	O
risk	O
of	O
clinically	O
significant	O
effects	O
including	O
severe	O
dysphagia	B
and	O
respiratory	B
compromise	I
from	O
typical	O
doses	O
of	O
XEOMIN	O
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Some	O
patients	O
had	O
residual	O
visual	B
acuity	I
loss	I
even	O
after	O
resolution	O
of	O
macular	B
edema	I
.	O
	
In	O
2-year	O
,	O
double-blind	O
,	O
placebo-controlled	O
studies	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
,	O
macular	B
edema	I
with	O
or	O
without	O
visual	B
symptoms	I
occurred	O
in	O
1.5	O
%	O
of	O
patients	O
(	O
11/799	O
)	O
treated	O
with	O
fingolimod	O
1.25	O
mg	O
,	O
0.5	O
%	O
of	O
patients	O
(	O
4/783	O
)	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
and	O
0.4	O
%	O
of	O
patients	O
(	O
3/773	O
)	O
treated	O
with	O
placebo	O
.	O
	
Infections	B
,	O
stomatitis	B
,	O
and	O
pneumonitis	B
were	O
the	O
most	O
common	O
reasons	O
for	O
treatment	O
delay	O
or	O
dose	O
reduction	O
.	O
	
Mean	O
percentage	O
decreases	B
in	I
BMD	I
from	O
baseline	O
to	O
Week	O
144	O
in	O
the	O
STRIBILD	O
group	O
were	O
comparable	O
to	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
at	O
the	O
lumbar	O
spine	O
(	O
-1.43	O
%	O
versus	O
-3.68	O
%	O
,	O
respectively	O
)	O
and	O
at	O
the	O
hip	O
(	O
-2.83	O
%	O
versus	O
-3.77	O
%	O
,	O
respectively	O
)	O
.	O
	
5.3	O
Local	O
Skin	O
Reactions	O
Severe	O
skin	B
reactions	I
in	I
the	I
treated	I
area	I
,	O
can	O
occur	O
after	O
topical	O
application	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Treatment	O
of	O
SJIA	O
A	O
total	O
of	O
201	O
SJIA	O
patients	O
aged	O
2	O
to	O
less	O
than	O
20	O
years	O
have	O
received	O
ILARIS	O
in	O
clinical	O
trials	O
.	O
	
The	O
adverse	O
drug	O
reactions	O
associated	O
with	O
ILARIS	O
treatment	O
in	O
SJIA	O
patients	O
were	O
infections	B
,	O
abdominal	B
pain	I
,	O
and	O
injection	B
site	I
reactions	I
.	O
	
5.6	O
Drug	O
Interactions	O
See	O
Table	O
2	O
for	O
a	O
listing	O
of	O
drugs	O
that	O
are	O
contraindicated	O
for	O
use	O
with	O
VICTRELIS	O
due	O
to	O
potentially	O
life-threatening	O
adverse	O
events	O
,	O
significant	O
drug	O
interactions	O
or	O
loss	O
of	O
virologic	O
activity	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
In	O
several	O
cases	O
,	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
dose	O
.	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
in	O
patients	O
:	O
*	O
with	O
chronic	O
or	O
recurrent	O
infection	O
;	O
*	O
who	O
have	O
been	O
exposed	O
to	O
tuberculosis	O
;	O
*	O
with	O
a	O
history	O
of	O
an	O
opportunistic	O
infection	O
;	O
*	O
who	O
have	O
resided	O
or	O
traveled	O
in	O
areas	O
of	O
endemic	O
tuberculosis	O
or	O
endemic	O
mycoses	O
,	O
such	O
as	O
histoplasmosis	O
,	O
coccidioidomycosis	O
,	O
or	O
blastomycosis	O
;	O
or	O
*	O
with	O
underlying	O
conditions	O
that	O
may	O
predispose	O
them	O
to	O
infection	O
.	O
	
The	O
following	O
events	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
in	O
the	O
three	O
placebo-controlled	O
3-month	O
clinical	O
trials	O
and/or	O
the	O
open-label	O
,	O
long-term	O
extension	O
study	O
lasting	O
12	O
months	O
.	O
	
5.2	O
Increase	O
in	O
Intraocular	O
Pressure	O
Acute	B
increases	I
in	I
intraocular	I
pressure	I
have	O
been	O
seen	O
within	O
60	O
minutes	O
of	O
intravitreal	O
injection	O
,	O
including	O
with	O
EYLEA	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Cases	O
of	O
MTC	B
in	O
patients	O
treated	O
with	O
liraglutide	O
,	O
another	O
GLP-1	O
receptor	O
agonist	O
,	O
have	O
been	O
reported	O
in	O
the	O
postmarketing	O
period	O
;	O
the	O
data	O
in	O
these	O
reports	O
are	O
insufficient	O
to	O
establish	O
or	O
exclude	O
a	O
causal	O
relationship	O
between	O
MTC	B
and	O
GLP-1	O
receptor	O
agonist	O
use	O
in	O
humans	O
.	O
	
With	O
the	O
interventions	O
used	O
for	O
anemia	O
management	O
in	O
the	O
clinical	O
trials	O
,	O
the	O
average	O
additional	O
decrease	O
of	O
hemoglobin	O
was	O
approximately	O
1	O
g	O
per	O
dL	O
.	O
	
Hemodialysis	O
does	O
not	O
appear	O
to	O
have	O
a	O
substantial	O
impact	O
on	O
apixaban	O
exposure	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=	O
2	O
%	O
of	O
Patients	O
Treated	O
with	O
STENDRA	O
in	O
a	O
Placebo-Controlled	O
Clinical	O
Trial	O
Lasting	O
2	O
Months	O
to	O
Determine	O
the	O
Time	O
to	O
Onset	O
of	O
Effect	O
(	O
Study	O
3	O
)	O
Adverse	O
Reaction	O
Placebon=143	O
STENDRA	O
100	O
mgn=146	O
STENDRA	O
200	O
mgn=146	O
Headache	B
0.7	O
%	O
1.4	O
%	O
8.9	O
%	O
Nasal	B
congestion	I
0.0	O
%	O
0.7	O
%	O
4.1	O
%	O
Gastroenteritis	B
viral	I
0.0	O
%	O
0.0	O
%	O
2.1	O
%	O
Across	O
all	O
trials	O
with	O
any	O
STENDRA	O
dose	O
,	O
1	O
subject	O
reported	O
a	O
change	B
in	I
color	I
vision	I
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
pancreatitis	B
adjudicated	O
as	O
likely	O
related	O
to	O
therapy	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
6	O
of	O
2,365	O
[	O
0.3	O
%	O
]	O
)	O
than	O
in	O
patients	O
receiving	O
placebo	O
(	O
0	O
of	O
468	O
[	O
0	O
%	O
]	O
)	O
or	O
active	O
comparators	O
(	O
2	O
of	O
2,065	O
[	O
0.1	O
%	O
]	O
)	O
.	O
	
Tuberculosis	O
should	O
be	O
strongly	O
considered	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
CIMZIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
drug	O
TUDORZA	O
PRESSAIR	O
.	O
	
If	O
you	O
would	O
like	O
more	O
information	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
.	O
	
6.3	O
Immunogenicity	O
Patients	O
with	O
classical	O
HL	O
and	O
sALCL	O
in	O
Studies	O
1	O
and	O
2	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
were	O
tested	O
for	O
antibodies	O
to	O
brentuximab	O
vedotin	O
every	O
3	O
weeks	O
using	O
a	O
sensitive	O
electrochemiluminescent	O
immunoassay	O
.	O
	
The	O
population	O
studied	O
had	O
a	O
mean	O
age	O
of	O
49	O
years	O
(	O
3	O
%	O
of	O
subjects	O
were	O
older	O
than	O
65	O
years	O
of	O
age	O
)	O
,	O
39	O
%	O
were	O
female	O
,	O
82	O
%	O
were	O
white	O
and	O
15	O
%	O
were	O
black	O
.	O
	
In	O
such	O
patients	O
,	O
consider	O
discontinuation	O
of	O
SAPHRIS	O
at	O
the	O
first	O
sign	O
of	O
a	O
clinically	O
significant	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Infections	O
:	O
PML	B
[	O
see	O
Boxed	O
Warning	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
]	O
,	O
serious	O
infections	B
and	O
opportunistic	B
infections	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
The	O
immunogenicity	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
EYLEA	O
in	O
immunoassays	O
.	O
	
The	O
protocol	O
specified	O
that	O
patients	O
continue	O
receiving	O
intravenous	O
hydration	O
,	O
urinary	O
alkalinization	O
and	O
leucovorin	O
,	O
and	O
that	O
leucovorin	O
administration	O
be	O
adjusted	O
to	O
ensure	O
that	O
it	O
was	O
not	O
administered	O
within	O
two	O
hours	O
before	O
or	O
after	O
VORAXAZE	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
)	O
in	O
Vizamyl-treated	O
subjects	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
(	O
Boxed	O
Warning	O
,	O
4	O
,	O
5.1	O
,	O
5.6	O
)	O
*	O
Other	O
malignancies	B
:	O
increased	O
risk	O
with	O
all	O
immunosuppressants	O
;	O
appears	O
related	O
to	O
intensity	O
and	O
duration	O
of	O
use	O
.	O
	
5.2	O
Thyroid	O
Accumulation	O
The	O
DaTscan	O
injection	O
may	O
contain	O
up	O
to	O
6	O
%	O
of	O
free	O
iodide	O
(	O
iodine	O
123	O
)	O
.	O
	
If	O
experiencing	O
Grade	O
>	O
=	O
3	O
diarrhea	O
,	O
dosage	O
should	O
be	O
modified	O
.	O
	
The	O
use	O
of	O
PRADAXA	O
for	O
the	O
prophylaxis	O
of	O
thromboembolic	O
events	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
in	O
the	O
setting	O
of	O
other	O
forms	O
of	O
valvular	O
heart	O
disease	O
,	O
including	O
the	O
presence	O
of	O
a	O
bioprosthetic	O
heart	O
valve	O
,	O
has	O
not	O
been	O
studied	O
and	O
is	O
not	O
recommended	O
.	O
	
In	O
CAPS	O
Study	O
1	O
,	O
no	O
pattern	O
was	O
observed	O
for	O
any	O
type	O
or	O
frequency	O
of	O
adverse	O
events	O
throughout	O
the	O
three	O
study	O
periods	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
for	O
subjects	O
taking	O
OTEZLA	O
were	O
nausea	B
(	O
1.6	O
%	O
)	O
,	O
diarrhea	B
(	O
1.0	O
%	O
)	O
,	O
and	O
headache	B
(	O
0.8	O
%	O
)	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
bone	B
fractures	I
occurred	O
in	O
27	O
subjects	O
(	O
3.9	O
%	O
)	O
in	O
the	O
STRIBILD	O
group	O
,	O
8	O
subjects	O
(	O
2.3	O
%	O
)	O
in	O
the	O
ATRIPLA	O
group	O
,	O
and	O
19	O
subjects	O
(	O
5.4	O
%	O
)	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
Infections	B
:	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
immunosuppressive	O
agents	O
,	O
including	O
BENLYSTA	O
.	O
	
Table	O
5	O
lists	O
treatment-emergent	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
with	O
PHN	O
treated	O
with	O
HORIZANT	O
1,200	O
mg/day	O
and	O
numerically	O
greater	O
than	O
placebo	O
.	O
	
Stop	O
Kyprolis	O
for	O
Grade	O
3	O
or	O
4	O
dyspnea	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
.	O
	
One	O
patient	O
with	O
a	O
history	O
of	O
Wolff-Parkinson-White	O
syndrome	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
supraventricular	B
tachycardia	I
.	O
	
All	O
second	B
degree	I
AV	I
blocks	I
on	I
placebo	I
were	I
Mobitz	I
Type	I
I	I
and	O
occurred	O
after	O
the	O
first	O
12	O
hours	O
postdose	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
systems	O
respond	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	B
opportunistic	I
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jirovecii	I
pneumonia	I
[	O
PCP	B
]	O
,	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
5	O
%	O
or	O
greater	O
in	O
either	O
indication	O
)	O
occurring	O
in	O
patients	O
receiving	O
ZERBAXA	O
were	O
nausea	B
,	O
diarrhea	B
,	O
headache	B
,	O
and	O
pyrexia	B
.	O
	
The	O
incidence	O
of	O
Grade	O
3	O
or	O
greater	O
non-hematologic	O
,	O
non-infectious	O
adverse	O
reactions	O
occurring	O
with	O
ERWINAZE	O
in	O
Study	O
1	O
,	O
Study	O
2	O
and	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
2	O
.	O
	
In	O
controlled	O
clinical	O
studies	O
,	O
98	O
%	O
of	O
patients	O
completed	O
>	O
=	O
90	O
%	O
of	O
the	O
intended	O
patch	O
application	O
duration	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
permanent	O
discontinuation	O
in	O
XALKORI-treated	O
patients	O
were	O
elevated	B
transaminases	I
(	O
1.2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
1.2	O
%	O
)	O
,	O
and	O
ILD	B
(	O
1.2	O
%	O
)	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
XALKORI-treated	O
patients	O
in	O
Study	O
2	O
occurred	O
in	O
9	O
(	O
5	O
%	O
)	O
patients	O
,	O
consisting	O
of	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
arrhythmia	B
,	O
dyspnea	B
,	O
pneumonia	B
,	O
pneumonitis	B
,	O
pulmonary	B
embolism	I
,	O
ILD	B
,	O
respiratory	B
failure	I
and	O
sepsis	B
.	O
	
During	O
the	O
clinical	O
trial	O
,	O
the	O
patient	O
experienced	O
prolonged	O
lymphopenia	B
(	O
lymphocyte	O
counts	O
predominantly	O
<	O
0.5x10	O
9	O
/L	O
for	O
3.5	O
years	O
)	O
while	O
taking	O
TECFIDERA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Consider	O
interruption	O
of	O
TECFIDERA	O
if	O
lymphocyte	O
counts	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
persist	O
for	O
more	O
than	O
six	O
months	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
below	O
and	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Distant	B
Spread	I
of	I
Toxin	I
Effect	I
[	O
seeBoxed	O
Warning	O
]	O
*	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Spread	B
of	I
Effects	I
from	I
Toxin	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Dysphagia	B
and	O
Breathing	B
Difficulties	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Pre-existing	O
Neuromuscular	O
Disorders	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Human	O
Albumin	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Intradermal	B
Immune	I
Reaction	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5	O
.	O
	
Pre-existing	O
hypertension	O
should	O
be	O
controlled	O
before	O
initiating	O
treatment	O
with	O
PRISTIQ	O
.	O
	
Use	O
of	O
ocular	O
steroids	O
may	O
prolong	O
the	O
course	O
and	O
may	O
exacerbate	B
the	I
severity	I
of	I
many	I
viral	I
infections	I
of	I
the	I
eye	I
)	O
.	O
	
Other	O
immune-mediated	B
adverse	I
reactions	I
,	O
including	O
ocular	B
manifestations	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Of	O
the	O
patients	O
who	O
developed	O
tuberculosis	B
through	O
3	O
years	O
,	O
all	O
but	O
one	O
NULOJIX	O
patient	O
lived	O
in	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Of	O
these	O
29	O
patients	O
,	O
5	O
(	O
17	O
%	O
)	O
required	O
catheterization	O
,	O
with	O
post-voiding	O
residuals	O
of	O
up	O
to	O
1,500	O
mL	O
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
10	O
%	O
and	O
21	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
treated	O
with	O
XIAFLEX	O
.	O
	
Dyslipidemia	O
Mean	O
values	O
of	O
total	O
cholesterol	O
,	O
HDL	O
,	O
LDL	O
,	O
and	O
triglycerides	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
during	O
treatment	O
for	O
the	O
emergence	O
of	O
possible	O
bacterial	O
,	O
fungal	O
,	O
or	O
viral	O
infections	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
,	O
consisting	O
of	O
:	O
pneumonia	B
(	O
4	O
patients	O
)	O
,	O
respiratory	B
failure	I
,	O
ILD/pneumonitis	O
,	O
pneumothorax	B
,	O
gastric	B
hemorrhage	I
,	O
general	B
physical	I
health	I
deterioration	I
,	O
pulmonary	B
tuberculosis	I
,	O
cardiac	B
tamponade	I
,	O
and	O
sepsis	B
(	O
1	O
patient	O
each	O
)	O
.	O
	
There	O
have	O
been	O
reports	O
of	O
anaphylactic	B
reactions	I
in	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
after	O
inhalation	O
of	O
other	O
powder	O
medications	O
containing	O
lactose	O
;	O
therefore	O
,	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
should	O
not	O
use	O
BREO	O
ELLIPTA	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
Drug	B
Rash	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
have	O
also	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
hepatic	B
failure	I
.	O
	
5.11	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
Hypersensitivity	B
reactions	I
such	O
as	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
urticaria	B
may	O
occur	O
after	O
administration	O
of	O
BREO	O
ELLIPTA	O
.	O
	
Monitor	O
closely	O
and	O
take	O
appropriate	O
measures	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
(	O
3.7	O
%	O
)	O
XIAFLEX-treated	O
patients	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
fatigue	B
,	O
joint	B
swelling	I
,	O
edema	B
,	O
hot	B
flush	I
,	O
diarrhea	B
,	O
vomiting	B
,	O
cough	B
,	O
hypertension	B
,	O
dyspnea	B
,	O
urinary	B
tract	I
infection	I
and	O
contusion	B
.	O
	
The	O
most	O
common	O
reasons	O
for	O
dose	O
reductions	O
were	O
elevated	B
transaminases	I
,	O
diarrhea	B
or	O
colitis	B
,	O
and	O
rash	B
.	O
	
In	O
Study	O
5	O
,	O
treatment	O
of	O
recurrent	O
contractures	O
with	O
XIAFLEX	O
resulted	O
in	O
similar	O
immunogenicity	O
results	O
as	O
seen	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5.5	O
Viral	O
Infections	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
#	O
Most	O
herpes	B
infections	I
were	O
non-serious	O
and	O
1	O
led	O
to	O
treatment	O
discontinuation	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
59	O
years	O
and	O
4	O
%	O
were	O
older	O
than	O
75	O
years	O
.	O
	
Treatment	O
with	O
PRISTIQ	O
and	O
any	O
concomitant	O
serotonergic	O
agents	O
should	O
be	O
discontinued	O
immediately	O
if	O
the	O
above	O
events	O
occur	O
and	O
supportive	O
symptomatic	O
treatment	O
should	O
be	O
initiated	O
.	O
	
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
Grade	O
3	O
or	O
greater	O
elevations	B
in	I
liver	I
enzymes	I
occurred	O
in	O
approximately	O
6	O
%	O
of	O
patients	O
outside	O
the	O
setting	O
of	O
CRS	B
and	O
resulted	O
in	O
treatment	O
discontinuation	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
.	O
	
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
in	O
the	O
IMBRUVICA	O
arm	O
.	O
	
(	O
5.1	O
)	O
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
:	O
Withhold	O
TECFIDERA	O
at	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
.	O
	
In	O
the	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
,	O
the	O
median	O
time	O
to	O
onset	O
for	O
diarrhea	O
(	O
all	O
grades	O
)	O
was	O
2	O
days	O
and	O
the	O
median	O
duration	O
per	O
event	O
was	O
1	O
day	O
.	O
	
Inhalation	O
of	O
airborne	O
capsaicin	O
can	O
result	O
in	O
coughing	B
or	O
sneezing	B
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
.	O
	
Across	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
,	O
more	O
than	O
1,600	O
patients	O
have	O
received	O
Qutenza	O
.	O
	
The	O
6-dose	O
Coartem	O
Tablets	O
population	O
was	O
patients	O
with	O
malaria	O
between	O
ages	O
2	O
months	O
and	O
71	O
years	O
:	O
67	O
%	O
(	O
1,332	O
)	O
were	O
16	O
years	O
and	O
younger	O
and	O
33	O
%	O
(	O
647	O
)	O
were	O
older	O
than	O
16	O
years	O
.	O
	
When	O
distant	O
effects	O
occur	O
,	O
additional	O
respiratory	O
muscles	O
may	O
be	O
involved	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.1	O
Spread	O
of	O
Toxin	O
Effect	O
Postmarketing	O
safety	O
data	O
from	O
XEOMIN	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
Postmarketing	O
Experience	O
In	O
the	O
postmarketing	O
setting	O
,	O
third-degree	B
AV	I
block	I
and	O
AV	B
block	I
with	O
junctional	B
escape	I
have	O
been	O
observed	O
during	O
the	O
first-dose	O
6-hour	O
observation	O
period	O
with	O
GILENYA	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
need	O
of	O
emergency	O
cardiorespiratory	O
support	O
.	O
	
In	O
an	O
exploratory	O
clinical	O
trial	O
evaluating	O
the	O
use	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
in	O
patients	O
with	O
severe	O
persistent	O
asthma	O
,	O
more	O
patients	O
treated	O
with	O
golimumab	O
reported	O
malignancies	B
compared	O
with	O
control	O
patients	O
.	O
	
5.6	O
Dyspnea	O
Dyspnea	B
was	O
reported	O
in	O
28	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
and	O
was	O
Grade	O
3	O
or	O
greater	O
in	O
4	O
%	O
of	O
patients	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
this	O
potential	O
risk	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
these	O
conditions	O
.	O
	
If	O
supine	O
hypertension	O
is	O
not	O
well-managed	O
,	O
NORTHERA	O
may	O
increase	O
the	O
risk	O
of	O
cardiovascular	O
events	O
.	O
	
6.2	O
Adverse	O
Events	O
Associated	O
With	O
Gabapentin	O
The	O
following	O
adverse	O
events	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
gabapentin	O
,	O
either	O
in	O
clinical	O
trials	O
or	O
postmarketing	O
:	O
breast	B
enlargement	I
,	O
gynecomastia	B
,	O
and	O
elevated	B
creatine	I
kinase	I
.	O
	
Monitor	O
blood	O
pressure	O
regularly	O
in	O
all	O
patients	O
.	O
	
Two	O
patients	O
receiving	O
alglucosidase	O
alfa	O
discontinued	O
the	O
trial	O
due	O
to	O
anaphylactic	B
reactions	I
.	O
	
Appropriate	O
laboratory	O
testing	O
prior	O
to	O
initiating	O
therapy	O
and	O
monitoring	O
for	O
hepatotoxicity	O
during	O
therapy	O
with	O
TIVICAY	O
is	O
recommended	O
in	O
patients	O
with	O
underlying	O
hepatic	O
disease	O
such	O
as	O
hepatitis	O
B	O
or	O
C.	O
(	O
5.2	O
)	O
*	O
accumulation	B
of	I
body	I
fat	I
and	O
immune	B
reconstitution	I
syndrome	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
.	O
	
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
irrespective	O
of	O
causality	O
)	O
leading	O
to	O
treatment	O
discontinuation	O
were	O
pneumonitis	B
and	O
dyspnea	B
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Advanced	O
PNET	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
glossodynia	B
,	O
lip	B
ulceration	I
,	O
mouth	B
ulceration	I
,	O
tongue	B
ulceration	I
,	O
and	O
mucosal	B
inflammation	I
.	O
	
5.6	O
Corneal	O
Exposure	O
,	O
Corneal	O
Ulceration	O
,	O
and	O
Ectropion	O
in	O
Patients	O
Treated	O
with	O
XEOMIN	O
for	O
Blepharospasm	O
Reduced	B
blinking	I
from	O
injection	O
of	O
botulinum	O
toxin	O
products	O
in	O
the	O
orbicularis	O
muscle	O
can	O
lead	O
to	O
corneal	B
exposure	I
and	O
corneal	B
ulceration	I
,	O
especially	O
in	O
patients	O
with	O
VII	O
nerve	O
disorders	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
and	O
BREO	O
ELLIPTA	O
200/25	O
is	O
shown	O
in	O
Table	O
3	O
.	O
	
Exposure	O
to	O
sunlight	O
and	O
ultraviolet	O
(	O
UV	O
)	O
light	O
should	O
be	O
limited	O
by	O
wearing	O
protective	O
clothing	O
and	O
using	O
a	O
sunscreen	O
with	O
a	O
high	O
protection	O
factor	O
.	O
	
Of	O
the	O
total	O
population	O
across	O
the	O
three	O
trials	O
,	O
229	O
patients	O
received	O
a	O
dose	O
of	O
125	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
141	O
days	O
,	O
69	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
139	O
days	O
,	O
102	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
,	O
54	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
146	O
days	O
,	O
and	O
242	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
.	O
	
Neonates	O
(	O
i.e	O
.	O
	
(	O
5.5	O
)	O
*	O
Impaired	B
wound	I
healing	I
:	O
Increased	O
risk	O
of	O
wound-related	B
complications	I
.	O
	
Physicians	O
should	O
consider	O
PTLD	O
in	O
patients	O
reporting	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
or	O
symptoms	O
.	O
	
Fatal	B
outcomes	O
have	O
been	O
observed	O
.	O
	
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
*	O
b	O
In	O
this	O
trial	O
,	O
no	O
documented	O
symptomatic	O
or	O
severe	O
hypoglycemia	B
were	O
reported	O
for	O
TANZEUM	O
50	O
mg	O
and	O
these	O
data	O
are	O
omitted	O
from	O
the	O
table	O
.	O
	
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Change	O
from	O
Baseline	O
(	O
kg	O
)	O
(	O
N*	O
)	O
0.5	O
(	O
89	O
)	O
1.7	O
(	O
92	O
)	O
1.6	O
(	O
90	O
)	O
1.4	O
(	O
87	O
)	O
Proportion	O
of	O
Subjects	O
with	O
a	O
>	O
=7	O
%	O
Increase	B
in	I
Body	I
Weight	I
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
1.1	O
%	O
12.0	O
%	O
8.9	O
%	O
8.0	O
%	O
5.6	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
,	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
(	O
e.g	O
.	O
	
Most	O
,	O
but	O
not	O
all	O
,	O
of	O
these	O
patients	O
had	O
underlying	O
anatomic	O
or	O
vascular	O
risk	O
factors	O
for	O
developing	O
NAION	O
,	O
including	O
but	O
not	O
necessarily	O
limited	O
to	O
:	O
low	O
cup	O
to	O
disc	O
ratio	O
(	O
``	O
crowded	O
disc	O
''	O
)	O
,	O
age	O
over	O
50	O
,	O
diabetes	O
,	O
hypertension	O
,	O
coronary	O
artery	O
disease	O
,	O
hyperlipidemia	O
,	O
and	O
smoking	O
.	O
	
Reported	O
infections	O
with	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
include	O
:	O
*	O
Active	B
tuberculosis	I
,	O
including	O
reactivation	B
of	I
latent	I
tuberculosis	I
.	O
	
transfusion	O
)	O
if	O
clinically	O
indicated	O
.	O
	
(	O
5.1	O
)	O
*	O
Rapid	O
intravenous	O
infusion	B
of	I
glycopeptide	I
antibacterial	I
agents	I
can	I
cause	I
reactions	I
.	O
	
SAPHRIS	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiac	O
arrhythmias	O
and	O
in	O
other	O
circumstances	O
that	O
may	O
increase	O
the	O
risk	O
of	O
the	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
and/or	O
sudden	O
death	O
in	O
association	O
with	O
the	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QTc	O
interval	O
,	O
including	O
bradycardia	O
;	O
hypokalemia	O
or	O
hypomagnesemia	O
;	O
and	O
presence	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O
	
Certain	O
adverse	O
reactions	O
consistent	O
with	O
symptoms	O
of	O
anemia	B
,	O
such	O
as	O
dyspnea	B
,	O
exertional	B
dyspnea	I
,	O
dizziness	B
and	O
syncope	B
were	O
reported	O
more	O
frequently	O
in	O
subjects	O
who	O
received	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
increase	O
in	O
risk	O
was	O
demonstrated	O
in	O
year	O
1	O
and	O
persisted	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
for	O
patients	O
treated	O
with	O
STENDRA	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
was	O
1.4	O
%	O
,	O
2.0	O
%	O
,	O
and	O
2.0	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
1.7	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
If	O
this	O
occurs	O
,	O
treatment	O
with	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
stopped	O
and	O
other	O
treatments	O
considered	O
.	O
	
(	O
8.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
do	O
not	O
start	O
CIMZIA	O
during	O
an	O
active	O
infection	O
.	O
	
Patients	O
in	O
SJIA	O
Study	O
1	O
received	O
a	O
single	O
dose	O
of	O
ILARIS	O
4	O
mg/kg	O
(	O
n=43	O
)	O
or	O
placebo	O
(	O
n=41	O
)	O
via	O
subcutaneous	O
injection	O
and	O
were	O
assessed	O
at	O
Day	O
15	O
for	O
the	O
efficacy	O
endpoints	O
and	O
had	O
a	O
safety	O
analysis	O
up	O
to	O
Day	O
29	O
.	O
	
The	O
development	O
of	O
pneumonitis	B
has	O
been	O
reported	O
even	O
at	O
a	O
reduced	O
dose	O
.	O
	
(	O
5.5	O
)	O
(	O
6	O
)	O
(	O
8.5	O
)	O
*	O
Hepatic	B
impairment	I
:	O
Reduce	O
the	O
JEVTANA	O
dose	O
to	O
20	O
mg/m	O
2	O
in	O
patients	O
with	O
mild	O
hepatic	O
impairment	O
and	O
to	O
15	O
mg/m	O
2	O
in	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
.	O
	
Consider	O
a	O
diagnosis	O
of	O
non-infectious	O
pneumonitis	O
in	O
patients	O
presenting	O
with	O
non-specific	O
respiratory	O
signs	O
and	O
symptoms	O
such	O
as	O
hypoxia	O
,	O
pleural	O
effusion	O
,	O
cough	O
,	O
or	O
dyspnea	O
,	O
and	O
in	O
whom	O
infectious	O
,	O
neoplastic	O
,	O
and	O
other	O
causes	O
have	O
been	O
excluded	O
by	O
means	O
of	O
appropriate	O
investigations	O
.	O
	
Routine	O
ophthalmological	O
examination	O
detected	O
macular	B
edema	I
in	O
some	O
patients	O
with	O
no	O
visual	B
symptoms	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
NORTHERA	O
can	O
cause	O
supine	B
hypertension	I
and	O
may	O
increase	O
cardiovascular	B
risk	I
if	O
supine	B
hypertension	I
is	O
not	O
well-managed	O
(	O
5.1	O
)	O
.	O
	
Careful	O
testing	O
of	O
corneal	O
sensation	O
in	O
eyes	O
previously	O
operated	O
upon	O
,	O
avoidance	O
of	O
injection	O
into	O
the	O
lower	O
lid	O
area	O
to	O
avoid	O
ectropion	O
,	O
and	O
vigorous	O
treatment	O
of	O
any	O
epithelial	O
defect	O
should	O
be	O
employed	O
.	O
	
Laboratory	O
Abnormalities	O
The	O
frequency	O
of	O
laboratory	O
abnormalities	O
(	O
Grades	O
3-4	O
)	O
occurring	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
receiving	O
STRIBILD	O
in	O
Studies	O
102	O
and	O
103	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
Perform	O
an	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
in	O
all	O
patients	O
before	O
starting	O
treatment	O
,	O
again	O
3-4	O
months	O
after	O
starting	O
treatment	O
,	O
and	O
again	O
at	O
any	O
time	O
after	O
a	O
patient	O
reports	O
visual	O
disturbances	O
while	O
on	O
GILENYA	O
therapy	O
.	O
	
The	O
reported	O
frequency	O
for	O
the	O
group	O
receiving	O
10	O
mg/kg	O
may	O
underestimate	O
the	O
actual	O
frequency	O
due	O
to	O
lower	O
assay	O
sensitivity	O
in	O
the	O
presence	O
of	O
high	O
drug	O
concentrations	O
.	O
	
5.2	O
Hyperpyrexia	O
and	O
Confusion	O
Post-marketing	O
cases	O
of	O
a	O
symptom	O
complex	O
resembling	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
have	O
been	O
reported	O
with	O
NORTHERA	O
use	O
during	O
post-marketing	O
surveillance	O
in	O
Japan	O
.	O
	
(	O
5.3	O
,	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	O
have	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
liver	B
injury	I
.	O
	
(	O
5.3	O
)	O
*	O
Tardive	B
dyskinesia	I
:	O
Discontinue	O
if	O
clinically	O
appropriate	O
.	O
	
difficile	O
.	O
	
5.4	O
Allergic	O
Reactions	O
This	O
product	O
contains	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
was	O
stomatitis	B
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
7.5	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
10.0	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
(	O
5.10	O
)	O
*	O
Liver	B
enzyme	I
elevation	I
has	O
been	O
observed	O
during	O
treatment	O
with	O
INLYTA	O
.	O
	
For	O
the	O
6-dose	O
regimen	O
,	O
Coartem	O
Tablets	O
was	O
studied	O
in	O
active-controlled	O
(	O
366	O
patients	O
)	O
and	O
non-controlled	O
,	O
open-label	O
trials	O
(	O
1,613	O
patients	O
)	O
.	O
	
A	O
total	O
of	O
394	O
patients	O
received	O
more	O
than	O
one	O
treatment	O
application	O
and	O
274	O
patients	O
were	O
followed	O
for	O
48	O
weeks	O
or	O
longer	O
.	O
	
Flush	O
eyes	O
and	O
mucous	O
membranes	O
with	O
cool	O
water	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
L	O
ong-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
s	O
(	O
LABA	O
)	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
TABLE	O
2	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Pediatric	O
Subjects	O
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Mean	O
Change	O
from	O
Baseline	O
in	O
Fasting	O
Glucose	O
at	O
Endpoint	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
(	O
N*	O
)	O
-2.24	O
(	O
56	O
)	O
1.43	O
(	O
51	O
)	O
-0.45	O
(	O
57	O
)	O
0.34	O
(	O
52	O
)	O
Proportion	O
of	O
Subjects	O
with	O
Shifts	O
from	O
Baseline	O
to	O
Endpoint	O
Normal	O
to	O
High	O
>	O
45	O
&	O
<	O
100	O
to	O
>	O
=126	O
mg/dL	O
0	O
%	O
0	O
%	O
1.8	O
%	O
0	O
%	O
(	O
n/N*	O
)	O
(	O
0/56	O
)	O
(	O
0/51	O
)	O
(	O
1/57	O
)	O
(	O
0/52	O
)	O
Dyslipidemia	B
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
Increases	O
in	O
Hemoglobin	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
hemoglobin	I
were	O
-0.18	O
g/dL	O
(	O
-1.1	O
%	O
)	O
with	O
placebo	O
,	O
0.47	O
g/dL	O
(	O
3.5	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
0.51	O
g/dL	O
(	O
3.8	O
%	O
)	O
with	O
INVOKANA	O
300	O
mg	O
.	O
	
As	O
with	O
all	O
antidepressants	O
,	O
PRISTIQ	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
or	O
family	O
history	O
of	O
mania	O
or	O
hypomania	O
.	O
	
Restless	O
Legs	O
Syndrome	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
1,201	O
patients	O
with	O
RLS	O
included	O
613	O
exposed	O
for	O
at	O
least	O
6	O
months	O
and	O
371	O
exposed	O
for	O
at	O
least	O
1	O
year	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
(	O
5.1	O
,	O
13.1	O
)	O
.	O
	
5.9	O
Hyponatremia	O
Hyponatremia	B
may	O
occur	O
as	O
a	O
result	O
of	O
treatment	O
with	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
.	O
	
Data	O
from	O
a	O
placebo-controlled	O
,	O
4-week	O
,	O
fixed-dose	O
study	O
,	O
in	O
which	O
fasting	O
blood	O
samples	O
were	O
drawn	O
,	O
in	O
adult	O
subjects	O
with	O
schizophrenia	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
are	O
based	O
on	O
one	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
Phase	O
3	O
trial	O
in	O
patients	O
with	O
RA	O
receiving	O
SIMPONI	O
ARIA	O
by	O
intravenous	O
infusion	O
(	O
Trial	O
1	O
)	O
.	O
	
In	O
placebo-controlled	O
trials	O
in	O
patients	O
with	O
epilepsy	O
,	O
dizziness	B
was	O
reported	O
in	O
23	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
9	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
*	O
Ferriprox	O
can	O
cause	O
agranulocytosis	B
that	O
can	O
lead	O
to	O
serious	O
infections	B
and	O
death	B
.	O
	
Long-term	O
cumulative	O
radiation	O
exposure	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cancer	B
.	O
	
Chromaturia	B
(	O
reddish/brown	O
discoloration	O
of	O
the	O
urine	O
)	O
is	O
a	O
result	O
of	O
the	O
excretion	O
of	O
the	O
iron	O
in	O
the	O
urine	O
.	O
	
cDefined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
fatal	B
outcome	O
.	O
	
Immediately	O
discontinue	O
treatment	O
if	O
severe	O
hypersensitivity	O
,	O
severe	O
rash	O
or	O
rash	O
with	O
systemic	O
symptoms	O
or	O
liver	O
transaminase	O
elevations	O
develops	O
and	O
monitor	O
clinical	O
status	O
,	O
including	O
liver	O
transaminases	O
closely	O
.	O
	
5.6	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Severe	O
Renal	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
renal	O
function	O
.	O
	
If	O
a	O
hypersensitivity	O
reaction	O
occurs	O
,	O
the	O
patient	O
should	O
discontinue	O
TRULICITY	O
and	O
promptly	O
seek	O
medical	O
advice	O
.	O
	
c	O
not	O
applicable	O
;	O
(	O
grading	O
system	O
does	O
not	O
specify	O
>	O
Grade	O
2	O
for	O
alopecia	B
)	O
.	O
	
Hypertension	O
Blood	O
pressure	O
and	O
use	O
of	O
antihypertensive	O
medications	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5.2	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
Major	O
bleeding	B
events	O
within	O
each	O
subcategory	O
were	O
counted	O
once	O
per	O
patient	O
,	O
but	O
patients	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
subcategories	O
.	O
	
Premedication	O
may	O
include	O
acetaminophen	O
,	O
an	O
antihistamine	O
,	O
and	O
a	O
corticosteroid	O
.	O
	
Cardiac	O
disorders	O
:	O
atrial	B
fibrillation	I
,	O
cardiac	B
failure	I
.	O
	
*	O
Pancreatitis	B
:	O
Has	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
(	O
6.1	O
)	O
*	O
PHN	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Patients	O
who	O
can	O
not	O
be	O
monitored	O
should	O
usually	O
not	O
be	O
treated	O
with	O
POTIGA	O
.	O
	
Infusion	O
Reactions	O
There	O
were	O
no	O
reports	O
of	O
anaphylaxis	B
or	O
drug	B
hypersensitivity	I
in	O
patients	O
treated	O
with	O
NULOJIX	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
.	O
	
The	O
patient	O
was	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
When	O
treating	O
pediatric	O
patients	O
,	O
weight	O
gain	O
should	O
be	O
monitored	O
and	O
assessed	O
against	O
that	O
expected	O
for	O
normal	O
growth	O
.	O
	
These	O
included	O
infections	B
,	O
subdural	B
hematomas	I
and	O
diarrhea	B
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
Life-threatening	O
anaphylactic	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
Vimizim	O
infusions	O
.	O
	
In	O
such	O
cases	O
,	O
promptly	O
discontinue	O
NESINA	O
,	O
assess	O
for	O
other	O
potential	O
causes	O
,	O
institute	O
appropriate	O
monitoring	O
and	O
treatment	O
and	O
initiate	O
alternative	O
treatment	O
for	O
diabetes	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
death	B
as	O
reported	O
by	O
the	O
investigator	O
was	O
TB	O
(	O
9	O
subjects	O
)	O
.	O
	
DALVANCE	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
53/1778	O
(	O
3	O
%	O
)	O
patients	O
and	O
the	O
comparator	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
35/1224	O
(	O
2.8	O
%	O
)	O
patients	O
.	O
	
The	O
median	O
duration	O
of	O
study	O
treatment	O
was	O
7.1	O
months	O
for	O
patients	O
who	O
received	O
XALKORI	O
and	O
2.8	O
months	O
for	O
patients	O
who	O
received	O
chemotherapy	O
.	O
	
(	O
5.4	O
,	O
5.5	O
)	O
5.1	O
Eye	O
and	O
Mucous	O
Membrane	O
Exposure	O
Do	O
not	O
apply	O
Qutenza	O
to	O
the	O
face	O
or	O
scalp	O
to	O
avoid	O
risk	O
of	O
exposure	O
to	O
the	O
eyes	O
or	O
mucous	O
membranes	O
.	O
	
Instruct	O
patients	O
receiving	O
GILENYA	O
to	O
report	O
symptoms	O
of	O
infections	O
to	O
a	O
physician	O
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
in	O
approved	O
indications	O
,	O
symptoms	O
consistent	O
with	O
spread	B
of	I
toxin	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Administer	O
this	O
product	O
in	O
a	O
setting	O
with	O
resuscitation	O
equipment	O
and	O
other	O
agents	O
necessary	O
to	O
treat	O
anaphylaxis	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Adjunctive	O
)	O
:	O
somnolence	B
,	O
oral	B
hypoesthesia	I
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
infections	B
,	O
dyspnea	B
,	O
fatigue	B
,	O
stomatitis	B
,	O
dehydration	B
,	O
pneumonitis	B
,	O
abdominal	B
pain	I
,	O
and	O
asthenia	B
.	O
	
BREO	O
ELLIPTA	O
100/25	O
was	O
studied	O
in	O
2,369	O
subjects	O
and	O
BREO	O
ELLIPTA	O
200/25	O
was	O
studied	O
in	O
956	O
subjects	O
.	O
	
Serum	O
Lipids	O
:	O
In	O
the	O
clinical	O
trials	O
of	O
STRIBILD	O
,	O
a	O
similar	O
percentage	O
of	O
subjects	O
receiving	O
STRIBILD	O
,	O
ATRIPLA	O
,	O
and	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
were	O
on	O
lipid	O
lowering	O
agents	O
at	O
baseline	O
(	O
12	O
%	O
,	O
12	O
%	O
,	O
and	O
13	O
%	O
,	O
respectively	O
)	O
.	O
	
Ecchymosis	O
easily	O
occurs	O
in	O
the	O
soft	O
tissues	O
of	O
the	O
eyelid	O
.	O
	
Continuation	O
of	O
GILENYA	O
in	O
patients	O
who	O
develop	O
macular	B
edema	I
has	O
not	O
been	O
evaluated	O
.	O
	
Some	O
events	O
have	O
been	O
fatal	B
.	O
	
Patients	O
should	O
be	O
advised	O
to	O
elevate	O
the	O
head	O
of	O
the	O
bed	O
when	O
resting	O
or	O
sleeping	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Decreased	O
Efficacy	O
in	O
Patients	O
with	O
Baseline	O
Creatinine	O
Clearance	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
In	O
a	O
subgroup	O
analysis	O
of	O
a	O
Phase	O
3	O
cIAI	O
trial	O
,	O
clinical	O
cure	O
rates	O
were	O
lower	O
in	O
patients	O
with	O
baseline	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
compared	O
to	O
those	O
with	O
CrCl	O
>	O
=50	O
mL/min	O
(	O
Table	O
4	O
)	O
.	O
	
Table	O
8	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=	O
10	O
%	O
of	O
AFINITOR-treated	O
Patients	O
with	O
Renal	O
Angiomyolipoma	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
mouth	B
ulceration	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
and	O
glossodynia	B
.	O
	
Thrombocytopenia	B
was	O
reported	O
in	O
approximately	O
40	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
Kyprolis	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
-	O
Asthenia	B
.	O
	
More	O
cases	O
of	O
pneumonia	B
in	O
the	O
group	O
receiving	O
TANZEUM	O
were	O
serious	O
(	O
0.4	O
%	O
for	O
TANZEUM	O
versus	O
0.1	O
%	O
for	O
all	O
comparators	O
)	O
.	O
	
A	O
total	O
of	O
108	O
subjects	O
treated	O
with	O
Picato	O
(	O
r	O
)	O
gel	O
on	O
the	O
face/scalp	O
and	O
38	O
subjects	O
treated	O
on	O
the	O
trunk/extremities	O
were	O
followed	O
for	O
12	O
months	O
.	O
	
To	O
decrease	O
thyroid	O
accumulation	O
of	O
iodine	O
123	O
,	O
block	O
the	O
thyroid	O
gland	O
before	O
administration	O
of	O
DaTscan	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
If	O
diagnosed	O
,	O
withhold	O
TAFINLAR	O
for	O
up	O
to	O
6	O
weeks	O
until	O
uveitis/iritis	O
resolves	O
to	O
Grade	O
0-1	O
.	O
	
5.6	O
Ocular	O
Toxicities	O
Retinal	O
Pigment	O
Epithelial	O
Detachment	O
(	O
RPED	O
)	O
:	O
Retinal	B
pigment	I
epithelial	I
detachments	I
(	O
RPED	B
)	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
An	O
increased	O
risk	O
of	O
stroke	B
and	O
DVT	B
has	O
been	O
reported	O
with	O
estrogen-alone	O
therapy	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
received	O
an	O
ESA	O
was	O
43	O
%	O
in	O
those	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
24	O
%	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
.	O
	
Evaluate	O
if	O
diarrhea	O
occurs	O
.	O
	
Monitoring	O
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
Five	O
of	O
the	O
six	O
patients	O
in	O
the	O
group	O
that	O
received	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
complication	I
within	O
30	O
days	O
of	O
completing	O
treatment	O
with	O
PROMACTA	O
and	O
at	O
a	O
platelet	O
count	O
above	O
200	O
x	O
10	O
9	O
/L	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
pancreatitis	O
for	O
patients	O
presenting	O
with	O
severe	O
abdominal	O
pain	O
.	O
	
As	O
with	O
other	O
PDE5	O
inhibitors	O
STENDRA	O
has	O
systemic	O
vasodilatory	O
properties	O
and	O
may	O
augment	O
the	O
blood	O
pressure-lowering	O
effect	O
of	O
other	O
anti-hypertensive	O
medications	O
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
,	O
Syncope	O
,	O
and	O
Other	O
Hemodynamic	O
Effects	O
SAPHRIS	O
may	O
induce	O
orthostatic	B
hypotension	I
and	O
syncope	B
in	O
some	O
patients	O
,	O
especially	O
early	O
in	O
treatment	O
,	O
because	O
of	O
its	O
alpha1-adrenergic	O
antagonist	O
activity	O
.	O
	
5.1	O
Serious	O
Infections	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
The	O
data	O
described	O
below	O
primarily	O
derive	O
from	O
two	O
randomized	O
,	O
active-controlled	O
three-year	O
trials	O
of	O
NULOJIX	O
in	O
de	O
novo	O
kidney	O
transplant	O
patients	O
.	O
	
ALT	B
elevations	I
were	O
reversible	O
in	O
all	O
subjects	O
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeated	O
dosing	O
appears	O
to	O
increase	O
the	O
risk	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	O
:	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
reactions	O
including	O
shock	B
can	O
occur	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
with	O
caution	O
in	O
(	O
1	O
)	O
patients	O
with	O
known	O
cardiovascular	O
disease	O
(	O
history	O
of	O
myocardial	O
infarction	O
or	O
ischemic	O
heart	O
disease	O
,	O
heart	O
failure	O
or	O
conduction	O
abnormalities	O
)	O
,	O
cerebrovascular	O
disease	O
,	O
or	O
conditions	O
which	O
would	O
predispose	O
patients	O
to	O
hypotension	O
(	O
dehydration	O
,	O
hypovolemia	O
,	O
and	O
treatment	O
with	O
antihypertensive	O
medications	O
)	O
;	O
and	O
(	O
2	O
)	O
in	O
the	O
elderly	O
.	O
	
(	O
6	O
)	O
The	O
most	O
common	O
adverse	O
events	O
occurring	O
in	O
at	O
least	O
20	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
in	O
the	O
combination	O
therapy	O
trial	O
:	O
decreased	B
lymphocytes	I
,	O
decreased	B
absolute	I
neutrophil	I
count	I
,	O
decreased	B
phosphorus	I
,	O
anemia	B
,	O
neutropenia	B
,	O
decreased	B
total	I
white	I
blood	I
cell	I
count	I
,	O
decreased	B
platelets	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
thrombocytopenia	B
,	O
pyrexia	B
,	O
muscle	B
spasm	I
,	O
cough	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
decreased	B
hemoglobin	I
,	O
hypokalemia	B
.	O
	
In	O
short-term	O
schizophrenia	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.2	O
%	O
(	O
1/572	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0.3	O
%	O
(	O
1/378	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
TANZEUM	O
.	O
	
(	O
5.5	O
)	O
*	O
Macrovascular	O
Outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
trials	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TANZEUM	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Symptoms	O
of	O
PVT	B
included	O
abdominal	B
pain	I
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
diarrhea	B
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
seizures	B
were	O
reported	O
in	O
0.3	O
%	O
(	O
5/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
Factors	O
that	O
can	O
increase	O
the	O
risk	O
of	O
developing	O
spinal	B
hematomas	I
in	O
these	O
patients	O
include	O
:	O
*	O
?	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
*	O
?	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
,	O
such	O
as	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
platelet	O
inhibitors	O
,	O
other	O
anticoagulants	O
*	O
?	O
a	O
history	O
of	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
punctures	O
*	O
?	O
a	O
history	O
of	O
spinal	O
deformity	O
or	O
spinal	O
surgery	O
*	O
?	O
optimal	O
timing	O
between	O
the	O
administration	O
of	O
ELIQUIS	O
and	O
neuraxial	O
procedures	O
is	O
not	O
known	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
are	O
upper	B
respiratory	I
tract	I
infection	I
,	O
bronchitis	B
,	O
cough	B
,	O
flatulence	B
and	O
increased	B
bilirubin	I
.	O
	
Avoid	O
the	O
use	O
of	O
Potassium	O
Iodide	O
Oral	O
Solution	O
or	O
Lugol	O
's	O
Solution	O
in	O
patients	O
who	O
are	O
sensitive	O
to	O
such	O
products	O
.	O
	
Monitoring	O
of	O
complete	O
blood	O
counts	O
is	O
essential	O
on	O
a	O
weekly	O
basis	O
during	O
cycle	O
1	O
and	O
before	O
each	O
treatment	O
cycle	O
thereafter	O
so	O
that	O
the	O
dose	O
can	O
be	O
adjusted	O
,	O
if	O
needed	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
The	O
reactions	O
have	O
generally	O
consisted	O
of	O
skin	B
erythema	I
and	O
pruritis	B
and	O
have	O
either	O
resolved	O
spontaneously	O
or	O
following	O
the	O
administration	O
of	O
corticosteroids	O
and	O
anti-histamines	O
.	O
	
*	O
Hyperpyrexia	B
and	O
confusion	B
(	O
5.2	O
)	O
*	O
May	O
exacerbate	B
symptoms	I
in	I
patients	I
with	I
existing	I
ischemic	I
heart	I
disease	I
(	O
5.3	O
)	O
*	O
Allergic	B
reactions	I
(	O
5.4	O
)	O
5.1	O
Supine	O
Hypertension	O
NORTHERA	O
therapy	O
may	O
cause	O
or	O
exacerbate	O
supine	B
hypertension	I
in	O
patients	O
with	O
NOH	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
GBCAs	O
have	O
been	O
associated	O
with	O
a	O
risk	O
for	O
NSF	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Macular	B
edema	I
has	O
also	O
been	O
reported	O
in	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
,	O
usually	O
within	O
the	O
first	O
6	O
months	O
of	O
treatment	O
.	O
	
Sometimes	O
both	O
ovaries	O
are	O
removed	O
during	O
an	O
operation	O
before	O
natural	O
menopause	O
takes	O
place	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
For	O
All	O
Indications	O
:	O
*	O
The	O
potency	O
Units	O
of	O
XEOMIN	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
.	O
	
In	O
addition	O
,	O
a	O
two-week	O
dose-ranging	O
trial	O
was	O
conducted	O
in	O
511	O
adult	O
patients	O
with	O
mild	O
persistent	O
asthma	O
taking	O
inhaled	O
corticosteroids	O
.	O
	
Withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
.	O
	
Monitor	O
blood	O
pressure	O
periodically	O
during	O
the	O
treatment	O
and	O
provide	O
adequate	O
support	O
for	O
treatment	O
related	O
pain	O
.	O
	
Prior	O
to	O
the	O
initiation	O
of	O
the	O
next	O
cycle	O
of	O
therapy	O
,	O
the	O
ANC	O
should	O
be	O
>	O
=	O
1	O
x	O
10	O
9	O
/L	O
and	O
the	O
platelet	O
count	O
should	O
be	O
>	O
=	O
75	O
x	O
10	O
9	O
/L	O
.	O
	
Dizziness	B
,	O
nausea	B
,	O
somnolence	B
,	O
and	O
fatigue	B
were	O
all	O
reported	O
at	O
lower	O
incidences	O
during	O
the	O
AED	O
Withdrawal	O
Phase	O
and	O
Monotherapy	O
Phase	O
compared	O
with	O
the	O
Titration	O
Phase	O
.	O
	
The	O
data	O
described	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
and	O
below	O
reflect	O
exposure	O
to	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
onset	O
tends	O
to	O
be	O
within	O
the	O
first	O
treatment	O
cycle	O
of	O
TREANDA	O
and	O
,	O
without	O
intervention	O
,	O
may	O
lead	O
to	O
acute	B
renal	I
failure	I
and	O
death	B
.	O
	
Clinical	O
monitoring	O
of	O
weight	O
is	O
recommended	O
.	O
	
Because	O
of	O
the	O
increased	O
risk	O
of	O
urinary	O
retention	O
on	O
POTIGA	O
,	O
urologic	O
symptoms	O
should	O
be	O
carefully	O
monitored	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
were	O
:	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=3	O
%	O
)	O
are	O
:	O
upper	B
respiratory	I
tract	I
infection	I
,	O
viral	B
infection	I
,	O
bronchitis	B
,	O
hypertension	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
c	O
Underlying	O
etiology	O
not	O
established	O
.	O
	
Cases	O
of	O
elevated	B
blood	I
pressure	I
requiring	O
immediate	O
treatment	O
have	O
been	O
reported	O
with	O
PRISTIQ	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
XenoPort	O
at	O
1-877-XENOPRT	O
(	O
1-877-936-6778	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
displays	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
5	O
%	O
of	O
patients	O
in	O
the	O
NORTHERA	O
group	O
and	O
with	O
at	O
least	O
a	O
3	O
%	O
greater	O
incidence	O
in	O
the	O
NORTHERA	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O
	
5.8	O
Hypercorticism	O
and	O
Adrenal	O
Suppression	O
Inhaled	O
fluticasone	O
furoate	O
is	O
absorbed	O
into	O
the	O
circulation	O
and	O
can	O
be	O
systemically	O
active	O
.	O
	
Congenital	O
,	O
familial	O
and	O
genetic	O
disorders	O
:	O
hypospadias	B
.	O
	
5.7	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Moderate	O
or	O
Severe	O
Hepatic	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
hepatic	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
There	O
were	O
no	O
treatment	O
discontinuations	O
and	O
one	O
death	B
due	O
to	O
cardiac	B
failure	I
in	O
the	O
placebo	O
group	O
.	O
	
Withhold	O
if	O
not	O
responsive	O
to	O
anti-emetics	O
or	O
anti-diarrheals	O
,	O
then	O
dose	O
reduce	O
ZYKADIA	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
requiring	O
oral	O
corticosteroids	O
should	O
be	O
weaned	O
slowly	O
from	O
systemic	O
corticosteroid	O
use	O
after	O
transferring	O
to	O
BREO	O
ELLIPTA	O
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
of	O
HALAVEN	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
with	O
ZYTIGA	O
was	O
8	O
months	O
.	O
	
Hold	O
ADCETRIS	O
dosing	O
for	O
any	O
suspected	O
case	O
of	O
PML	O
and	O
discontinue	O
ADCETRIS	O
dosing	O
if	O
a	O
diagnosis	O
of	O
PML	O
is	O
confirmed	O
.	O
	
In	O
vitro	O
studies	O
showed	O
no	O
evidence	O
of	O
cross-reactivity	O
between	O
anti-drug-antibody	O
positive	O
patient	O
sera	O
and	O
a	O
series	O
of	O
relevant	O
MMPs	O
.	O
	
After	O
five	O
years	O
more	O
than	O
90	O
percent	O
of	O
patients	O
remained	O
seropositive	O
for	O
anti-AUX-I	O
and	O
anti-AUX-II	O
antibody	O
(	O
Study	O
4	O
)	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
enterocolitis	B
,	O
rectal	B
hemorrhage	I
,	O
gastric	B
ulcer	I
,	O
pancreatitis	B
,	O
parotid	B
gland	I
enlargement	I
.	O
	
5.10	O
Paradoxical	O
Bronchospasm	O
As	O
with	O
other	O
inhaled	O
medicines	O
,	O
BREO	O
ELLIPTA	O
can	O
produce	O
paradoxical	B
bronchospasm	I
,	O
which	O
may	O
be	O
life	O
threatening	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
=2	O
%	O
and	O
at	O
a	O
rate	O
greater	O
than	O
the	O
placebo	O
rate	O
)	O
for	O
AMPYRA	O
were	O
urinary	B
tract	I
infection	I
,	O
insomnia	B
,	O
dizziness	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
back	B
pain	I
,	O
balance	B
disorder	I
,	O
multiple	B
sclerosis	I
relapse	I
,	O
paresthesia	B
,	O
nasopharyngitis	B
,	O
constipation	B
,	O
dyspepsia	B
,	O
and	O
pharyngolaryngeal	B
pain	I
(	O
6.1	O
)	O
.	O
	
This	O
risk	O
increases	O
with	O
age	O
,	O
particularly	O
in	O
women	O
over	O
35	O
years	O
of	O
age	O
,	O
and	O
with	O
the	O
number	O
of	O
cigarettes	O
smoked	O
.	O
	
By	O
Year	O
3	O
,	O
one	O
or	O
more	O
antihypertensive	O
medications	O
were	O
used	O
in	O
85	O
%	O
of	O
NULOJIX-treated	O
patients	O
and	O
92	O
%	O
of	O
cyclosporine-treated	O
patients	O
.	O
	
Of	O
56	O
patients	O
who	O
tested	O
negative	O
for	O
antibodies	O
during	O
treatment	O
and	O
reassessed	O
approximately	O
7	O
half-lives	O
after	O
discontinuation	O
of	O
NULOJIX	O
,	O
1	O
tested	O
antibody	O
positive	O
.	O
	
[	O
See	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
.	O
]	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
RLS	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
at	O
least	O
2	O
times	O
the	O
rate	O
of	O
placebo	O
)	O
were	O
somnolence/sedation	O
and	O
dizziness	B
.	O
	
For	O
patients	O
who	O
experience	O
a	O
sustained	O
increase	O
in	O
blood	O
pressure	O
while	O
receiving	O
PRISTIQ	O
,	O
either	O
dose	O
reduction	O
or	O
discontinuation	O
should	O
be	O
considered	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
overall	O
trial	O
population	O
had	O
a	O
median	O
age	O
of	O
61	O
years	O
;	O
61	O
%	O
of	O
patients	O
in	O
the	O
GILOTRIF	O
arm	O
and	O
60	O
%	O
of	O
patients	O
in	O
the	O
pemetrexed/cisplatin	O
arm	O
were	O
younger	O
than	O
65	O
years	O
.	O
	
The	O
causative	O
organisms	O
for	O
these	O
reactions	O
are	O
identified	O
when	O
provided	O
by	O
the	O
physician	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
of	O
TECFIDERA	O
in	O
the	O
uncontrolled	O
clinical	O
studies	O
was	O
consistent	O
with	O
the	O
experience	O
in	O
the	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
TECFIDERA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
Hyperglycemia	O
and	O
Diabetes	O
Mellitus	O
Hyperglycemia	B
,	O
in	O
some	O
cases	O
extreme	O
and	O
associated	O
with	O
ketoacidosis	B
or	O
hyperosmolar	B
coma	I
or	O
death	B
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
adults	O
(	O
>	O
30	O
%	O
)	O
are	O
headache	B
,	O
anorexia	B
,	O
dizziness	B
,	O
asthenia	B
,	O
arthralgia	B
and	O
myalgia	B
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
mean	O
serum	B
phosphate	I
levels	I
increased	I
by	O
1.2	O
%	O
,	O
5.0	O
%	O
,	O
and	O
9.3	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Across	O
the	O
347	O
patients	O
who	O
were	O
randomized	O
to	O
study	O
treatment	O
(	O
343	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
treatment	O
)	O
,	O
the	O
median	O
age	O
was	O
50	O
years	O
;	O
14	O
%	O
of	O
patients	O
were	O
older	O
than	O
65	O
years	O
.	O
	
Almost	O
all	O
these	O
patients	O
had	O
received	O
treatment	O
with	O
azathioprine	O
(	O
AZA	O
)	O
or	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
concomitantly	O
with	O
a	O
TNF-blocker	O
at	O
or	O
prior	O
to	O
diagnosis	O
.	O
	
Atrioventricular	O
Blocks	O
Initiation	O
of	O
GILENYA	O
treatment	O
has	O
resulted	O
in	O
transient	O
AV	B
conduction	I
delays	I
.	O
	
*	O
Bipolar	O
Disorder	O
Pediatric	O
Patients	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
increased	B
weight	I
.	O
	
5.3	O
Dysphagia	O
and	O
Breathing	O
Difficulties	O
Treatment	O
with	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
botulinum	O
toxin	O
products	O
can	O
result	O
in	O
breathing	B
difficulties	I
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
61	O
years	O
(	O
range	O
27-85	O
)	O
,	O
88	O
%	O
were	O
Caucasian	O
,	O
and	O
78	O
%	O
were	O
male	O
.	O
	
Grades	O
2	O
to	O
4	O
ALT	B
abnormalities	I
in	O
hepatitis	O
B	O
and/or	O
C	O
co-infected	O
compared	O
with	O
HIV	O
mono-infected	O
subjects	O
receiving	O
TIVICAY	O
were	O
observed	O
in	O
18	O
%	O
vs.	O
3	O
%	O
with	O
the	O
50-mg	O
once-daily	O
dose	O
and	O
13	O
%	O
vs.	O
8	O
%	O
with	O
the	O
50-mg	O
twice-daily	O
dose	O
.	O
	
Laboratory	O
abnormalities	O
observed	O
in	O
the	O
FLAMINGO	O
trial	O
were	O
generally	O
consistent	O
with	O
observations	O
in	O
SPRING-2	O
and	O
SINGLE	O
.	O
	
The	O
mechanism	O
and	O
clinical	O
significance	O
are	O
unknown	O
.	O
	
In	O
order	O
to	O
reduce	O
the	O
complication	O
of	O
ptosis	O
the	O
following	O
steps	O
should	O
be	O
taken	O
:	O
*	O
Avoid	O
injection	O
near	O
the	O
levator	O
palpebrae	O
superioris	O
,	O
particularly	O
in	O
patients	O
with	O
larger	O
brow	O
depressor	O
complexes	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
serious	O
infections	B
(	O
6.0	O
%	O
and	O
5.2	O
%	O
in	O
the	O
groups	O
receiving	O
BENLYSTA	O
and	O
placebo	O
,	O
respectively	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
5.11	O
Hepatic	O
Toxicity	O
and	O
Hepatic	O
Failure	O
Cases	O
of	O
hepatic	B
failure	I
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
(	O
<	O
1	O
%	O
)	O
during	O
treatment	O
with	O
Kyprolis	O
.	O
	
Patients	O
were	O
randomized	O
in	O
a	O
2:1	O
ratio	O
and	O
received	O
alglucosidase	O
alfa	O
or	O
placebo	O
every	O
other	O
week	O
for	O
78	O
weeks	O
(	O
18	O
months	O
)	O
.	O
	
At	O
screening	O
,	O
the	O
mean	O
postbronchodilator	O
percent	O
predicted	O
FEV1was	O
48	O
%	O
(	O
range	O
:	O
14	O
%	O
to	O
87	O
%	O
)	O
,	O
the	O
mean	O
postbronchodilator	O
FEV1/forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
ratio	O
was	O
47	O
%	O
(	O
range	O
:	O
17	O
%	O
to	O
88	O
%	O
)	O
,	O
and	O
the	O
mean	O
percent	O
reversibility	O
was	O
14	O
%	O
(	O
range	O
:	O
-41	O
%	O
to	O
152	O
%	O
)	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Laryngeal	O
Attacks	O
Given	O
the	O
potential	O
for	O
airway	O
obstruction	O
during	O
acute	O
laryngeal	O
HAE	O
attacks	O
,	O
patients	O
should	O
be	O
advised	O
to	O
seek	O
medical	O
attention	O
in	O
an	O
appropriate	O
healthcare	O
facility	O
immediately	O
in	O
addition	O
to	O
treatment	O
with	O
FIRAZYR	O
.	O
	
All	O
events	O
resolved	O
with	O
continued	O
treatment	O
with	O
ILARIS	O
.	O
	
Investigations	O
-	O
Weight	B
increased	I
,	O
liver	B
function	I
test	I
abnormal	I
,	O
blood	B
prolactin	I
increased	I
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
ILARIS	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
All	O
other	O
patients	O
were	O
eligible	O
for	O
these	O
studies	O
if	O
the	O
plasma	O
methotrexate	O
level	O
was	O
greater	O
than	O
10	O
mumol/L	O
more	O
than	O
42	O
hours	O
after	O
the	O
start	O
of	O
the	O
methotrexate	O
or	O
the	O
plasma	O
level	O
was	O
greater	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
mean	O
methotrexate	O
excretion	O
curve	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
and	O
the	O
serum	O
creatinine	O
was	O
greater	O
than	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
the	O
creatinine	O
clearance	O
was	O
less	O
than	O
60	O
mL/min	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
administration	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=1	O
%	O
of	O
ULORIC-Treated	O
Patients	O
and	O
at	O
Least	O
0.5	O
%	O
Greater	O
than	O
Seen	O
in	O
Patients	O
Receiving	O
Placebo	O
in	O
Controlled	O
Studies	O
Adverse	O
Reactions	O
Placebo	O
ULORIC	O
allopurinolOf	O
the	O
subjects	O
who	O
received	O
allopurinol	O
,	O
10	O
received	O
100	O
mg	O
,	O
145	O
received	O
200	O
mg	O
,	O
and	O
1122	O
received	O
300	O
mg	O
,	O
based	O
on	O
level	O
of	O
renal	O
impairment	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
cabazitaxel	O
or	O
to	O
other	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Contraindications	O
(	O
4	O
)	O
,	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
trametinib	O
.	O
	
5.5	O
Urinary	O
Tract	O
Infections	O
JARDIANCE	O
increases	O
the	O
risk	O
for	O
urinary	B
tract	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
TANZEUM	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
to	O
determine	O
whether	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
for	O
pancreatitis	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
XALKORI	O
and	O
for	O
at	O
least	O
45	O
days	O
following	O
the	O
final	O
dose	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
,	O
8.3	O
)	O
]	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
MTC	B
,	O
in	O
humans	O
[	O
see	O
Boxed	O
Warning	O
,	O
Contraindications	O
(	O
4.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
See	O
Full	O
Prescribing	O
Information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
thromboembolic	B
complications	I
may	O
result	O
from	O
increases	B
in	I
platelet	I
counts	I
with	O
PROMACTA	O
.	O
	
Dose	O
modifications	O
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
delays	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
were	O
neutropenia	B
(	O
14	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
11	O
%	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Three	O
subjects	O
experienced	O
severe	O
or	O
life-threatening	O
infections	B
associated	O
with	O
neutropenia	B
,	O
and	O
two	O
subjects	O
experienced	O
life-threatening	O
neutropenia	B
while	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
.	O
	
In	O
short-term	O
bipolar	O
mania	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.3	O
%	O
(	O
1/379	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
pneumonia	B
(	O
4	O
%	O
)	O
,	O
pyrexia	B
(	O
4	O
%	O
)	O
,	O
vomiting	B
(	O
3	O
%	O
)	O
,	O
nausea	B
(	O
2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
2	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
2	O
%	O
)	O
.	O
	
Renal	O
and	O
hematuria	B
.	O
	
Opportunistic	B
infections	I
,	O
or	O
other	O
opportunistic	O
pathogens	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
.	O
	
Reported	O
thromboembolic	B
complications	I
and	O
were	O
observed	O
at	O
low	O
and	O
at	O
normal	O
platelet	O
counts	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
ADCETRIS	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypersensitivity	B
Reactions	I
:	O
Discontinue	O
TANZEUM	O
if	O
suspected	O
.	O
	
One	O
of	O
these	O
forms	O
of	O
contraception	O
can	O
be	O
a	O
combined	O
oral	O
contraceptive	O
product	O
containing	O
at	O
least	O
1	O
mg	O
of	O
norethindrone	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
of	O
XALKORI	O
in	O
Studies	O
1	O
and	O
2	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
Study	O
1	O
,	O
conducted	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
,	O
enrolled	O
184	O
patients	O
;	O
safety	O
information	O
is	O
available	O
for	O
149	O
patients	O
.	O
	
If	O
irritation	O
persists	O
,	O
consult	O
a	O
physician	O
.	O
	
Treatment	O
of	O
CAPS	O
The	O
data	O
described	O
herein	O
reflect	O
exposure	O
to	O
ILARIS	O
in	O
104	O
adult	O
and	O
pediatric	O
CAPS	O
patients	O
,	O
including	O
20	O
FCAS	O
,	O
72	O
MWS	O
,	O
10	O
MWS/NOMID	O
(	O
Neonatal	O
Onset	O
Multisystem	O
Inflammatory	O
Disorder	O
)	O
overlap	O
,	O
1	O
non-FCAS	O
non-MWS	O
,	O
and	O
1	O
misdiagnosed	O
in	O
placebo-controlled	O
(	O
35	O
patients	O
)	O
and	O
uncontrolled	O
trials	O
.	O
	
Corticosteroids	O
may	O
be	O
indicated	O
until	O
clinical	O
symptoms	O
resolve	O
.	O
	
Diarrhea	B
,	O
nausea	B
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
were	O
the	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Effects	O
on	O
Driving	O
HORIZANT	O
may	O
cause	O
significant	O
driving	B
impairment	I
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
Skin	B
discoloration	I
has	O
been	O
reported	O
with	O
higher	O
frequency	O
among	O
emtricitabine-treated	O
subjects	O
;	O
it	O
was	O
manifested	O
by	O
hyperpigmentation	B
on	I
the	I
palms	I
and	O
was	O
generally	O
mild	O
and	O
asymptomatic	O
.	O
	
5.4	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
DYSPORT	O
(	O
r	O
)	O
to	O
patients	O
with	O
surgical	O
alterations	O
to	O
the	O
facial	O
anatomy	O
,	O
excessive	O
weakness	O
or	O
atrophy	O
in	O
the	O
target	O
muscle	O
(	O
s	O
)	O
,	O
marked	O
facial	O
asymmetry	O
,	O
inflammation	O
at	O
the	O
injection	O
site	O
(	O
s	O
)	O
,	O
ptosis	O
,	O
excessive	O
dermatochalasis	O
,	O
deep	O
dermal	O
scarring	O
,	O
thick	O
sebaceous	O
skin	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.3	O
]	O
or	O
the	O
inability	O
to	O
substantially	O
lessen	O
glabellar	O
lines	O
by	O
physically	O
spreading	O
them	O
apart	O
[	O
seeClinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Psoriatic	O
arthritis	O
:	O
During	O
the	O
0	O
to	O
16	O
week	O
placebo-controlled	O
period	O
of	O
the	O
3	O
controlled	O
clinical	O
trials	O
,	O
1.0	O
%	O
(	O
10/998	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
reported	O
depression	B
or	O
depressed	B
mood	I
compared	O
to	O
0.8	O
%	O
(	O
4/495	O
)	O
treated	O
with	O
placebo	O
.	O
	
The	O
malignancies	O
occurred	O
after	O
a	O
median	O
of	O
30	O
months	O
(	O
range	O
1	O
to	O
84	O
months	O
)	O
after	O
the	O
first	O
dose	O
of	O
TNF-blocker	O
therapy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Cardiac	B
toxicities	I
include	O
cardiac	B
failure	I
and	O
myocardial	B
infarction	I
with	O
fatal	B
outcome	O
,	O
and	O
myocardial	B
ischemia	I
.	O
	
Of	O
the	O
patients	O
in	O
those	O
trials	O
,	O
approximately	O
95	O
%	O
were	O
between	O
18	O
and	O
60	O
years	O
old	O
,	O
approximately	O
50	O
%	O
were	O
male	O
,	O
and	O
approximately	O
80	O
%	O
were	O
Caucasian	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
increased	B
weight	I
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
evidence	O
of	O
untreated	O
brain	O
metastasis	O
or	O
recent	O
active	O
gastrointestinal	O
bleeding	O
and	O
should	O
not	O
be	O
used	O
in	O
those	O
patients	O
.	O
	
5.4	O
Demyelinating	O
Disorders	O
Use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
exacerbation	B
of	I
central	I
nervous	I
system	I
(	I
CNS	I
)	I
demyelinating	I
disorders	I
,	O
including	O
multiple	B
sclerosis	I
(	O
MS	B
)	O
and	O
peripheral	B
demyelinating	I
disorders	I
,	O
including	O
Guillain-Barre	B
syndrome	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
and	O
respiratory	B
tract	I
infection	I
.	O
	
Consider	O
suspending	O
treatment	O
with	O
GILENYA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
,	O
and	O
reassess	O
the	O
benefits	O
and	O
risks	O
prior	O
to	O
reinitiation	O
of	O
therapy	O
.	O
	
Monitor	O
blood	O
pressure	O
during	O
and	O
following	O
the	O
treatment	O
procedure	O
.	O
	
No	O
new	O
major	O
safety	O
findings	O
were	O
reported	O
from	O
a	O
50-week	O
,	O
open-label	O
,	O
uncontrolled	O
safety	O
trial	O
.	O
	
(	O
5.3	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
:	O
Acute	B
renal	I
failure	I
and	O
death	B
;	O
anticipate	O
and	O
use	O
supportive	O
measures	O
.	O
	
Study	O
1	O
Adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
from	O
the	O
CLL	O
trial	O
(	O
N=48	O
)	O
using	O
single	O
agent	O
IMBRUVICA	O
420	O
mg	O
daily	O
occurring	O
at	O
a	O
rate	O
of	O
>	O
=	O
10	O
%	O
are	O
presented	O
in	O
Tables	O
3	O
and	O
4	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
other	O
clinical	O
trials	O
or	O
experience	O
with	O
therapeutics	O
in	O
the	O
same	O
class	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
88	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
11	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
82	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
5.6	O
Activation	O
of	O
Mania/Hypomania	O
During	O
all	O
MDD	O
phase	O
2	O
and	O
phase	O
3	O
studies	O
,	O
mania	B
was	O
reported	O
for	O
approximately	O
0.02	O
%	O
of	O
patients	O
treated	O
with	O
PRISTIQ	O
.	O
	
The	O
retinal	B
abnormalities	I
observed	O
with	O
POTIGA	O
have	O
been	O
reported	O
in	O
patients	O
who	O
were	O
originally	O
enrolled	O
in	O
clinical	O
trials	O
with	O
POTIGA	O
and	O
who	O
have	O
generally	O
taken	O
the	O
drug	O
for	O
a	O
long	O
period	O
of	O
time	O
in	O
2	O
ongoing	O
extension	O
trials	O
.	O
	
c	O
Includes	O
the	O
terms	O
feeling	B
cold	I
and	O
chills	B
.	O
	
Interrupt	O
BLINCYTO	O
if	O
the	O
transaminases	O
rise	O
to	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
if	O
bilirubin	O
rises	O
to	O
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
Table	O
3	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Occurring	O
in	O
>	O
10	O
%	O
(	O
All	O
NCI	O
CTCAE	O
Grades	O
)	O
of	O
ALK-Positive	O
Patients	O
Treated	O
with	O
ZYKADIA	O
in	O
Study	O
1	O
ZYKADIAN=255	O
All	O
Grades	O
Grade	O
3-4	O
%	O
%	O
Hemoglobin	B
decreased	I
84	O
5	O
ALT	B
)	I
increased	I
80	O
27	O
AST	B
)	I
increased	I
75	O
13	O
Creatinine	B
increased	I
58	O
2	O
Glucose	B
increased	I
49	O
13	O
Phosphate	B
decreased	I
36	O
7	O
Lipase	B
increased	I
28	O
10	O
Bilirubin	B
(	I
total	I
)	I
increased	I
15	O
1	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Severe	O
or	O
Persistent	O
Gastrointestinal	O
Toxicity	O
:	O
Dose	O
modification	O
due	O
to	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
or	O
abdominal	B
pain	I
occurred	O
in	O
38	O
%	O
of	O
patients	O
.	O
	
Intracranial	B
hemorrhage	I
included	O
subdural	B
bleeds	I
.	O
	
Adverse	O
reaction	O
information	O
for	O
Ferriprox	O
represents	O
the	O
pooled	O
data	O
collected	O
from	O
642	O
patients	O
who	O
participated	O
in	O
single	O
arm	O
or	O
active-controlled	O
clinical	O
studies	O
.	O
	
Dose	O
reduction	O
due	O
to	O
peripheral	B
neuropathy	I
was	O
required	O
by	O
3	O
%	O
(	O
14/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
.	O
	
Neutralizing	O
antibodies	O
were	O
assayed	O
for	O
a	O
subset	O
of	O
70	O
samples	O
selected	O
to	O
be	O
representative	O
of	O
high	O
and	O
low	O
titer	O
binding	O
antibody	O
responses	O
at	O
week	O
12	O
of	O
treatment	O
.	O
